uuid stringlengths 4 8 | template_uuid stringclasses 40
values | question stringlengths 13 193 | answer stringlengths 29 2.2k | benchmark_query stringlengths 133 622 | execution_results stringlengths 2 1.14M | query_type stringclasses 2
values | sql_category stringclasses 26
values | bio_category stringclasses 14
values |
|---|---|---|---|---|---|---|---|---|
Q17.561 | Q17 | What gene does the drug Epoetin Alfa target? | The drug Epoetin Alfa targets the gene EPOR. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%epoetin alfa%" OR LOWER(tradeNames_string) LIKE "%epoetin alfa%" OR LOWER(drugSynonyms_string) LIKE "%epoetin alfa%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4530', 'drugName': 'Methoxy Polyethylene Glycol-Epoetin Beta', 'tradeNames_string': 'Mircera', 'drugSynonyms_string': 'Methoxy polyethylene glycol-epoetin beta, Pegzerepoetin alfa, R-744, R744', 'linkedDiseasesDrug_string': 'Anemia (Phenotype) (EFO_0004272), Anemia (MONDO_0002280), Kidney Disease (EFO_0003086), Chronic Kidney Disease (EFO_0003884)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'EPOR (ENSG00000187266)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_4490', 'drugName': 'Darbepoetin Alfa', 'tradeNames_string': 'Aranesp, Aranesp sureclick', 'drugSynonyms_string': 'Darbepoetin, Darbepoetin alfa, Darbepoetin alfa,recombinant, KRN-321, KRN321, NESP, Nespo', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Chronic Lymphocytic Leukemia (EFO_0000095), Encephalopathy (HP_0001298), Myelodysplastic Syndrome (EFO_0000198), Lymphoid Neoplasm (EFO_0001642), Breast Cancer (MONDO_0007254), Lymphoma (EFO_0000574), Brain Ischemia (MONDO_0005299), Acute Myeloid Leukemia (EFO_0000222), Acute Myocardial Infarction (EFO_0008583), Diffuse Large B-Cell Lymphoma (EFO_0000403), Dysgerminoma (MONDO_0003002), Small Cell Lung Carcinoma (EFO_0000702), Anemia (Phenotype) (EFO_0004272), Myocardial Infarction (EFO_0000612), Anemia (MONDO_0002280), Brain Injury (MONDO_0043510), Chronic Kidney Disease (EFO_0003884), Leukemia (EFO_0000565), Kidney Disease (EFO_0003086), Acute Kidney Injury (HP_0001919)', 'yearOfFirstApproval': 2001, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'EPOR (ENSG00000187266)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_4769', 'drugName': 'Epoetin Alfa', 'tradeNames_string': 'Binocrit, Epogen, Eprex, Procrit', 'drugSynonyms_string': 'EPO, Epoetin, Epoetin alfa, Erythropoietin, Erythropoietin for bioassays', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Neonatal Anemia (MONDO_0001240), Coronary Artery Disease (EFO_0001645), Friedreich Ataxia (MONDO_0100339), Peripheral Neuropathy (EFO_0003100), Peritoneal Neoplasm (EFO_1001100), St Elevation Myocardial Infarction (EFO_0008585), Venous Thrombosis (HP_0004936), Stage 5 Chronic Kidney Disease (EFO_0009909), Myelodysplastic Syndrome (EFO_0000198), Prostate Carcinoma (EFO_0001663), Ovarian Cancer (MONDO_0008170), Hepatitis C Virus Infection (EFO_0003047), Cervical Adenocarcinoma (EFO_0001416), Breast Cancer (MONDO_0007254), Beta-Thalassemia (Orphanet_848), Asphyxia (EFO_0009446), Chronic Myelomonocytic Leukemia (EFO_1001779), Brain Ischemia (MONDO_0005299), Diabetic Foot (EFO_1001459), Acute Myeloid Leukemia (EFO_0000222), Pancreatic Carcinoma (EFO_0002618), Cardiac Arrest (EFO_0009492), Premature Birth (EFO_0003917), Drug Dependence (EFO_0003890), Anemia (Phenotype) (EFO_0004272), Stroke (EFO_0000712), Sickle Cell Anemia (MONDO_0011382), Myocardial Infarction (EFO_0000612), Anemia (MONDO_0002280), Brain Injury (MONDO_0043510), Chronic Kidney Disease (EFO_0003884), Head And Neck Malignant Neoplasia (EFO_0006859), Hiv Infection (EFO_0000764), Lung Cancer (MONDO_0008903), Fatigue (HP_0012378)', 'yearOfFirstApproval': 1989, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'EPOR (ENSG00000187266)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_423', 'drugName': 'Efepoetin Alfa', 'tradeNames_string': '', 'drugSynonyms_string': 'Efepoetin alfa', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 3, 'drugIsApproved': False, 'newLinkedTargets_string': 'EPOR (ENSG00000187266)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.81 | Q17 | What gene does the drug Azilsartan Kamedoxomil target? | The drug Azilsartan Kamedoxomil targets the gene AGTR1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%azilsartan kamedoxomil%" OR LOWER(tradeNames_string) LIKE "%azilsartan kamedoxomil%" OR LOWER(drugSynonyms_string) LIKE "%azilsartan kamedoxomil%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1209', 'drugName': 'Azilsartan Kamedoxomil', 'tradeNames_string': 'Edarbi', 'drugSynonyms_string': 'Azilsartan kamedoxomil, Azilsartan medoxomil potassium, TAK-491', 'linkedDiseasesDrug_string': 'Stroke (EFO_0000712), Hypertension (EFO_0000537)', 'yearOfFirstApproval': 2011, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'AGTR1 (ENSG00000144891)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1042 | Q17 | What gene does the drug Disulfiram target? | The drug Disulfiram targets the gene ALDH2. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%disulfiram%" OR LOWER(tradeNames_string) LIKE "%disulfiram%" OR LOWER(drugSynonyms_string) LIKE "%disulfiram%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5934', 'drugName': 'Disulfiram', 'tradeNames_string': 'Antabuse, Disulfiram, Esperal', 'drugSynonyms_string': 'Disulfiram, NSC-25953, ORA-102, ORA102', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Multiple Myeloma (EFO_0001378), Parasitic Infection (EFO_0001067), Covid-19 (MONDO_0100096), Obesity (EFO_0001073), Metastatic Melanoma (EFO_0002617), Prostate Cancer (MONDO_0008315), Breast Cancer (MONDO_0007254), Cocaine Dependence (EFO_0002610), Pancreatic Carcinoma (EFO_0002618), Methamphetamine Dependence (EFO_0004701), Alcohol-Related Disorders (MONDO_0021698), Alcohol Dependence (MONDO_0007079), Opioid Dependence (EFO_0005611), Hiv Infection (EFO_0000764), Non-Small Cell Lung Carcinoma (EFO_0003060), Sarcoma (EFO_0000691), Melanoma (EFO_0000756), Fatigue (HP_0012378), Glioblastoma Multiforme (EFO_0000519), Germ Cell Tumor (EFO_0000514)', 'yearOfFirstApproval': 1951, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ALDH2 (ENSG00000111275)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1314 | Q17 | What gene does the drug Monomethyl Fumarate target? | The drug Monomethyl Fumarate targets the gene KEAP1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%monomethyl fumarate%" OR LOWER(tradeNames_string) LIKE "%monomethyl fumarate%" OR LOWER(drugSynonyms_string) LIKE "%monomethyl fumarate%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_313', 'drugName': 'Monomethyl Fumarate', 'tradeNames_string': 'Bafiertam', 'drugSynonyms_string': 'Fumaric acid monomethyl ester, Methyl Fumarate, Monomethyl fumarate, NSC-523835', 'linkedDiseasesDrug_string': 'Multiple Sclerosis (MONDO_0005301), Relapsing-Remitting Multiple Sclerosis (EFO_0003929)', 'yearOfFirstApproval': 2020, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'KEAP1 (ENSG00000079999)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.33 | Q17 | What gene does the drug Pioglitazone Hydrochloride target? | The drug Pioglitazone Hydrochloride targets the gene PPARG. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%pioglitazone hydrochloride%" OR LOWER(tradeNames_string) LIKE "%pioglitazone hydrochloride%" OR LOWER(drugSynonyms_string) LIKE "%pioglitazone hydrochloride%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_878', 'drugName': 'Pioglitazone Hydrochloride', 'tradeNames_string': 'Actos, Diabiom, Glidipion, Glizofar, Pioglitazone hydrochloride', 'drugSynonyms_string': 'Actos, NSC-758876, Pioglitazone (as hydrochloride), Pioglitazone hcl, Pioglitazone hydrochloride, Piomed, STR-001, U-72107A', 'linkedDiseasesDrug_string': 'Pancreatic Carcinoma (EFO_0002618), Chronic Kidney Disease (EFO_0003884), Oral Leukoplakia (HP_0002745), Amyotrophic Lateral Sclerosis (MONDO_0004976), Liver Disease (EFO_0001421), Non-Small Cell Lung Carcinoma (EFO_0003060), Non-Alcoholic Fatty Liver Disease (EFO_0003095), Major Depressive Disorder (MONDO_0002009), Type 2 Diabetes Mellitus (MONDO_0005148)', 'yearOfFirstApproval': 1999, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'PPARG (ENSG00000132170)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1739 | Q17 | What gene does the drug Medi-500 target? | The drug Medi-500 is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target 4 genes: TRBV7-9, TRAC, TRGV3 and TRAV29DV5 | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%medi-500%" OR LOWER(tradeNames_string) LIKE "%medi-500%" OR LOWER(drugSynonyms_string) LIKE "%medi-500%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1483', 'drugName': 'Medi-500', 'tradeNames_string': '', 'drugSynonyms_string': 'MEDI-500, Medi-500, T10B9', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 3, 'drugIsApproved': False, 'newLinkedTargets_string': 'TRAV29DV5 (ENSG00000211810), TRAC (ENSG00000277734), TRBV7-9 (ENSG00000278030), TRGV3 (ENSG00000211699)', 'numberLinkedTargets': 4}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.358 | Q17 | What gene does the drug Vernakalant Hydrochloride target? | The drug Vernakalant Hydrochloride is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target 6 genes: KCND3, KCNJ3, KCNJ5, SCN5A, KCNA5 and KCNH2 | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%vernakalant hydrochloride%" OR LOWER(tradeNames_string) LIKE "%vernakalant hydrochloride%" OR LOWER(drugSynonyms_string) LIKE "%vernakalant hydrochloride%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1589', 'drugName': 'Vernakalant Hydrochloride', 'tradeNames_string': '', 'drugSynonyms_string': 'Brinavess, Kynapid, RSD-1235, RSD1235, Vernakalant hcl, Vernakalant hydrochloride', 'linkedDiseasesDrug_string': 'Atrial Flutter (EFO_0003911), Atrial Fibrillation (EFO_0000275)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 3, 'drugIsApproved': False, 'newLinkedTargets_string': 'KCNA5 (ENSG00000130037), KCNJ3 (ENSG00000162989), KCNJ5 (ENSG00000120457), KCNH2 (ENSG00000055118), SCN5A (ENSG00000183873), KCND3 (ENSG00000171385)', 'numberLinkedTargets': 6}, {'UUID': 'DrugGeneTargets_v2_1586', 'drugName': 'Vernakalant Hydrochloride', 'tradeNames_string': '', 'drugSynonyms_string': 'Brinavess, Kynapid, RSD-1235, RSD1235, Vernakalant hcl, Vernakalant hydrochloride', 'linkedDiseasesDrug_string': 'Atrial Flutter (EFO_0003911), Atrial Fibrillation (EFO_0000275)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 3, 'drugIsApproved': False, 'newLinkedTargets_string': 'KCNA5 (ENSG00000130037), KCNJ3 (ENSG00000162989), KCNJ5 (ENSG00000120457), KCNH2 (ENSG00000055118), SCN5A (ENSG00000183873), KCND3 (ENSG00000171385)', 'numberLinkedTargets': 6}, {'UUID': 'DrugGeneTargets_v2_1587', 'drugName': 'Vernakalant Hydrochloride', 'tradeNames_string': '', 'drugSynonyms_string': 'Brinavess, Kynapid, RSD-1235, RSD1235, Vernakalant hcl, Vernakalant hydrochloride', 'linkedDiseasesDrug_string': 'Atrial Flutter (EFO_0003911), Atrial Fibrillation (EFO_0000275)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 3, 'drugIsApproved': False, 'newLinkedTargets_string': 'KCNA5 (ENSG00000130037), KCNJ3 (ENSG00000162989), KCNJ5 (ENSG00000120457), KCNH2 (ENSG00000055118), SCN5A (ENSG00000183873), KCND3 (ENSG00000171385)', 'numberLinkedTargets': 6}, {'UUID': 'DrugGeneTargets_v2_1590', 'drugName': 'Vernakalant Hydrochloride', 'tradeNames_string': '', 'drugSynonyms_string': 'Brinavess, Kynapid, RSD-1235, RSD1235, Vernakalant hcl, Vernakalant hydrochloride', 'linkedDiseasesDrug_string': 'Atrial Flutter (EFO_0003911), Atrial Fibrillation (EFO_0000275)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 3, 'drugIsApproved': False, 'newLinkedTargets_string': 'KCNA5 (ENSG00000130037), KCNJ3 (ENSG00000162989), KCNJ5 (ENSG00000120457), KCNH2 (ENSG00000055118), SCN5A (ENSG00000183873), KCND3 (ENSG00000171385)', 'numberLinkedTargets': 6}, {'UUID': 'DrugGeneTargets_v2_1588', 'drugName': 'Vernakalant Hydrochloride', 'tradeNames_string': '', 'drugSynonyms_string': 'Brinavess, Kynapid, RSD-1235, RSD1235, Vernakalant hcl, Vernakalant hydrochloride', 'linkedDiseasesDrug_string': 'Atrial Flutter (EFO_0003911), Atrial Fibrillation (EFO_0000275)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 3, 'drugIsApproved': False, 'newLinkedTargets_string': 'KCNA5 (ENSG00000130037), KCNJ3 (ENSG00000162989), KCNJ5 (ENSG00000120457), KCNH2 (ENSG00000055118), SCN5A (ENSG00000183873), KCND3 (ENSG00000171385)', 'numberLinkedTargets': 6}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1077 | Q17 | What gene does the drug Naphazoline Hydrochloride target? | The drug Naphazoline Hydrochloride targets 6 genes: ADRA2A, ADRA2C, ADRA1A, ADRA1D, ADRA2B and ADRA1B. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%naphazoline hydrochloride%" OR LOWER(tradeNames_string) LIKE "%naphazoline hydrochloride%" OR LOWER(drugSynonyms_string) LIKE "%naphazoline hydrochloride%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_327', 'drugName': 'Naphazoline Hydrochloride', 'tradeNames_string': 'Albalon, Antistin-privine, Gppe nsl soln, Nafazair, Naphaz hcl, Naphazoline hydrochloride, Naphcon, Naphcon forte, Opcon, Vasocon', 'drugSynonyms_string': 'NSC-35711, Naphazoline HCl, Naphazoline hcl, Naphazoline hydrochloride, Naphazoline nitrate', 'linkedDiseasesDrug_string': 'Sinusitis (EFO_0007486), Common Cold (EFO_0007214), Seasonal Allergic Rhinitis (EFO_0003956), Inflammation (MP_0001845), Influenza (EFO_0007328), Nasal Congestion (HP_0001742), Pterygium (EFO_0000678)', 'yearOfFirstApproval': 1971, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ADRA1A (ENSG00000120907), ADRA2A (ENSG00000150594), ADRA2C (ENSG00000184160), ADRA1D (ENSG00000171873), ADRA1B (ENSG00000170214), ADRA2B (ENSG00000274286)', 'numberLinkedTargets': 6}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1692 | Q17 | What gene does the drug Tafamidis target? | The drug Tafamidis targets the gene TTR. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%tafamidis%" OR LOWER(tradeNames_string) LIKE "%tafamidis%" OR LOWER(drugSynonyms_string) LIKE "%tafamidis%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_8', 'drugName': 'Tafamidis Meglumine', 'tradeNames_string': 'Vyndaqel', 'drugSynonyms_string': 'FX-1006A, Tafamidis meglumine', 'linkedDiseasesDrug_string': 'Amyloidosis (EFO_1001875), Al Amyloidosis (MONDO_0019438), Polyneuropathy (EFO_0009562), Familial Amyloid Neuropathy (EFO_0004129), Cardiomyopathy (EFO_0000318)', 'yearOfFirstApproval': 2019, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'TTR (ENSG00000118271)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_3770', 'drugName': 'Tafamidis', 'tradeNames_string': 'Vyndamax, Vyndaqel', 'drugSynonyms_string': 'FX-1005, FX-1006, FX1006, Tafamidis', 'linkedDiseasesDrug_string': 'Amyloidosis (EFO_1001875), Al Amyloidosis (MONDO_0019438), Polyneuropathy (EFO_0009562), Familial Amyloid Neuropathy (EFO_0004129), Cardiomyopathy (EFO_0000318)', 'yearOfFirstApproval': 2019, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'TTR (ENSG00000118271)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.127 | Q17 | What gene does the drug Alcuronium target? | The drug Alcuronium targets the gene CHRM2. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%alcuronium%" OR LOWER(tradeNames_string) LIKE "%alcuronium%" OR LOWER(drugSynonyms_string) LIKE "%alcuronium%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4023', 'drugName': 'Alcuronium', 'tradeNames_string': '', 'drugSynonyms_string': "Alcuronium, Alcuronium cation, Alcuronium ion, Diallylnortoxiferine, N,n'-diallylnortoxiferinium", 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CHRM2 (ENSG00000181072)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1031 | Q17 | What gene does the drug Nesvacumab target? | The drug Nesvacumab is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene ANGPT2. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%nesvacumab%" OR LOWER(tradeNames_string) LIKE "%nesvacumab%" OR LOWER(drugSynonyms_string) LIKE "%nesvacumab%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1274', 'drugName': 'Nesvacumab', 'tradeNames_string': 'Regn910', 'drugSynonyms_string': 'Nesvacumab, REGN-910, REGN910', 'linkedDiseasesDrug_string': 'Age-Related Macular Degeneration (EFO_0001365), Neoplasm (EFO_0000616)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'ANGPT2 (ENSG00000091879)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.399 | Q17 | What gene does the drug Cinacalcet target? | The drug Cinacalcet targets the gene CASR. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%cinacalcet%" OR LOWER(tradeNames_string) LIKE "%cinacalcet%" OR LOWER(drugSynonyms_string) LIKE "%cinacalcet%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_841', 'drugName': 'Cinacalcet Hydrochloride', 'tradeNames_string': 'Mimpara, Sensipar', 'drugSynonyms_string': 'AMG-073, AMG-073 HCL, AMG073 HCL, AMG073 HYDROCHLORIDE, Cinacalcet hcl, Cinacalcet hydrochloride', 'linkedDiseasesDrug_string': 'Chronic Kidney Disease (EFO_0003884), Secondary Hyperparathyroidism (EFO_1001173), Parathyroid Gland Carcinoma (EFO_1000456), Carcinoma (EFO_0000313), Prostate Adenocarcinoma (EFO_0000673)', 'yearOfFirstApproval': 2004, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CASR (ENSG00000036828)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_247', 'drugName': 'Cinacalcet', 'tradeNames_string': 'Sensipar', 'drugSynonyms_string': 'AMG 073, AMG-073, AMG073, Cinacalcet, KRN-1493, KRN1493', 'linkedDiseasesDrug_string': 'Chronic Kidney Disease (EFO_0003884), Memory Impairment (EFO_0001072), Secondary Hyperparathyroidism (EFO_1001173), Hyperparathyroidism (EFO_0008506), Parathyroid Gland Carcinoma (EFO_1000456), Primary Hyperparathyroidism (EFO_0008519), Parathyroid Disease (EFO_0005754), Renal Osteodystrophy (EFO_1001152), Hypophosphatemic Rickets (MONDO_0024300), Carcinoma (EFO_0000313), Prostate Adenocarcinoma (EFO_0000673)', 'yearOfFirstApproval': 2004, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CASR (ENSG00000036828)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.444 | Q17 | What gene does the drug Abrocitinib target? | The drug Abrocitinib targets the gene JAK1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%abrocitinib%" OR LOWER(tradeNames_string) LIKE "%abrocitinib%" OR LOWER(drugSynonyms_string) LIKE "%abrocitinib%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1422', 'drugName': 'Abrocitinib', 'tradeNames_string': 'Cibinqo', 'drugSynonyms_string': 'Abrocitinib, Cibinqo, PF-04965842, Pf-04965842', 'linkedDiseasesDrug_string': 'Eczema (HP_0000964), Psoriasis (EFO_0000676), Liver Disease (EFO_0001421), Atopic Eczema (EFO_0000274), Kidney Disease (EFO_0003086), Food Allergy (EFO_1001890)', 'yearOfFirstApproval': 2022, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'JAK1 (ENSG00000162434)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.166 | Q17 | What gene does the drug Moxetumomab Pasudotox target? | The drug Moxetumomab Pasudotox targets 2 genes: EEF2 and CD22. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%moxetumomab pasudotox%" OR LOWER(tradeNames_string) LIKE "%moxetumomab pasudotox%" OR LOWER(drugSynonyms_string) LIKE "%moxetumomab pasudotox%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1477', 'drugName': 'Moxetumomab Pasudotox', 'tradeNames_string': 'Lumoxiti', 'drugSynonyms_string': 'CAT-8015, HA-22, HA22, Moxetumomab pasudotox, Moxetumomab pasudotox tdfk, Moxetumomab pasudotox-tdfk', 'linkedDiseasesDrug_string': 'Non-Hodgkins Lymphoma (EFO_0005952), Chronic Lymphocytic Leukemia (EFO_0000095), Neoplasm (EFO_0000616), Leukemia (EFO_0000565), Acute Lymphoblastic Leukemia (EFO_0000220), Lymphoma (EFO_0000574), Childhood Acute Lymphoblastic Leukemia (MONDO_0000870), Hairy Cell Leukemia (EFO_1000956)', 'yearOfFirstApproval': 2018, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CD22 (ENSG00000012124), EEF2 (ENSG00000167658)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_1478', 'drugName': 'Moxetumomab Pasudotox', 'tradeNames_string': 'Lumoxiti', 'drugSynonyms_string': 'CAT-8015, HA-22, HA22, Moxetumomab pasudotox, Moxetumomab pasudotox tdfk, Moxetumomab pasudotox-tdfk', 'linkedDiseasesDrug_string': 'Non-Hodgkins Lymphoma (EFO_0005952), Chronic Lymphocytic Leukemia (EFO_0000095), Neoplasm (EFO_0000616), Leukemia (EFO_0000565), Acute Lymphoblastic Leukemia (EFO_0000220), Lymphoma (EFO_0000574), Childhood Acute Lymphoblastic Leukemia (MONDO_0000870), Hairy Cell Leukemia (EFO_1000956)', 'yearOfFirstApproval': 2018, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CD22 (ENSG00000012124), EEF2 (ENSG00000167658)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.206 | Q17 | What gene does the drug Memantine target? | The drug Memantine targets 7 genes: GRIN2B, GRIN2A, GRIN3A, GRIN2D, GRIN3B, GRIN1 and GRIN2C. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%memantine%" OR LOWER(tradeNames_string) LIKE "%memantine%" OR LOWER(drugSynonyms_string) LIKE "%memantine%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2817', 'drugName': 'Memantine', 'tradeNames_string': '', 'drugSynonyms_string': 'D-145, DRG-0267, Memantine, NSC-757843, Namenda', 'linkedDiseasesDrug_string': 'Autism (EFO_0003758), Alzheimer Disease (MONDO_0004975), Intracranial Subdural Hematoma (EFO_1001801), Substance Abuse (MONDO_0002491), Multiple Sclerosis (MONDO_0005301), Migraine Disorder (MONDO_0005277), Pain (EFO_0003843), Obesity (EFO_0001073), Open-Angle Glaucoma (EFO_0004190), Central Nervous System Cancer (EFO_0000326), Systemic Lupus Erythematosus (MONDO_0007915), Central Nervous System Disease (EFO_0009386), Gliosarcoma (EFO_1001465), Alcohol Abuse (MONDO_0002046), Ischemic Stroke (HP_0002140), Nicotine Dependence (EFO_0003768), Fragile X Syndrome (MONDO_0010383), Huntington Disease (MONDO_0007739), Schizoaffective Disorder (EFO_0005411), Parkinson Disease (MONDO_0005180), Anxiety (EFO_0005230), Dementia (HP_0000726), Neuropathic Pain (EFO_0005762), Fibromyalgia (EFO_0005687), Cocaine Dependence (EFO_0002610), Tension-Type Headache (HP_0012228), Autism Spectrum Disorder (EFO_0003756), Heroin Dependence (EFO_0004240), Mental Deterioration (HP_0001268), Alcohol Drinking (EFO_0004329), Drug Dependence (EFO_0003890), Obsessive-Compulsive Disorder (EFO_0004242), Sickle Cell Anemia (MONDO_0011382), Hair-Pulling (HP_0012167), Brain Neoplasm (EFO_0003833), Learning Disability (MONDO_0004681), Bipolar Disorder (MONDO_0004985), Influenza (EFO_0007328), Depressive Disorder (MONDO_0002050), Alcohol Dependence (MONDO_0007079), Opioid Dependence (EFO_0005611), Gambling Behaviour (EFO_0004699), Psychosis (EFO_0005407), Frontotemporal Dementia (MONDO_0017276), Cognitive Impairment (HP_0100543), Amyotrophic Lateral Sclerosis (MONDO_0004976), Asperger Syndrome (EFO_0003757), Major Depressive Disorder (MONDO_0002009), Glioblastoma Multiforme (EFO_0000519), Schizophrenia (MONDO_0005090)', 'yearOfFirstApproval': 2003, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'GRIN1 (ENSG00000176884), GRIN2A (ENSG00000183454), GRIN2B (ENSG00000273079), GRIN2D (ENSG00000105464), GRIN3B (ENSG00000116032), GRIN2C (ENSG00000161509), GRIN3A (ENSG00000198785)', 'numberLinkedTargets': 7}, {'UUID': 'DrugGeneTargets_v2_4606', 'drugName': 'Memantine Hydrochloride', 'tradeNames_string': 'Akatinol, Ebixa, Marixino, Memantine, Memantine hydrochloride, Namenda, Namenda xr, Nemdatine, Valios', 'drugSynonyms_string': 'Acrescent, Auxura, Balaxur, FP-01, Memantine accord, Memantine hcl, Memantine hydrochloride, Memantine lek, Memantine merz, Memantine mylan, Memantine ratiopharm, Memary, NSC-102290, SUN-Y7017', 'linkedDiseasesDrug_string': 'Autism (EFO_0003758), Gliosarcoma (EFO_1001465), Intracranial Subdural Hematoma (EFO_1001801), Alzheimer Disease (MONDO_0004975), Frontotemporal Dementia (MONDO_0017276), Amyotrophic Lateral Sclerosis (MONDO_0004976), Asperger Syndrome (EFO_0003757), Sickle Cell Anemia (MONDO_0011382), Dementia (HP_0000726), Central Nervous System Cancer (EFO_0000326), Learning Disability (MONDO_0004681), Brain Neoplasm (EFO_0003833), Influenza (EFO_0007328), Gambling Behaviour (EFO_0004699)', 'yearOfFirstApproval': 2003, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'GRIN1 (ENSG00000176884), GRIN2A (ENSG00000183454), GRIN2B (ENSG00000273079), GRIN2D (ENSG00000105464), GRIN3B (ENSG00000116032), GRIN2C (ENSG00000161509), GRIN3A (ENSG00000198785)', 'numberLinkedTargets': 7}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1571 | Q17 | What gene does the drug Cer-002 target? | The drug Cer-002 is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene PPARD. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%cer-002%" OR LOWER(tradeNames_string) LIKE "%cer-002%" OR LOWER(drugSynonyms_string) LIKE "%cer-002%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_300', 'drugName': 'Cer-002', 'tradeNames_string': '', 'drugSynonyms_string': 'Cer-002', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 1, 'drugIsApproved': False, 'newLinkedTargets_string': 'PPARD (ENSG00000112033)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1641 | Q17 | What gene does the drug Methsuximide target? | The drug Methsuximide targets 3 genes: CACNA1G, CACNA1I and CACNA1H. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%methsuximide%" OR LOWER(tradeNames_string) LIKE "%methsuximide%" OR LOWER(drugSynonyms_string) LIKE "%methsuximide%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4085', 'drugName': 'Methsuximide', 'tradeNames_string': 'Celontin', 'drugSynonyms_string': 'Mesuximide, Methsuximide, NSC-760075', 'linkedDiseasesDrug_string': 'Epilepsy (EFO_0000474), Seizure (HP_0001250)', 'yearOfFirstApproval': 1957, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CACNA1H (ENSG00000196557), CACNA1G (ENSG00000006283), CACNA1I (ENSG00000100346)', 'numberLinkedTargets': 3}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1565 | Q17 | What gene does the drug Carbachol target? | The drug Carbachol targets the gene CHRM3. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%carbachol%" OR LOWER(tradeNames_string) LIKE "%carbachol%" OR LOWER(drugSynonyms_string) LIKE "%carbachol%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_990', 'drugName': 'Carbachol', 'tradeNames_string': '', 'drugSynonyms_string': 'Carbachol, Carbastat, Miostat', 'linkedDiseasesDrug_string': 'Cataract (MONDO_0005129), Presbyopia (MONDO_0001330), Miosis (HP_0000616), Glaucoma (MONDO_0005041)', 'yearOfFirstApproval': 1972, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CHRM3 (ENSG00000133019)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_4597', 'drugName': 'Carbachol', 'tradeNames_string': 'Carbachol, Carbastat, Doryl, Miostat', 'drugSynonyms_string': 'Carbachol, Carbachol chloride, Carbacholine Chloride, Carbacholine chloride, Carbamoylcholine chloride, NSC-32865', 'linkedDiseasesDrug_string': 'Cataract (MONDO_0005129), Presbyopia (MONDO_0001330), Miosis (HP_0000616), Glaucoma (MONDO_0005041)', 'yearOfFirstApproval': 1972, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CHRM3 (ENSG00000133019)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.491 | Q17 | What gene does the drug Bms-911543 target? | The drug Bms-911543 is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene JAK2. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%bms-911543%" OR LOWER(tradeNames_string) LIKE "%bms-911543%" OR LOWER(drugSynonyms_string) LIKE "%bms-911543%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_691', 'drugName': 'Bms-911543', 'tradeNames_string': '', 'drugSynonyms_string': 'Bms-911543, JAK2 INHIBITOR BMS-911543', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'JAK2 (ENSG00000096968)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1966 | Q17 | What gene does the drug Guanethidine target? | The drug Guanethidine targets the gene SLC6A2. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%guanethidine%" OR LOWER(tradeNames_string) LIKE "%guanethidine%" OR LOWER(drugSynonyms_string) LIKE "%guanethidine%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4086', 'drugName': 'Guanethidine', 'tradeNames_string': '', 'drugSynonyms_string': 'Esimil, Guanethidine, Ismelin', 'linkedDiseasesDrug_string': 'Hypertension (EFO_0000537), Glaucoma (MONDO_0005041)', 'yearOfFirstApproval': 1960, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SLC6A2 (ENSG00000103546)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_2340', 'drugName': 'Guanethidine Monosulfate', 'tradeNames_string': 'Ganda, Guanethidine monosulfate, Ismelin, Ismeline, Lotens', 'drugSynonyms_string': 'Guanethidine monosulfate, Guanethidine monosulphate', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1960, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SLC6A2 (ENSG00000103546)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1800 | Q17 | What gene does the drug Cobicistat target? | The drug Cobicistat targets 4 genes: CYP3A43, CYP3A5, CYP3A4 and CYP3A7. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%cobicistat%" OR LOWER(tradeNames_string) LIKE "%cobicistat%" OR LOWER(drugSynonyms_string) LIKE "%cobicistat%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4493', 'drugName': 'Cobicistat', 'tradeNames_string': 'Tybost', 'drugSynonyms_string': 'Cobicistat, Cobicistat on silicon dioxide, Cobicistat, (r,r,s)-, GS-9350', 'linkedDiseasesDrug_string': 'Insulin Resistance (EFO_0002614), Infection (EFO_0000544), Hiv Infection (EFO_0000764), Non-Small Cell Lung Carcinoma (EFO_0003060), Covid-19 (MONDO_0100096), Acute Lymphoblastic Leukemia (EFO_0000220), Hiv-1 Infection (EFO_0000180), Pancreatic Ductal Adenocarcinoma (EFO_0002517), Aids (EFO_0000765), Pneumocystosis (EFO_0007448), Malaria (EFO_0001068)', 'yearOfFirstApproval': 2012, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CYP3A4 (ENSG00000160868), CYP3A5 (ENSG00000106258), CYP3A43 (ENSG00000021461), CYP3A7 (ENSG00000160870)', 'numberLinkedTargets': 4}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1330 | Q17 | What gene does the drug Triflupromazine Hydrochloride target? | The drug Triflupromazine Hydrochloride targets the gene DRD2. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%triflupromazine hydrochloride%" OR LOWER(tradeNames_string) LIKE "%triflupromazine hydrochloride%" OR LOWER(drugSynonyms_string) LIKE "%triflupromazine hydrochloride%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4009', 'drugName': 'Triflupromazine Hydrochloride', 'tradeNames_string': 'Vesprin', 'drugSynonyms_string': 'MC-4703, NSC-14959, NSC-17473, Triflupromazine hcl, Triflupromazine hydrochloride', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1957, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'DRD2 (ENSG00000149295)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.285 | Q17 | What gene does the drug Eprosartan target? | The drug Eprosartan targets the gene AGTR1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%eprosartan%" OR LOWER(tradeNames_string) LIKE "%eprosartan%" OR LOWER(drugSynonyms_string) LIKE "%eprosartan%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5954', 'drugName': 'Eprosartan', 'tradeNames_string': 'Teveten', 'drugSynonyms_string': 'Eprosartan, SK&F 108566, SK&F-108566, SK-108566, Teveten', 'linkedDiseasesDrug_string': 'Kidney Disease (EFO_0003086), Hypertension (EFO_0000537), Cardiovascular Disease (EFO_0000319), Essential Hypertension (MONDO_0001134)', 'yearOfFirstApproval': 1997, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'AGTR1 (ENSG00000144891)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_5528', 'drugName': 'Eprosartan Mesylate', 'tradeNames_string': 'Eprosartan mesylate, Teveten', 'drugSynonyms_string': 'Eprosartan mesilate, Eprosartan mesylate, Eprosartan monomethanesulfonate, SK&F 108566-J, SK&F-108566-J', 'linkedDiseasesDrug_string': 'Hypertension (EFO_0000537), Essential Hypertension (MONDO_0001134)', 'yearOfFirstApproval': 1997, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'AGTR1 (ENSG00000144891)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1375 | Q17 | What gene does the drug Midodrine Hydrochloride target? | The drug Midodrine Hydrochloride targets 3 genes: ADRA1D, ADRA1B and ADRA1A. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%midodrine hydrochloride%" OR LOWER(tradeNames_string) LIKE "%midodrine hydrochloride%" OR LOWER(drugSynonyms_string) LIKE "%midodrine hydrochloride%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5117', 'drugName': 'Midodrine Hydrochloride', 'tradeNames_string': 'Bramox, Gutron, Midodrine hydrochloride, Midon, Orvaten, Proamatine', 'drugSynonyms_string': 'A-4020 LINZ, Amatine, Hipertan, Metligine, Midodrine hcl, Midodrine hydrochloride, Midodrine monohydrochloride, NSC-758429, ST 1085 HYDROCHLORIDE, ST 1085 [AS THE BASE], ST-1085, ST-1085 BASE, ST-1085 HYDROCHLORIDE, ST-PETER-224, ST. PETER 224, ST1085 HYDROCHLORIDE', 'linkedDiseasesDrug_string': 'Septic Shock (EFO_0006834), Stroke (EFO_0000712), Orthostatic Hypotension (EFO_0005252), Sepsis (HP_0100806)', 'yearOfFirstApproval': 1996, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ADRA1A (ENSG00000120907), ADRA1D (ENSG00000171873), ADRA1B (ENSG00000170214)', 'numberLinkedTargets': 3}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.221 | Q17 | What gene does the drug Testosterone Enanthate target? | The drug Testosterone Enanthate targets the gene AR. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%testosterone enanthate%" OR LOWER(tradeNames_string) LIKE "%testosterone enanthate%" OR LOWER(drugSynonyms_string) LIKE "%testosterone enanthate%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5959', 'drugName': 'Testosterone Enanthate', 'tradeNames_string': 'Delatestryl, Primoteston depot, Testosterone enanthate, Xyosted (autoinjector)', 'drugSynonyms_string': 'Androtardyl, NSC-17591, Testosterone enantate, Testosterone enanthate, Testosterone enanthate ciii, Testosterone heptanoate, Testosteroni enantas, Xyosted', 'linkedDiseasesDrug_string': 'Hypogonadism (MONDO_0002146), Prostate Cancer (MONDO_0008315), Hypogonadotropic Hypogonadism (HP_0000044), Metastatic Prostate Cancer (EFO_0000196), Chronic Obstructive Pulmonary Disease (EFO_0000341), Weight Loss (HP_0001824), Hiv Wasting Syndrome (EFO_0007312), Facioscapulohumeral Dystrophy (Orphanet_269), Prostate Adenocarcinoma (EFO_0000673)', 'yearOfFirstApproval': 1953, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'AR (ENSG00000169083)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1931 | Q17 | What gene does the drug Nilotinib Hydrochloride Monohydrate target? | The drug Nilotinib Hydrochloride Monohydrate targets 2 genes: BCR and ABL1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%nilotinib hydrochloride monohydrate%" OR LOWER(tradeNames_string) LIKE "%nilotinib hydrochloride monohydrate%" OR LOWER(drugSynonyms_string) LIKE "%nilotinib hydrochloride monohydrate%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_435', 'drugName': 'Nilotinib Hydrochloride Monohydrate', 'tradeNames_string': 'Tasigna', 'drugSynonyms_string': 'Nilotinib (as hydrochloride), Nilotinib Hydrochloride Monohydrate, Nilotinib hydrochloride, Nilotinib hydrochloride anhydrous, Nilotinib hydrochloride hydrate, Nilotinib hydrochloride monohydrate', 'linkedDiseasesDrug_string': 'Systemic Scleroderma (EFO_0000717), Chronic Myelogenous Leukemia (EFO_0000339), Breast Cancer (MONDO_0007254), Parkinson Disease (MONDO_0005180)', 'yearOfFirstApproval': 2007, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ABL1 (ENSG00000097007), BCR (ENSG00000186716)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_436', 'drugName': 'Nilotinib Hydrochloride Monohydrate', 'tradeNames_string': 'Tasigna', 'drugSynonyms_string': 'Nilotinib (as hydrochloride), Nilotinib Hydrochloride Monohydrate, Nilotinib hydrochloride, Nilotinib hydrochloride anhydrous, Nilotinib hydrochloride hydrate, Nilotinib hydrochloride monohydrate', 'linkedDiseasesDrug_string': 'Systemic Scleroderma (EFO_0000717), Chronic Myelogenous Leukemia (EFO_0000339), Breast Cancer (MONDO_0007254), Parkinson Disease (MONDO_0005180)', 'yearOfFirstApproval': 2007, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ABL1 (ENSG00000097007), BCR (ENSG00000186716)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.888 | Q17 | What gene does the drug Telotristat Etiprate target? | The drug Telotristat Etiprate targets 2 genes: TPH2 and TPH1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%telotristat etiprate%" OR LOWER(tradeNames_string) LIKE "%telotristat etiprate%" OR LOWER(drugSynonyms_string) LIKE "%telotristat etiprate%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1064', 'drugName': 'Telotristat Etiprate', 'tradeNames_string': 'Xermelo', 'drugSynonyms_string': 'LX1032 HIPPURATE, LX1606 HIPPURATE, Telotristat ethyl hippurate, Telotristat etiprate', 'linkedDiseasesDrug_string': 'Diarrhea (HP_0002014)', 'yearOfFirstApproval': 2017, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'TPH2 (ENSG00000139287), TPH1 (ENSG00000129167)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1623 | Q17 | What gene does the drug Chlorpromazine Hydrochloride target? | The drug Chlorpromazine Hydrochloride targets 4 genes: DRD3, HTR2A, DRD4 and DRD2. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%chlorpromazine hydrochloride%" OR LOWER(tradeNames_string) LIKE "%chlorpromazine hydrochloride%" OR LOWER(drugSynonyms_string) LIKE "%chlorpromazine hydrochloride%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2783', 'drugName': 'Chlorpromazine Hydrochloride', 'tradeNames_string': 'Chloractil, Chlorazine, Chlorpromazine hydrochloride, Chlorpromazine hydrochloride intensol, Largactil, Largactil fte, Promapar, Rimazine, Sonazine, Thorazine', 'drugSynonyms_string': 'Chlorpromazine HCl, Chlorpromazine hcl, Chlorpromazine hydrochloride, Chlorpromazini hydrochloridum, Klorproman, Marazine, NSC-17479, Nci-c05210, Norcozine', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1957, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'DRD2 (ENSG00000149295), DRD3 (ENSG00000151577), DRD4 (ENSG00000069696), HTR2A (ENSG00000102468)', 'numberLinkedTargets': 4}, {'UUID': 'DrugGeneTargets_v2_2784', 'drugName': 'Chlorpromazine Hydrochloride', 'tradeNames_string': 'Chloractil, Chlorazine, Chlorpromazine hydrochloride, Chlorpromazine hydrochloride intensol, Largactil, Largactil fte, Promapar, Rimazine, Sonazine, Thorazine', 'drugSynonyms_string': 'Chlorpromazine HCl, Chlorpromazine hcl, Chlorpromazine hydrochloride, Chlorpromazini hydrochloridum, Klorproman, Marazine, NSC-17479, Nci-c05210, Norcozine', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1957, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'DRD2 (ENSG00000149295), DRD3 (ENSG00000151577), DRD4 (ENSG00000069696), HTR2A (ENSG00000102468)', 'numberLinkedTargets': 4}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.701 | Q17 | What gene does the drug Pf-4136309 target? | The drug Pf-4136309 is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene CCR2. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%pf-4136309%" OR LOWER(tradeNames_string) LIKE "%pf-4136309%" OR LOWER(drugSynonyms_string) LIKE "%pf-4136309%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2719', 'drugName': 'Pf-4136309', 'tradeNames_string': '', 'drugSynonyms_string': 'INCB-8761, INCB8761, PF-04136309, PF-4136309, Pf-04136309, Pf-4136309', 'linkedDiseasesDrug_string': 'Pancreatic Ductal Adenocarcinoma (EFO_0002517), Chronic Hepatitis C Virus Infection (EFO_0004220), Pancreatic Neoplasm (EFO_0003860), Osteoarthritis, Knee (EFO_0004616)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'CCR2 (ENSG00000121807)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.61 | Q17 | What gene does the drug Estrone target? | The drug Estrone targets the gene ESR1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%estrone%" OR LOWER(tradeNames_string) LIKE "%estrone%" OR LOWER(drugSynonyms_string) LIKE "%estrone%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2018', 'drugName': 'Estrone Sulfuric Acid', 'tradeNames_string': '', 'drugSynonyms_string': 'Estrone Sulphate', 'linkedDiseasesDrug_string': 'Osteoporosis (EFO_0003882), Hypogonadism (MONDO_0002146), Menopause (EFO_0003922), Atrophy (EFO_1000096), Primary Ovarian Insufficiency (EFO_0004266)', 'yearOfFirstApproval': 1977, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ESR1 (ENSG00000091831)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_4799', 'drugName': 'Progesterone', 'tradeNames_string': 'Crinone, Cyclogest, Endometrin, Gesterol, Lutigest, Milprosa, Prochieve, Progesta-care, Progestasert, Progesterone, Progestin, Prometrium, Regumate, Serenity for women, Syngestrone, Utrogestan', 'drugSynonyms_string': 'NSC-64377, NSC-9704, Progesterone, Progesterone, micronized, Progesteronum, U 3672', 'linkedDiseasesDrug_string': 'Diabetes Mellitus (EFO_0000400), Alzheimer Disease (MONDO_0004975), Coronary Artery Disease (EFO_0001645), Hemorrhage (MP_0001914), Covid-19 (MONDO_0100096), Uterine Fibroid (EFO_0000731), Cannabis Dependence (EFO_0007191), Ovarian Hyperstimulation Syndrome (MONDO_0011972), Placenta Praevia (EFO_0007442), Endometrial Cancer (MONDO_0011962), Pregnancy (EFO_0002950), Anorexia Nervosa (MONDO_0005351), Myocardial Ischemia (EFO_1001375), Breast Neoplasm (EFO_0003869), Osteopenia (HP_0000938), Polycystic Ovary Syndrome (EFO_0000660), Gliosarcoma (EFO_1001465), Postpartum Depression (EFO_0007453), Preeclampsia (EFO_0000668), Breast Cancer (MONDO_0007254), Vulvar Lichen Sclerosus (EFO_1000623), Nicotine Dependence (EFO_0003768), Osteoporosis (EFO_0003882), Hypertension (EFO_0000537), Thrombotic Disease (MONDO_0000831), Intermediate Coronary Syndrome (EFO_1000985), Amenorrhea (EFO_0010269), Epilepsy (EFO_0000474), Cocaine Dependence (EFO_0002610), Methamphetamine Dependence (EFO_0004701), Memory Impairment (EFO_0001072), Cervical Intraepithelial Neoplasia (MONDO_0022394), Premature Birth (EFO_0003917), Menopause (EFO_0003922), Orthostatic Intolerance (EFO_1000645), Infertility (EFO_0000545), Hypercholesterolemia (HP_0003124), Hiv-1 Infection (EFO_0000180), Brain Injury (MONDO_0043510), Ovarian Neoplasm (EFO_0003893), Female Infertility (EFO_0008560), Bulimia Nervosa (EFO_0005204), Type 1 Diabetes Mellitus (MONDO_0005147)', 'yearOfFirstApproval': 1976, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'PGR (ENSG00000082175)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_3573', 'drugName': 'Estrone', 'tradeNames_string': 'Estrogenic substance, Estrone, Natural estrogenic substance-estrone, Oestrone, Theelin', 'drugSynonyms_string': '1,3,5-estratrien-3-ol-17-one, Estradiol metabolite e1, Estrone, Follicular hormone, Follicular-hormone, Folliculin, Folliculinum, Ketohydroxyestrin, NSC-9699, Oestrone, Theelin, Thelykinin, Tokokin, WAY 164397', 'linkedDiseasesDrug_string': 'Obesity (EFO_0001073), Premenstrual Tension (MONDO_0004169)', 'yearOfFirstApproval': 1979, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ESR1 (ENSG00000091831)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_2257', 'drugName': 'Estropipate', 'tradeNames_string': 'Estropipate, Harmogen, Ogen, Ogen .625, Ogen 1.25, Ogen 2.5, Ogen 5, Ortho-est', 'drugSynonyms_string': 'Estrone sulfate piperazine salt, Estropipate, NSC-758912, Piperazine estrone sulfate, Piperazine estrone sulphate, Sulestrex piperazine', 'linkedDiseasesDrug_string': 'Osteoporosis (EFO_0003882), Hypogonadism (MONDO_0002146), Menopause (EFO_0003922), Atrophy (EFO_1000096), Primary Ovarian Insufficiency (EFO_0004266)', 'yearOfFirstApproval': 1977, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ESR1 (ENSG00000091831)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.843 | Q17 | What gene does the drug Ladiratuzumab Vedotin target? | The drug Ladiratuzumab Vedotin is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target 16 genes: TUBB, TUBA4A, TUBA3E, TUBB3, TUBB4B, TUBB2A, TUBA1A, TUBA1C, TUBB1, TUBB2B, TUBB8, TUBB6, TUBB4A, TUBA3C, SLC39A6 and TUBA1B | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%ladiratuzumab vedotin%" OR LOWER(tradeNames_string) LIKE "%ladiratuzumab vedotin%" OR LOWER(drugSynonyms_string) LIKE "%ladiratuzumab vedotin%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2652', 'drugName': 'Ladiratuzumab Vedotin', 'tradeNames_string': '', 'drugSynonyms_string': 'Ladiratuzumab vedotin, SGN-LIV1A, Sgn-liv1a', 'linkedDiseasesDrug_string': 'Breast Neoplasm (EFO_0003869), Angiosarcoma (EFO_0003968), Breast Cancer (MONDO_0007254), Triple-Negative Breast Cancer (EFO_0005537)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014), SLC39A6 (ENSG00000141424)', 'numberLinkedTargets': 16}, {'UUID': 'DrugGeneTargets_v2_2653', 'drugName': 'Ladiratuzumab Vedotin', 'tradeNames_string': '', 'drugSynonyms_string': 'Ladiratuzumab vedotin, SGN-LIV1A, Sgn-liv1a', 'linkedDiseasesDrug_string': 'Breast Neoplasm (EFO_0003869), Angiosarcoma (EFO_0003968), Breast Cancer (MONDO_0007254), Triple-Negative Breast Cancer (EFO_0005537)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014), SLC39A6 (ENSG00000141424)', 'numberLinkedTargets': 16}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1356 | Q17 | What gene does the drug Emactuzumab target? | The drug Emactuzumab is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene CSF1R. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%emactuzumab%" OR LOWER(tradeNames_string) LIKE "%emactuzumab%" OR LOWER(drugSynonyms_string) LIKE "%emactuzumab%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5215', 'drugName': 'Emactuzumab', 'tradeNames_string': '', 'drugSynonyms_string': '7i1955n5wx, CXD-301, CXD301, Emactuzumab, RG-7155, RG7155, RO-5509554, RO5509554, RO5509554 (ANTI-CSF-R1)', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Giant Cell Tumor (MONDO_0002171), Non-Hodgkins Lymphoma (EFO_0005952), Neoplasm (EFO_0000616)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 3, 'drugIsApproved': False, 'newLinkedTargets_string': 'CSF1R (ENSG00000182578)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.76 | Q17 | What gene does the drug Ethoxzolamide target? | The drug Ethoxzolamide targets 12 genes: CA5B, CA4, CA6, CA1, CA13, CA2, CA7, CA9, CA12, CA3, CA14 and CA5A. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%ethoxzolamide%" OR LOWER(tradeNames_string) LIKE "%ethoxzolamide%" OR LOWER(drugSynonyms_string) LIKE "%ethoxzolamide%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3089', 'drugName': 'Ethoxzolamide', 'tradeNames_string': 'Cardrase, Ethamide', 'drugSynonyms_string': 'Ethoxzolamide, NSC-10679', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1982, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CA2 (ENSG00000104267), CA7 (ENSG00000168748), CA1 (ENSG00000133742), CA3 (ENSG00000164879), CA6 (ENSG00000131686), CA12 (ENSG00000074410), CA14 (ENSG00000118298), CA9 (ENSG00000107159), CA4 (ENSG00000167434), CA13 (ENSG00000185015), CA5B (ENSG00000169239), CA5A (ENSG00000174990)', 'numberLinkedTargets': 12}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.165 | Q17 | What gene does the drug Gsk-461364 target? | The drug Gsk-461364 is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene PLK1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%gsk-461364%" OR LOWER(tradeNames_string) LIKE "%gsk-461364%" OR LOWER(drugSynonyms_string) LIKE "%gsk-461364%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2668', 'drugName': 'Gsk-461364', 'tradeNames_string': '', 'drugSynonyms_string': 'GSK-461364A, Gsk 461364, Gsk-461364', 'linkedDiseasesDrug_string': 'Non-Hodgkins Lymphoma (EFO_0005952)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 1, 'drugIsApproved': False, 'newLinkedTargets_string': 'PLK1 (ENSG00000166851)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.576 | Q17 | What gene does the drug Diflorasone Diacetate target? | The drug Diflorasone Diacetate targets the gene NR3C1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%diflorasone diacetate%" OR LOWER(tradeNames_string) LIKE "%diflorasone diacetate%" OR LOWER(drugSynonyms_string) LIKE "%diflorasone diacetate%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4747', 'drugName': 'Diflorasone Diacetate', 'tradeNames_string': 'Diflorasone diacetate, Florone, Florone e, Psorcon, Psorcon e', 'drugSynonyms_string': 'Diflorasone, Diflorasone diacetate, Murode, U-34,865, U-34865', 'linkedDiseasesDrug_string': 'Skin Disease (EFO_0000701)', 'yearOfFirstApproval': 1977, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'NR3C1 (ENSG00000113580)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.959 | Q17 | What gene does the drug Halazepam target? | The drug Halazepam targets 16 genes: GABRG2, GABRE, GABRA4, GABRQ, GABRD, GABRA3, GABRP, GABRA5, GABRG3, GABRB2, GABRB3, GABRG1, GABRA2, GABRB1, GABRA6 and GABRA1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%halazepam%" OR LOWER(tradeNames_string) LIKE "%halazepam%" OR LOWER(drugSynonyms_string) LIKE "%halazepam%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4122', 'drugName': 'Halazepam', 'tradeNames_string': 'Paxipam', 'drugSynonyms_string': 'Halazepam, Halazepam civ, SCH 12041, SCH-12041', 'linkedDiseasesDrug_string': 'Anxiety (EFO_0005230)', 'yearOfFirstApproval': 1981, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863)', 'numberLinkedTargets': 16}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1540 | Q17 | What gene does the drug Sarilumab target? | The drug Sarilumab targets the gene IL6R. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%sarilumab%" OR LOWER(tradeNames_string) LIKE "%sarilumab%" OR LOWER(drugSynonyms_string) LIKE "%sarilumab%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3005', 'drugName': 'Sarilumab', 'tradeNames_string': 'Kevzara', 'drugSynonyms_string': 'REG-N88, REGN-88, REGN88, SAR-153191, SAR153191, Sarilumab', 'linkedDiseasesDrug_string': 'Uveitis (EFO_1001231), Localised Scleroderma (EFO_1001361), Temporal Arteritis (EFO_1001209), Immune System Disease (EFO_0000540), Pneumonia (EFO_0003106), Juvenile Idiopathic Arthritis (EFO_0002609), Ankylosing Spondylitis (EFO_0003898), Covid-19 (MONDO_0100096), Melanoma (EFO_0000756), Rheumatoid Arthritis (EFO_0000685), Systemic Mastocytosis (MONDO_0016586), Influenza (EFO_0007328), Polymyalgia Rheumatica (EFO_0008518), Severe Acute Respiratory Syndrome (EFO_0000694)', 'yearOfFirstApproval': 2017, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'IL6R (ENSG00000160712)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1046 | Q17 | What gene does the drug Perindopril Erbumine target? | The drug Perindopril Erbumine targets the gene ACE. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%perindopril erbumine%" OR LOWER(tradeNames_string) LIKE "%perindopril erbumine%" OR LOWER(drugSynonyms_string) LIKE "%perindopril erbumine%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1718', 'drugName': 'Perindopril Erbumine', 'tradeNames_string': 'Aceon, Coversyl, Perindopril erbumine', 'drugSynonyms_string': 'MCN-A-2833-109, NSC-758929, Perindopril erbumine, Perindopril tert-butylamine, S-9490-3', 'linkedDiseasesDrug_string': 'Coronary Artery Disease (EFO_0001645), Hypertension (EFO_0000537), Essential Hypertension (MONDO_0001134)', 'yearOfFirstApproval': 1993, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ACE (ENSG00000159640)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1706 | Q17 | What gene does the drug Daclizumab target? | The drug Daclizumab targets 3 genes: IL2RA, IL2RB and IL2RG. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%daclizumab%" OR LOWER(tradeNames_string) LIKE "%daclizumab%" OR LOWER(drugSynonyms_string) LIKE "%daclizumab%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5681', 'drugName': 'Daclizumab', 'tradeNames_string': 'Zenapax, Zinbryta', 'drugSynonyms_string': 'Daclizumab, Daclizumab beta, RO 24-7375, RO-24-7375', 'linkedDiseasesDrug_string': 'Diabetes Mellitus (EFO_0000400), Psoriasis (EFO_0000676), Multiple Myeloma (EFO_0001378), Pure Red Cell Aplasia (HP_0012410), Multiple Sclerosis (MONDO_0005301), Graft Versus Host Disease (MONDO_0013730), Wet Macular Degeneration (EFO_0004683), Pure Red-Cell Aplasia (MONDO_0001705), Myelodysplastic Syndrome (EFO_0000198), Ulcerative Colitis (EFO_0000729), Uveitis (EFO_1001231), Lymphoma (EFO_0000574), Relapsing-Remitting Multiple Sclerosis (EFO_0003929), Aplastic Anemia (HP_0001915), Granulomatosis With Polyangiitis (EFO_0005297), Immune System Disease (EFO_0000540), Thrombocytopenia (HP_0001873), Asthma (MONDO_0004979), 22Q11.2 Deletion Syndrome (MONDO_0018923), Chronic Kidney Disease (EFO_0003884), Hiv Infection (EFO_0000764), Neoplasm (EFO_0000616), Leukemia (EFO_0000565), Melanoma (EFO_0000756), Kidney Disease (EFO_0003086), Type 1 Diabetes Mellitus (MONDO_0005147)', 'yearOfFirstApproval': 1997, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'IL2RA (ENSG00000134460), IL2RG (ENSG00000147168), IL2RB (ENSG00000100385)', 'numberLinkedTargets': 3}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.513 | Q17 | What gene does the drug Norethynodrel target? | The drug Norethynodrel targets the gene PGR. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%norethynodrel%" OR LOWER(tradeNames_string) LIKE "%norethynodrel%" OR LOWER(drugSynonyms_string) LIKE "%norethynodrel%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1815', 'drugName': 'Norethynodrel', 'tradeNames_string': '', 'drugSynonyms_string': 'Enidrel, NSC-15432, Norethynodrel, Noretynodrel, SC-4642', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1961, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'PGR (ENSG00000082175)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.46 | Q17 | What gene does the drug Mepivacaine Hydrochloride target? | The drug Mepivacaine Hydrochloride targets 10 genes: SCN1A, SCN9A, SCN7A, SCN8A, SCN11A, SCN10A, SCN2A, SCN5A, SCN4A and SCN3A. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%mepivacaine hydrochloride%" OR LOWER(tradeNames_string) LIKE "%mepivacaine hydrochloride%" OR LOWER(drugSynonyms_string) LIKE "%mepivacaine hydrochloride%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5592', 'drugName': 'Mepivacaine Hydrochloride', 'tradeNames_string': 'Arestocaine hydrochloride, Carbocaine, Isocaine hydrochloride, Mepivacaine hydrochloride, Polocaine, Polocaine-mpf, Scandicaine, Scandonest, Scandonest plain', 'drugSynonyms_string': 'Mepivacaine hcl, Mepivacaine hydrochloride, Mepivacaine monohydrochloride, NSC-758674, Optocain, Scandicain', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1960, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SCN1A (ENSG00000144285), SCN5A (ENSG00000183873), SCN4A (ENSG00000007314), SCN7A (ENSG00000136546), SCN2A (ENSG00000136531), SCN9A (ENSG00000169432), SCN3A (ENSG00000153253), SCN11A (ENSG00000168356), SCN8A (ENSG00000196876), SCN10A (ENSG00000185313)', 'numberLinkedTargets': 10}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.946 | Q17 | What gene does the drug Fk453 target? | The drug Fk453 is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene ADORA1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%fk453%" OR LOWER(tradeNames_string) LIKE "%fk453%" OR LOWER(drugSynonyms_string) LIKE "%fk453%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_508', 'drugName': 'Fk453', 'tradeNames_string': '', 'drugSynonyms_string': 'FK-453, Fk453', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 1, 'drugIsApproved': False, 'newLinkedTargets_string': 'ADORA1 (ENSG00000163485)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.366 | Q17 | What gene does the drug Fluorouracil target? | The drug Fluorouracil targets the gene TYMS. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%fluorouracil%" OR LOWER(tradeNames_string) LIKE "%fluorouracil%" OR LOWER(drugSynonyms_string) LIKE "%fluorouracil%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1558', 'drugName': 'Fluorouracil', 'tradeNames_string': '5.f.u., Accusite, Actikerall, Adrucil, Carac, Efudex, Efudix, Fluoro-uracil roche, Fluoroplex, Fluorouracil, Tolak', 'drugSynonyms_string': '5 FU, 5-FU, 5-Fluorouracil, 5-fluoruracil, Fluorouracil, Fluorouracilum, Fluorouricil, Fluracil, NSC-19893, Phthoruracil, Queroplex, RO 2-9757, RO-2-9757, RO-29757', 'linkedDiseasesDrug_string': 'Ovarian Carcinoma (EFO_0001075), Multiple Myeloma (EFO_0001378), Keratosis (EFO_1000720), Malignant Colon Neoplasm (MONDO_0021063), Signet Ring Cell Carcinoma (EFO_0000698), Inflammatory Breast Carcinoma (EFO_1000984), Neuroendocrine Neoplasm (EFO_1001901), Urinary Bladder Carcinoma (MONDO_0004986), Pharynx Cancer (EFO_0005577), Carcinoma (EFO_0000313), Liver Cancer (MONDO_0002691), Cervical Cancer (MONDO_0002974), Lymphoma, Aids-Related (EFO_1001365), Anus Cancer (MONDO_0001879), Colorectal Adenocarcinoma (EFO_0000365), Cancer (MONDO_0004992), Non-Hodgkins Lymphoma (EFO_0005952), Gastrointestinal Stromal Tumor (MONDO_0011719), Central Nervous System Cancer (EFO_0000326), Myelodysplastic Syndrome (EFO_0000198), Colorectal Carcinoma (EFO_1001951), Neuroendocrine Carcinoma (MONDO_0002120), Digestive System Cancer (MONDO_0002516), Hepatocellular Carcinoma (EFO_0000182), Fallopian Tube Carcinoma (EFO_1000251), Mucinous Carcinoma (EFO_0000197), Uterine Neoplasm (EFO_0003859), Gastric Adenocarcinoma (EFO_0000503), Basal Cell Carcinoma (EFO_0004193), Gastric Carcinoma (EFO_0000178), Metastasis (EFO_0009708), Hypopharyngeal Carcinoma (EFO_0002938), Proliferative Vitreoretinopathy (EFO_1001129), Head And Neck Neoplasia (EFO_0005950), Actinic Keratosis (EFO_0002496), Oropharynx Squamous Cell Carcinoma (MONDO_0044704), Dysplasia Of Cervix (EFO_1000910), Laryngeal Neoplasm (EFO_0003817), Rectum Cancer (EFO_1000657), Merkel Cell Skin Cancer (EFO_1001471), Esophageal Squamous Cell Carcinoma (EFO_0005922), Non-Small Cell Lung Carcinoma (EFO_0003060), Colonic Neoplasm (EFO_0004288), Head And Neck Carcinoma (MONDO_0002038), Peripheral Neuropathy (EFO_0003100), Upper Aerodigestive Tract Neoplasm (EFO_0004284), Urothelial Carcinoma (EFO_0008528), Intrahepatic Cholangiocarcinoma (EFO_1001961), Glaucoma (MONDO_0005041), Hepatoblastoma (EFO_1000292), Esophageal Carcinoma (EFO_0002916), Gastric Cancer (MONDO_0001056), Gastrointestinal Disease (EFO_0010282), Ovarian Cancer (MONDO_0008170), Breast Neoplasm (EFO_0003869), Breast Cancer (MONDO_0007254), Lymphoma (EFO_0000574), Pancreatic Ductal Adenocarcinoma (EFO_0002517), Head And Neck Squamous Cell Carcinoma (EFO_0000181), Biliary Tract Cancer (MONDO_0003060), Cholangiocarcinoma (EFO_0005221), Paranasal Sinus Neoplasm (EFO_0003866), Pancreatic Carcinoma (EFO_0002618), Lynch Syndrome (MONDO_0005835), Meibomian Cyst (EFO_0007363), Colorectal Cancer (MONDO_0005575), Skin Carcinoma (EFO_0009259), Peritoneum Cancer (MONDO_0002087), Cutaneous Melanoma (EFO_0000389), Biliary Tract Neoplasm (EFO_0003891), Chronic Myeloproliferative Disorder (EFO_0002428), Neoplasm (EFO_0000616), Adenocarcinoma (EFO_0000228), Urinary Bladder Cancer (MONDO_0001187), Colon Adenocarcinoma (EFO_1001949), Laryngeal Carcinoma (MONDO_0002358), Stomach Neoplasm (EFO_0003897), Oral Cavity Cancer (EFO_0005570), Neoplasm Of Esophagus (MONDO_0021355), Peritoneal Neoplasm (EFO_1001100), Metastatic Melanoma (EFO_0002617), Anal Neoplasm (EFO_0003835), Rectal Carcinoma (MONDO_0044937), Breast Carcinoma (EFO_0000305), Bile Duct Cancer (MONDO_0003059), Colorectal Neoplasm (EFO_0004142), Thrombotic Disease (MONDO_0000831), Oral Squamous Cell Carcinoma (EFO_0000199), Pancreatic Endocrine Carcinoma (EFO_0007416), Urethra Cancer (MONDO_0004192), Renal Cell Carcinoma (EFO_0000681), Ependymoma (EFO_1000028), Digestive System Neoplasm (EFO_0008549), Anal Carcinoma (MONDO_0003199), Head And Neck Malignant Neoplasia (EFO_0006859), Squamous Cell Carcinoma (EFO_0000707), Nasopharyngeal Neoplasm (EFO_0004252), Kidney Cancer (MONDO_0002367), Melanoma (EFO_0000756), Squamous Cell Intraepithelial Neoplasia (MONDO_0024475), Pancreatic Neoplasm (EFO_0003860), Esophageal Cancer (MONDO_0007576), Bladder Tumor (EFO_0000294)', 'yearOfFirstApproval': 1962, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'TYMS (ENSG00000176890)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.540 | Q17 | What gene does the drug Tesofensine target? | The drug Tesofensine is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target 3 genes: SLC6A4, SLC6A2 and SLC6A3 | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%tesofensine%" OR LOWER(tradeNames_string) LIKE "%tesofensine%" OR LOWER(drugSynonyms_string) LIKE "%tesofensine%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5362', 'drugName': 'Tesofensine', 'tradeNames_string': '', 'drugSynonyms_string': 'NS 2330, NS-2330, Tesofensine', 'linkedDiseasesDrug_string': 'Alzheimer Disease (MONDO_0004975), Obesity (EFO_0001073), Parkinson Disease (MONDO_0005180), Prader-Willi Syndrome (MONDO_0008300), Type 2 Diabetes Mellitus (MONDO_0005148)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'SLC6A4 (ENSG00000108576), SLC6A3 (ENSG00000142319), SLC6A2 (ENSG00000103546)', 'numberLinkedTargets': 3}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.79 | Q17 | What gene does the drug Halothane target? | The drug Halothane targets 23 genes: GLRB, GABRG2, GABRA4, KCNK9, GABRB3, GABRA2, KCNK3, KCNK10, GABRA1, GLRA1, GABRE, GABRP, GABRG3, GABRB1, GABRA6, KCNK2, KCNK18, GABRA5, GABRQ, GABRD, GABRA3, GABRB2 and GABRG1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%halothane%" OR LOWER(tradeNames_string) LIKE "%halothane%" OR LOWER(drugSynonyms_string) LIKE "%halothane%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5042', 'drugName': 'Halothane', 'tradeNames_string': 'Fluothane, Halothane, Rhidialothan', 'drugSynonyms_string': 'FREON 123B1, Halothane, Halothanum, NSC-143490', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1958, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863), KCNK9 (ENSG00000169427), KCNK2 (ENSG00000082482), KCNK10 (ENSG00000100433), KCNK3 (ENSG00000171303), KCNK18 (ENSG00000186795), GLRA1 (ENSG00000145888), GLRB (ENSG00000109738)', 'numberLinkedTargets': 23}, {'UUID': 'DrugGeneTargets_v2_5040', 'drugName': 'Halothane', 'tradeNames_string': 'Fluothane, Halothane, Rhidialothan', 'drugSynonyms_string': 'FREON 123B1, Halothane, Halothanum, NSC-143490', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1958, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863), KCNK9 (ENSG00000169427), KCNK2 (ENSG00000082482), KCNK10 (ENSG00000100433), KCNK3 (ENSG00000171303), KCNK18 (ENSG00000186795), GLRA1 (ENSG00000145888), GLRB (ENSG00000109738)', 'numberLinkedTargets': 23}, {'UUID': 'DrugGeneTargets_v2_5038', 'drugName': 'Halothane', 'tradeNames_string': 'Fluothane, Halothane, Rhidialothan', 'drugSynonyms_string': 'FREON 123B1, Halothane, Halothanum, NSC-143490', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1958, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863), KCNK9 (ENSG00000169427), KCNK2 (ENSG00000082482), KCNK10 (ENSG00000100433), KCNK3 (ENSG00000171303), KCNK18 (ENSG00000186795), GLRA1 (ENSG00000145888), GLRB (ENSG00000109738)', 'numberLinkedTargets': 23}, {'UUID': 'DrugGeneTargets_v2_5037', 'drugName': 'Halothane', 'tradeNames_string': 'Fluothane, Halothane, Rhidialothan', 'drugSynonyms_string': 'FREON 123B1, Halothane, Halothanum, NSC-143490', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1958, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863), KCNK9 (ENSG00000169427), KCNK2 (ENSG00000082482), KCNK10 (ENSG00000100433), KCNK3 (ENSG00000171303), KCNK18 (ENSG00000186795), GLRA1 (ENSG00000145888), GLRB (ENSG00000109738)', 'numberLinkedTargets': 23}, {'UUID': 'DrugGeneTargets_v2_5043', 'drugName': 'Halothane', 'tradeNames_string': 'Fluothane, Halothane, Rhidialothan', 'drugSynonyms_string': 'FREON 123B1, Halothane, Halothanum, NSC-143490', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1958, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863), KCNK9 (ENSG00000169427), KCNK2 (ENSG00000082482), KCNK10 (ENSG00000100433), KCNK3 (ENSG00000171303), KCNK18 (ENSG00000186795), GLRA1 (ENSG00000145888), GLRB (ENSG00000109738)', 'numberLinkedTargets': 23}, {'UUID': 'DrugGeneTargets_v2_5041', 'drugName': 'Halothane', 'tradeNames_string': 'Fluothane, Halothane, Rhidialothan', 'drugSynonyms_string': 'FREON 123B1, Halothane, Halothanum, NSC-143490', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1958, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863), KCNK9 (ENSG00000169427), KCNK2 (ENSG00000082482), KCNK10 (ENSG00000100433), KCNK3 (ENSG00000171303), KCNK18 (ENSG00000186795), GLRA1 (ENSG00000145888), GLRB (ENSG00000109738)', 'numberLinkedTargets': 23}, {'UUID': 'DrugGeneTargets_v2_5039', 'drugName': 'Halothane', 'tradeNames_string': 'Fluothane, Halothane, Rhidialothan', 'drugSynonyms_string': 'FREON 123B1, Halothane, Halothanum, NSC-143490', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1958, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863), KCNK9 (ENSG00000169427), KCNK2 (ENSG00000082482), KCNK10 (ENSG00000100433), KCNK3 (ENSG00000171303), KCNK18 (ENSG00000186795), GLRA1 (ENSG00000145888), GLRB (ENSG00000109738)', 'numberLinkedTargets': 23}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1917 | Q17 | What gene does the drug Atogepant target? | The drug Atogepant targets the gene CALCRL. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%atogepant%" OR LOWER(tradeNames_string) LIKE "%atogepant%" OR LOWER(drugSynonyms_string) LIKE "%atogepant%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2683', 'drugName': 'Atogepant', 'tradeNames_string': 'Qulipta', 'drugSynonyms_string': 'AGN-241689, Atogepant, MK-8031', 'linkedDiseasesDrug_string': 'Migraine Disorder (MONDO_0005277)', 'yearOfFirstApproval': 2021, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CALCRL (ENSG00000064989)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1416 | Q17 | What gene does the drug Formoterol target? | The drug Formoterol targets the gene ADRB2. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%formoterol%" OR LOWER(tradeNames_string) LIKE "%formoterol%" OR LOWER(drugSynonyms_string) LIKE "%formoterol%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4428', 'drugName': 'Formoterol', 'tradeNames_string': '', 'drugSynonyms_string': 'Foradil, Formoterol', 'linkedDiseasesDrug_string': 'Alzheimer Disease (MONDO_0004975), Asthma (MONDO_0004979), Chronic Bronchitis (EFO_0006505), Bronchospasm (HP_0025428), Lung Cancer (MONDO_0008903), Bronchiectasis (HP_0002110), Nicotine Dependence (EFO_0003768), Covid-19 (MONDO_0100096), Chronic Obstructive Pulmonary Disease (EFO_0000341), Airway Obstruction (HP_0006536), Acute Respiratory Distress Syndrome (EFO_1000637), Emphysema (EFO_0000464), Allergic Disease (MONDO_0005271), Bronchitis (EFO_0009661), Bronchiolitis Obliterans (EFO_0007183)', 'yearOfFirstApproval': 2001, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ADRB2 (ENSG00000169252)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_3747', 'drugName': 'Formoterol Fumarate', 'tradeNames_string': 'Atimos modulite, Foradil, Foradil certihaler, Oxis 12, Oxis 6, Performist, Perforomist', 'drugSynonyms_string': 'Atock, BD 40A, BD-40A, CGP 25827A, CGP-25827A, Eformoterol, Fomoterol fumarate, Foraseq, Formoterol fumarate, Formoterol fumarate (superceded), Formoterol fumarate anhydrous, Formoterol fumarate dihydrate, Formoterol fumarate hydrate, Formoterol hemifumarate, NSC-299587, Oxeze, YM-08316', 'linkedDiseasesDrug_string': 'Asthma (MONDO_0004979), Chronic Bronchitis (EFO_0006505), Bronchospasm (HP_0025428), Lung Cancer (MONDO_0008903), Bronchiectasis (HP_0002110), Nicotine Dependence (EFO_0003768), Covid-19 (MONDO_0100096), Chronic Obstructive Pulmonary Disease (EFO_0000341), Acute Respiratory Distress Syndrome (EFO_1000637), Emphysema (EFO_0000464), Allergic Disease (MONDO_0005271), Bronchitis (EFO_0009661), Bronchiolitis Obliterans (EFO_0007183)', 'yearOfFirstApproval': 2001, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ADRB2 (ENSG00000169252)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_6308', 'drugName': 'Arformoterol', 'tradeNames_string': '', 'drugSynonyms_string': 'Arformoterol, Formoterol r,r-form', 'linkedDiseasesDrug_string': 'Chronic Bronchitis (EFO_0006505), Bronchospasm (HP_0025428), Asthma (MONDO_0004979), Chronic Obstructive Pulmonary Disease (EFO_0000341), Emphysema (EFO_0000464), Bronchitis (EFO_0009661)', 'yearOfFirstApproval': 2006, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ADRB2 (ENSG00000169252)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_440', 'drugName': 'Arformoterol Tartrate', 'tradeNames_string': 'Brovana', 'drugSynonyms_string': 'Arformoterol tartrate, Formoterol r,r-form l-tartrate', 'linkedDiseasesDrug_string': 'Chronic Bronchitis (EFO_0006505), Bronchitis (EFO_0009661), Chronic Obstructive Pulmonary Disease (EFO_0000341), Emphysema (EFO_0000464)', 'yearOfFirstApproval': 2006, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ADRB2 (ENSG00000169252)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.586 | Q17 | What gene does the drug Anagrelide Hydrochloride target? | The drug Anagrelide Hydrochloride targets 2 genes: PDE3A and PDE3B. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%anagrelide hydrochloride%" OR LOWER(tradeNames_string) LIKE "%anagrelide hydrochloride%" OR LOWER(drugSynonyms_string) LIKE "%anagrelide hydrochloride%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_350', 'drugName': 'Anagrelide Hydrochloride', 'tradeNames_string': 'Agrelin, Agrylin, Anagrelide hydrochloride, Xagrid', 'drugSynonyms_string': 'Anagrelide hcl, Anagrelide hydrochloride, Anagrelide hydrochloride hydrate, Anagrelide hydrochloride monohydrate, BL-4162A, BMY-26538-01, NSC-724577, NSC-759170, Thromboreductin', 'linkedDiseasesDrug_string': 'Myeloproliferative Disorder (EFO_0004251), Essential Thrombocythemia (EFO_0000479), Thrombotic Disease (MONDO_0000831), Recurrent Thrombophlebitis (HP_0004419)', 'yearOfFirstApproval': 1997, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'PDE3A (ENSG00000172572), PDE3B (ENSG00000152270)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1795 | Q17 | What gene does the drug Gw-274150 target? | The drug Gw-274150 is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene NOS2. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%gw-274150%" OR LOWER(tradeNames_string) LIKE "%gw-274150%" OR LOWER(drugSynonyms_string) LIKE "%gw-274150%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4087', 'drugName': 'Gw-274150', 'tradeNames_string': '', 'drugSynonyms_string': 'GW274150, Gw-274150', 'linkedDiseasesDrug_string': 'Migraine Disorder (MONDO_0005277), Asthma (MONDO_0004979), Rheumatoid Arthritis (EFO_0000685)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'NOS2 (ENSG00000007171)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.771 | Q17 | What gene does the drug Molindone target? | The drug Molindone targets 2 genes: HTR2A and DRD2. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%molindone%" OR LOWER(tradeNames_string) LIKE "%molindone%" OR LOWER(drugSynonyms_string) LIKE "%molindone%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_789', 'drugName': 'Molindone', 'tradeNames_string': '', 'drugSynonyms_string': 'Moban, Molindone, Spn-810', 'linkedDiseasesDrug_string': 'Psychosis (EFO_0005407), Schizophrenia (MONDO_0005090), Attention Deficit Hyperactivity Disorder (EFO_0003888)', 'yearOfFirstApproval': 1974, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HTR2A (ENSG00000102468), DRD2 (ENSG00000149295)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_788', 'drugName': 'Molindone', 'tradeNames_string': '', 'drugSynonyms_string': 'Moban, Molindone, Spn-810', 'linkedDiseasesDrug_string': 'Psychosis (EFO_0005407), Schizophrenia (MONDO_0005090), Attention Deficit Hyperactivity Disorder (EFO_0003888)', 'yearOfFirstApproval': 1974, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HTR2A (ENSG00000102468), DRD2 (ENSG00000149295)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_3042', 'drugName': 'Molindone Hydrochloride', 'tradeNames_string': 'Moban, Molindone hydrochloride', 'drugSynonyms_string': 'EN-1733A, Molindone hcl, Molindone hydrochloride', 'linkedDiseasesDrug_string': 'Schizophrenia (MONDO_0005090)', 'yearOfFirstApproval': 1974, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'DRD2 (ENSG00000149295), HTR2A (ENSG00000102468)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_3041', 'drugName': 'Molindone Hydrochloride', 'tradeNames_string': 'Moban, Molindone hydrochloride', 'drugSynonyms_string': 'EN-1733A, Molindone hcl, Molindone hydrochloride', 'linkedDiseasesDrug_string': 'Schizophrenia (MONDO_0005090)', 'yearOfFirstApproval': 1974, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'DRD2 (ENSG00000149295), HTR2A (ENSG00000102468)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.371 | Q17 | What gene does the drug Filanesib target? | The drug Filanesib is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene KIF11. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%filanesib%" OR LOWER(tradeNames_string) LIKE "%filanesib%" OR LOWER(drugSynonyms_string) LIKE "%filanesib%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5918', 'drugName': 'Filanesib', 'tradeNames_string': '', 'drugSynonyms_string': 'ARRY-520, Filanesib', 'linkedDiseasesDrug_string': 'Multiple Myeloma (EFO_0001378), Neoplasm (EFO_0000616), Acute Myeloid Leukemia (EFO_0000222), Myelodysplastic Syndrome (EFO_0000198), Plasma Cell Leukemia (EFO_0006475)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'KIF11 (ENSG00000138160)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.809 | Q17 | What gene does the drug Levothyroxine target? | The drug Levothyroxine targets 2 genes: THRA and THRB. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%levothyroxine%" OR LOWER(tradeNames_string) LIKE "%levothyroxine%" OR LOWER(drugSynonyms_string) LIKE "%levothyroxine%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_83', 'drugName': 'Liothyronine', 'tradeNames_string': 'Cytomel, Tertroxin', 'drugSynonyms_string': "3,5,3'-triiodothyronine, l-, Cyronine, Euthroid-0.5, Euthroid-1, Euthroid-2, Euthroid-3, Levothyroxine sodium related compound liothyronine, Liothyronine, NSC-80203, Rathyronine, Rathyronine, (s)-, Thyrolar-0.25, Thyrolar-0.5, Thyrolar-1, Thyrolar-2, Thyrolar-3, Thyrolar-5, Triiodothyronine (T3 Or Liothyronine, Active) (6-11%), Triostat", 'linkedDiseasesDrug_string': 'Myxedema (EFO_1001055), Multiple Sclerosis (MONDO_0005301), Hypothyroidism (EFO_0004705), Differentiated Thyroid Carcinoma (EFO_1002017), Abnormality Of Cardiovascular System Morphology (HP_0030680), Atrial Fibrillation (EFO_0000275), Gliosarcoma (EFO_1001465), Prostate Cancer (MONDO_0008315), Breast Cancer (MONDO_0007254), Septic Shock (EFO_0006834), Relapsing-Remitting Multiple Sclerosis (EFO_0003929), Thyroid Neoplasm (EFO_0003841), Chronic Progressive Multiple Sclerosis (EFO_0003840), Bipolar Disorder (MONDO_0004985), Depressive Disorder (MONDO_0002050), Euthyroid Sick Syndrome (EFO_1000931), Congenital Heart Disease (EFO_0005207), Head And Neck Malignant Neoplasia (EFO_0006859), Unipolar Depression (EFO_0003761), Heart Failure (EFO_0003144)', 'yearOfFirstApproval': 1956, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'THRA (ENSG00000126351), THRB (ENSG00000151090)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_5964', 'drugName': 'Levothyroxine Sodium', 'tradeNames_string': 'Eltroxin, Ermeza, Euthyrox, Evotrox, L-thyroxine henning, Levo-t, Levolet, Levothroid, Levothyroid, Levothyroxine sodium, Levoxine, Levoxyl, Novothyrox, Soloxine, Synthroid, Thyquidity, Thyro-tabs, Thyrol L, Thyroxine, Tirosint, Tirosint-sol, Unithroid', 'drugSynonyms_string': 'Eferox, Levaxin, Levothyrox, Levothyroxine sodium, Levothyroxine sodium anhydrous, Levothyroxine sodium hydrate, Levothyroxine sodium pentahydrate, Levothyroxinum natricum anhydrous, Liotrix (t4), Monosodium l-thyroxine hydrate, NSC-259940, Oroxine, Sodium levothyroxine pentahydrate, Soloxine, T4, T4 (liotrix), Thyroxine, Thyroxine sodium, Thyroxine sodium salt', 'linkedDiseasesDrug_string': 'Congenital Hypothyroidism (MONDO_0018612), Pain (EFO_0003843), Thyroid Carcinoma (EFO_0002892), Thyroid Cancer (MONDO_0002108), Bipolar Disorder (MONDO_0004985), Hypothyroidism (EFO_0004705), Differentiated Thyroid Carcinoma (EFO_1002017)', 'yearOfFirstApproval': 2000, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'THRA (ENSG00000126351), THRB (ENSG00000151090)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_637', 'drugName': 'Levothyroxine', 'tradeNames_string': '', 'drugSynonyms_string': 'L-thyroxine, Levothyroxin, Levothyroxine, NSC-36397, Synthetic levothyroxine, Thyroxine, l-', 'linkedDiseasesDrug_string': 'Diabetes Mellitus (EFO_0000400), Congenital Hypothyroidism (MONDO_0018612), Thyroid Carcinoma (EFO_0002892), Graves Disease (EFO_0004237), Pain (EFO_0003843), Thyroid Cancer (MONDO_0002108), Bipolar Disorder (MONDO_0004985), Disorder Of Lipid Metabolism (Orphanet_309005), Pregnancy (EFO_0002950), Hypothyroidism (EFO_0004705), Differentiated Thyroid Carcinoma (EFO_1002017)', 'yearOfFirstApproval': 2000, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'THRA (ENSG00000126351), THRB (ENSG00000151090)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.31 | Q17 | What gene does the drug Pheniramine target? | The drug Pheniramine targets the gene HRH1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%pheniramine%" OR LOWER(tradeNames_string) LIKE "%pheniramine%" OR LOWER(drugSynonyms_string) LIKE "%pheniramine%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3635', 'drugName': 'Dexchlorpheniramine', 'tradeNames_string': '', 'drugSynonyms_string': 'Chlorphenamine, (s)-, Chlorpheniramine d-form, Chlorpheniramine, (s)-, Chlorpheniramine, d-, Dapriton, Dexchlorpheniramine', 'linkedDiseasesDrug_string': 'Allergic Conjunctivitis (EFO_0007141), Multiple Sclerosis (MONDO_0005301), Rhinitis, Allergic, Perennial (EFO_1001417), Seasonal Allergic Rhinitis (EFO_0003956), Angioedema (EFO_0005532), Vasomotor Rhinitis (EFO_0007533), Allergic Rhinitis (EFO_0005854), Allergic Disease (MONDO_0005271), Urticaria (EFO_0005531), Sunburn (EFO_0003958)', 'yearOfFirstApproval': 1981, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HRH1 (ENSG00000196639)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_1578', 'drugName': 'Pheniramine', 'tradeNames_string': '', 'drugSynonyms_string': 'NSC-47965, Pheniramine, Propheniramine, Prophenpyridamine, Pyriton, Tripoton', 'linkedDiseasesDrug_string': 'Common Cold (EFO_0007214), Respiratory Tract Infectious Disorder (MONDO_0024355), Influenza (EFO_0007328), Allergic Disease (MONDO_0005271), Pruritus (HP_0000989)', 'yearOfFirstApproval': 1994, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HRH1 (ENSG00000196639)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_431', 'drugName': 'Dexbrompheniramine Maleate', 'tradeNames_string': 'Disomer', 'drugSynonyms_string': 'Brompheniramine d-form maleate, Dexbrompheniramine fumarate, Dexbrompheniramine maleate', 'linkedDiseasesDrug_string': 'Seasonal Allergic Rhinitis (EFO_0003956)', 'yearOfFirstApproval': 1963, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HRH1 (ENSG00000196639)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_706', 'drugName': 'Chlorpheniramine Polistirex', 'tradeNames_string': '', 'drugSynonyms_string': 'Chlorpheniramine polistirex', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1984, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HRH1 (ENSG00000196639)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_6367', 'drugName': 'Brompheniramine', 'tradeNames_string': '', 'drugSynonyms_string': 'BPN, Bromfed, Bromfenex, Brompheniramine, Brotane, Dimetane, Dimetapp, Lodrane', 'linkedDiseasesDrug_string': 'Allergic Disease (MONDO_0005271), Cough (HP_0012735), Common Cold (EFO_0007214)', 'yearOfFirstApproval': 1957, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HRH1 (ENSG00000196639)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_221', 'drugName': 'Chlorpheniramine Maleate', 'tradeNames_string': 'Allercalm allergy relief, Allerief, Alunex, Antagonate, Calimal, Chlor-trimeton, Chlorphenamine, Chlorpheniramine maleate, Efidac 24 chlorpheniramine maleate, Hayleve, Kloromin, Phenetron, Piriject, Piriton, Piriton allergy, Pyridamal 100, Rhino-syrup allergy, Rimarin, Teldrin', 'drugSynonyms_string': '(+)-Chlorpheniramine Maleate, Chlorphenamine hydrogen maleate, Chlorphenamine maleate, Chlorphenamini hydrogenomaleas, Chlorpheniramine Maleate, Chlorpheniramine maleate, Chlorprophenpyridamine maleate, Efidac, Histaspan, NSC-756684, Neorestamin, Pyridamal, Synistamin', 'linkedDiseasesDrug_string': 'Sinusitis (EFO_0007486), Seasonal Allergic Rhinitis (EFO_0003956), Cough (HP_0012735), Allergic Rhinitis (EFO_0005854), Sunburn (EFO_0003958)', 'yearOfFirstApproval': 1950, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HRH1 (ENSG00000196639)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_4827', 'drugName': 'Chlorpheniramine', 'tradeNames_string': '', 'drugSynonyms_string': 'Antagonate, Chlor-Trimeton, Chlorphenamine, Chlorpheniramine, Isoclor, Kloromin, Phenetron, Teldrin', 'linkedDiseasesDrug_string': 'Sinusitis (EFO_0007486), Chronic Hepatitis B Virus Infection (EFO_0004239), Seasonal Allergic Rhinitis (EFO_0003956), Cough (HP_0012735), Allergic Rhinitis (EFO_0005854), Influenza (EFO_0007328), Allergic Disease (MONDO_0005271), Sunburn (EFO_0003958)', 'yearOfFirstApproval': 1950, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HRH1 (ENSG00000196639)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_463', 'drugName': 'Pheniramine Maleate', 'tradeNames_string': 'Avil ret, Daneral-sa', 'drugSynonyms_string': 'Antolozine, Daneral, Fervex, Inhiston, NSC-757270, Naphcon a, PM-241, Pheniramine Maleate, Pheniramine hydrogen maleate, Pheniramine maleate, Prophenpyridamine maleate, Trimeton, Trimetose', 'linkedDiseasesDrug_string': 'Respiratory Tract Infectious Disorder (MONDO_0024355), Common Cold (EFO_0007214), Influenza (EFO_0007328)', 'yearOfFirstApproval': 1994, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HRH1 (ENSG00000196639)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_6213', 'drugName': 'Dexchlorpheniramine Maleate', 'tradeNames_string': 'Dexchlorpheniramine maleate, Mylaramine, Polaramine', 'drugSynonyms_string': 'Chlorpheniramine d-form maleate, Chlorpheniramine maleate, (s)-, D-chlorpheniramine maleate, Dexchlorpheniramine maleate, NSC-759156', 'linkedDiseasesDrug_string': 'Allergic Conjunctivitis (EFO_0007141), Multiple Sclerosis (MONDO_0005301), Rhinitis, Allergic, Perennial (EFO_1001417), Seasonal Allergic Rhinitis (EFO_0003956), Angioedema (EFO_0005532), Vasomotor Rhinitis (EFO_0007533), Allergic Rhinitis (EFO_0005854), Allergic Disease (MONDO_0005271), Urticaria (EFO_0005531), Sunburn (EFO_0003958)', 'yearOfFirstApproval': 1981, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HRH1 (ENSG00000196639)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_4355', 'drugName': 'Dexbrompheniramine', 'tradeNames_string': '', 'drugSynonyms_string': 'Brompheniramine d-form, Brompheniramine, (s)-, Dexbrompheniramine', 'linkedDiseasesDrug_string': 'Allergic Disease (MONDO_0005271), Seasonal Allergic Rhinitis (EFO_0003956)', 'yearOfFirstApproval': 1963, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HRH1 (ENSG00000196639)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_1014', 'drugName': 'Brompheniramine Maleate', 'tradeNames_string': 'Brompheniramine maleate, Dimegan, Dimetane, Dimetane-ten, Dimotane, Dimotane l.a.', 'drugSynonyms_string': '(+)-Brompheniramine Maleate, Brompheniramine fumarate, Brompheniramine maleate, NSC-758652, Parabromdylamine maleate', 'linkedDiseasesDrug_string': 'Allergic Disease (MONDO_0005271), Cough (HP_0012735), Common Cold (EFO_0007214)', 'yearOfFirstApproval': 1957, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HRH1 (ENSG00000196639)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1960 | Q17 | What gene does the drug Propoxycaine Hydrochloride target? | The drug Propoxycaine Hydrochloride targets 10 genes: SCN1A, SCN9A, SCN7A, SCN8A, SCN11A, SCN10A, SCN2A, SCN5A, SCN4A and SCN3A. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%propoxycaine hydrochloride%" OR LOWER(tradeNames_string) LIKE "%propoxycaine hydrochloride%" OR LOWER(drugSynonyms_string) LIKE "%propoxycaine hydrochloride%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1701', 'drugName': 'Propoxycaine Hydrochloride', 'tradeNames_string': 'Blockain hydrochloride, Ravocaine hydrochloride', 'drugSynonyms_string': 'NSC-760044, Propoxycaine HCl, Propoxycaine hcl, Propoxycaine hydrochloride', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1982, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SCN1A (ENSG00000144285), SCN5A (ENSG00000183873), SCN4A (ENSG00000007314), SCN7A (ENSG00000136546), SCN2A (ENSG00000136531), SCN9A (ENSG00000169432), SCN3A (ENSG00000153253), SCN11A (ENSG00000168356), SCN8A (ENSG00000196876), SCN10A (ENSG00000185313)', 'numberLinkedTargets': 10}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1742 | Q17 | What gene does the drug Hydrocodone target? | The drug Hydrocodone targets 3 genes: OPRK1, OPRM1 and OPRD1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%hydrocodone%" OR LOWER(tradeNames_string) LIKE "%hydrocodone%" OR LOWER(drugSynonyms_string) LIKE "%hydrocodone%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3008', 'drugName': 'Benzhydrocodone Hydrochloride', 'tradeNames_string': '', 'drugSynonyms_string': 'Benzhydrocodone hydrochloride, KP-201, KP201', 'linkedDiseasesDrug_string': 'Pain (EFO_0003843), Drug Dependence (EFO_0003890)', 'yearOfFirstApproval': 2018, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'OPRK1 (ENSG00000082556), OPRD1 (ENSG00000116329), OPRM1 (ENSG00000112038)', 'numberLinkedTargets': 3}, {'UUID': 'DrugGeneTargets_v2_4513', 'drugName': 'Hydrocodone', 'tradeNames_string': '', 'drugSynonyms_string': 'Hydrocodone', 'linkedDiseasesDrug_string': 'Ankle Fracture (EFO_0009615), Head And Neck Malignant Neoplasia (EFO_0006859), Osteoarthritis (MONDO_0005178), Drug Dependence (EFO_0003890), Rotator Cuff Tear (EFO_1001250), Nausea (HP_0002018), Liver Disease (EFO_0001421), Pain (EFO_0003843), Chronic Pain (HP_0012532), Eye Disease (EFO_0003966), Cough (HP_0012735), Neuropathic Pain (EFO_0005762), Kidney Disease (EFO_0003086), Vomiting (HP_0002013), Injury (EFO_0000546), Low Back Pain (HP_0003419)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'OPRK1 (ENSG00000082556), OPRD1 (ENSG00000116329), OPRM1 (ENSG00000112038)', 'numberLinkedTargets': 3}, {'UUID': 'DrugGeneTargets_v2_2476', 'drugName': 'Hydrocodone Bitartrate', 'tradeNames_string': 'Dicodid, Hysingla, Hysingla er, Mercodinone, Vantrela er, Zohydro er', 'drugSynonyms_string': 'CEP-33237, Dihydrocodeinone bitartrate, Hycodan, Hydrocodone bitartrate, Hydrocodone bitartrate cii, Hydrocodone bitartrate hemipentahydrate, Hydrocodone tartrate, Vantrela, Zohydro', 'linkedDiseasesDrug_string': 'Drug Dependence (EFO_0003890), Osteoarthritis (MONDO_0005178), Rotator Cuff Tear (EFO_1001250), Liver Disease (EFO_0001421), Pain (EFO_0003843), Chronic Pain (HP_0012532), Neuropathic Pain (EFO_0005762), Kidney Disease (EFO_0003086), Injury (EFO_0000546), Low Back Pain (HP_0003419)', 'yearOfFirstApproval': 1943, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'OPRK1 (ENSG00000082556), OPRD1 (ENSG00000116329), OPRM1 (ENSG00000112038)', 'numberLinkedTargets': 3}, {'UUID': 'DrugGeneTargets_v2_2492', 'drugName': 'Hydrocodone Polistirex', 'tradeNames_string': '', 'drugSynonyms_string': 'Hydrocodone polistirex', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1987, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'OPRK1 (ENSG00000082556), OPRD1 (ENSG00000116329), OPRM1 (ENSG00000112038)', 'numberLinkedTargets': 3}, {'UUID': 'DrugGeneTargets_v2_529', 'drugName': 'Benzhydrocodone', 'tradeNames_string': '', 'drugSynonyms_string': 'Benzhydrocodone', 'linkedDiseasesDrug_string': 'Pain (EFO_0003843), Drug Dependence (EFO_0003890)', 'yearOfFirstApproval': 2018, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'OPRK1 (ENSG00000082556), OPRD1 (ENSG00000116329), OPRM1 (ENSG00000112038)', 'numberLinkedTargets': 3}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1577 | Q17 | What gene does the drug Enmd-981693 target? | The drug Enmd-981693 is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target 19 genes: FLT3, FGFR4, PDGFRB, BLK, YES1, FRK, PDGFRA, SRC, FGR, FGFR1, HCK, LYN, FYN, FGFR2, FGFR3, KDR, AURKA, LCK and SRMS | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%enmd-981693%" OR LOWER(tradeNames_string) LIKE "%enmd-981693%" OR LOWER(drugSynonyms_string) LIKE "%enmd-981693%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2126', 'drugName': 'Enmd-981693', 'tradeNames_string': '', 'drugSynonyms_string': 'ENMD 981693, ENMD-2076, ENMD-981693, Enmd-2076 free base, Enmd-981693, MKC-1, Mkc 1, R-440, RO 31-7453, RO-31-7453, Ro-317453', 'linkedDiseasesDrug_string': 'Pancreatic Carcinoma (EFO_0002618), Cancer (MONDO_0004992), Breast Cancer (MONDO_0007254), Neoplasm (EFO_0000616), Non-Small Cell Lung Carcinoma (EFO_0003060), Colorectal Carcinoma (EFO_1001951)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'KDR (ENSG00000128052), FYN (ENSG00000010810), SRC (ENSG00000197122), LCK (ENSG00000182866), YES1 (ENSG00000176105), BLK (ENSG00000136573), HCK (ENSG00000101336), LYN (ENSG00000254087), FRK (ENSG00000111816), FGR (ENSG00000000938), SRMS (ENSG00000125508), FLT3 (ENSG00000122025), PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853), AURKA (ENSG00000087586), FGFR3 (ENSG00000068078), FGFR1 (ENSG00000077782), FGFR4 (ENSG00000160867), FGFR2 (ENSG00000066468)', 'numberLinkedTargets': 19}, {'UUID': 'DrugGeneTargets_v2_2122', 'drugName': 'Enmd-981693', 'tradeNames_string': '', 'drugSynonyms_string': 'ENMD 981693, ENMD-2076, ENMD-981693, Enmd-2076 free base, Enmd-981693, MKC-1, Mkc 1, R-440, RO 31-7453, RO-31-7453, Ro-317453', 'linkedDiseasesDrug_string': 'Pancreatic Carcinoma (EFO_0002618), Cancer (MONDO_0004992), Breast Cancer (MONDO_0007254), Neoplasm (EFO_0000616), Non-Small Cell Lung Carcinoma (EFO_0003060), Colorectal Carcinoma (EFO_1001951)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'KDR (ENSG00000128052), FYN (ENSG00000010810), SRC (ENSG00000197122), LCK (ENSG00000182866), YES1 (ENSG00000176105), BLK (ENSG00000136573), HCK (ENSG00000101336), LYN (ENSG00000254087), FRK (ENSG00000111816), FGR (ENSG00000000938), SRMS (ENSG00000125508), FLT3 (ENSG00000122025), PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853), AURKA (ENSG00000087586), FGFR3 (ENSG00000068078), FGFR1 (ENSG00000077782), FGFR4 (ENSG00000160867), FGFR2 (ENSG00000066468)', 'numberLinkedTargets': 19}, {'UUID': 'DrugGeneTargets_v2_2121', 'drugName': 'Enmd-981693', 'tradeNames_string': '', 'drugSynonyms_string': 'ENMD 981693, ENMD-2076, ENMD-981693, Enmd-2076 free base, Enmd-981693, MKC-1, Mkc 1, R-440, RO 31-7453, RO-31-7453, Ro-317453', 'linkedDiseasesDrug_string': 'Pancreatic Carcinoma (EFO_0002618), Cancer (MONDO_0004992), Breast Cancer (MONDO_0007254), Neoplasm (EFO_0000616), Non-Small Cell Lung Carcinoma (EFO_0003060), Colorectal Carcinoma (EFO_1001951)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'KDR (ENSG00000128052), FYN (ENSG00000010810), SRC (ENSG00000197122), LCK (ENSG00000182866), YES1 (ENSG00000176105), BLK (ENSG00000136573), HCK (ENSG00000101336), LYN (ENSG00000254087), FRK (ENSG00000111816), FGR (ENSG00000000938), SRMS (ENSG00000125508), FLT3 (ENSG00000122025), PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853), AURKA (ENSG00000087586), FGFR3 (ENSG00000068078), FGFR1 (ENSG00000077782), FGFR4 (ENSG00000160867), FGFR2 (ENSG00000066468)', 'numberLinkedTargets': 19}, {'UUID': 'DrugGeneTargets_v2_2124', 'drugName': 'Enmd-981693', 'tradeNames_string': '', 'drugSynonyms_string': 'ENMD 981693, ENMD-2076, ENMD-981693, Enmd-2076 free base, Enmd-981693, MKC-1, Mkc 1, R-440, RO 31-7453, RO-31-7453, Ro-317453', 'linkedDiseasesDrug_string': 'Pancreatic Carcinoma (EFO_0002618), Cancer (MONDO_0004992), Breast Cancer (MONDO_0007254), Neoplasm (EFO_0000616), Non-Small Cell Lung Carcinoma (EFO_0003060), Colorectal Carcinoma (EFO_1001951)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'KDR (ENSG00000128052), FYN (ENSG00000010810), SRC (ENSG00000197122), LCK (ENSG00000182866), YES1 (ENSG00000176105), BLK (ENSG00000136573), HCK (ENSG00000101336), LYN (ENSG00000254087), FRK (ENSG00000111816), FGR (ENSG00000000938), SRMS (ENSG00000125508), FLT3 (ENSG00000122025), PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853), AURKA (ENSG00000087586), FGFR3 (ENSG00000068078), FGFR1 (ENSG00000077782), FGFR4 (ENSG00000160867), FGFR2 (ENSG00000066468)', 'numberLinkedTargets': 19}, {'UUID': 'DrugGeneTargets_v2_2125', 'drugName': 'Enmd-981693', 'tradeNames_string': '', 'drugSynonyms_string': 'ENMD 981693, ENMD-2076, ENMD-981693, Enmd-2076 free base, Enmd-981693, MKC-1, Mkc 1, R-440, RO 31-7453, RO-31-7453, Ro-317453', 'linkedDiseasesDrug_string': 'Pancreatic Carcinoma (EFO_0002618), Cancer (MONDO_0004992), Breast Cancer (MONDO_0007254), Neoplasm (EFO_0000616), Non-Small Cell Lung Carcinoma (EFO_0003060), Colorectal Carcinoma (EFO_1001951)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'KDR (ENSG00000128052), FYN (ENSG00000010810), SRC (ENSG00000197122), LCK (ENSG00000182866), YES1 (ENSG00000176105), BLK (ENSG00000136573), HCK (ENSG00000101336), LYN (ENSG00000254087), FRK (ENSG00000111816), FGR (ENSG00000000938), SRMS (ENSG00000125508), FLT3 (ENSG00000122025), PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853), AURKA (ENSG00000087586), FGFR3 (ENSG00000068078), FGFR1 (ENSG00000077782), FGFR4 (ENSG00000160867), FGFR2 (ENSG00000066468)', 'numberLinkedTargets': 19}, {'UUID': 'DrugGeneTargets_v2_2123', 'drugName': 'Enmd-981693', 'tradeNames_string': '', 'drugSynonyms_string': 'ENMD 981693, ENMD-2076, ENMD-981693, Enmd-2076 free base, Enmd-981693, MKC-1, Mkc 1, R-440, RO 31-7453, RO-31-7453, Ro-317453', 'linkedDiseasesDrug_string': 'Pancreatic Carcinoma (EFO_0002618), Cancer (MONDO_0004992), Breast Cancer (MONDO_0007254), Neoplasm (EFO_0000616), Non-Small Cell Lung Carcinoma (EFO_0003060), Colorectal Carcinoma (EFO_1001951)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'KDR (ENSG00000128052), FYN (ENSG00000010810), SRC (ENSG00000197122), LCK (ENSG00000182866), YES1 (ENSG00000176105), BLK (ENSG00000136573), HCK (ENSG00000101336), LYN (ENSG00000254087), FRK (ENSG00000111816), FGR (ENSG00000000938), SRMS (ENSG00000125508), FLT3 (ENSG00000122025), PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853), AURKA (ENSG00000087586), FGFR3 (ENSG00000068078), FGFR1 (ENSG00000077782), FGFR4 (ENSG00000160867), FGFR2 (ENSG00000066468)', 'numberLinkedTargets': 19}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.794 | Q17 | What gene does the drug Ardeparin Sodium target? | The drug Ardeparin Sodium targets the gene SERPINC1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%ardeparin sodium%" OR LOWER(tradeNames_string) LIKE "%ardeparin sodium%" OR LOWER(drugSynonyms_string) LIKE "%ardeparin sodium%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2927', 'drugName': 'Ardeparin Sodium', 'tradeNames_string': 'Normiflo', 'drugSynonyms_string': 'Ardeparin sodium, Ardeparin sodium salt, RD-11885, WY-90493 RD, WY-90493-RD', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1997, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SERPINC1 (ENSG00000117601)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1249 | Q17 | What gene does the drug Cyproheptadine Hydrochloride target? | The drug Cyproheptadine Hydrochloride targets the gene HRH1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%cyproheptadine hydrochloride%" OR LOWER(tradeNames_string) LIKE "%cyproheptadine hydrochloride%" OR LOWER(drugSynonyms_string) LIKE "%cyproheptadine hydrochloride%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3426', 'drugName': 'Cyproheptadine Hydrochloride', 'tradeNames_string': 'Cyproheptadine Hydrocloride, Cyproheptadine hydrochloride, Periactin', 'drugSynonyms_string': 'Cyproheptadine HCl, Cyproheptadine hcl, Cyproheptadine hydrochloride, Cyproheptadine hydrochloride hydrate, Cyproheptadine hydrochloride sesquihydrate, NSC-169911, NSC-759282, Periactine, Peritol', 'linkedDiseasesDrug_string': 'Allergic Conjunctivitis (EFO_0007141), Cancer (MONDO_0004992), Seasonal Allergic Rhinitis (EFO_0003956), Urticaria (EFO_0005531)', 'yearOfFirstApproval': 1961, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HRH1 (ENSG00000196639)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.501 | Q17 | What gene does the drug Petesicatib target? | The drug Petesicatib is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene CTSS. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%petesicatib%" OR LOWER(tradeNames_string) LIKE "%petesicatib%" OR LOWER(drugSynonyms_string) LIKE "%petesicatib%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1222', 'drugName': 'Petesicatib', 'tradeNames_string': '', 'drugSynonyms_string': 'Petesicatib, RG-7625, RG7625, RO-5459072, RO5459072, Rg7625, Ro5459072', 'linkedDiseasesDrug_string': 'Sjogren Syndrome (EFO_0000699), Celiac Disease (EFO_0001060)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'CTSS (ENSG00000163131)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1551 | Q17 | What gene does the drug Lorcaserin Hydrochloride target? | The drug Lorcaserin Hydrochloride targets the gene HTR2C. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%lorcaserin hydrochloride%" OR LOWER(tradeNames_string) LIKE "%lorcaserin hydrochloride%" OR LOWER(drugSynonyms_string) LIKE "%lorcaserin hydrochloride%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4924', 'drugName': 'Lorcaserin Hydrochloride', 'tradeNames_string': 'Belviq, Belviq xr', 'drugSynonyms_string': 'APD-356, APD356, Lorcaserin hcl, Lorcaserin hydrochloride, Lorqess', 'linkedDiseasesDrug_string': 'Smoking Cessation (EFO_0004319), Obesity (EFO_0001073)', 'yearOfFirstApproval': 2012, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HTR2C (ENSG00000147246)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1568 | Q17 | What gene does the drug Lurasidone Hydrochloride target? | The drug Lurasidone Hydrochloride targets 2 genes: HTR2A and DRD2. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%lurasidone hydrochloride%" OR LOWER(tradeNames_string) LIKE "%lurasidone hydrochloride%" OR LOWER(drugSynonyms_string) LIKE "%lurasidone hydrochloride%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3924', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_string': 'Latuda', 'drugSynonyms_string': 'Lurasidone hcl, Lurasidone hydrochloride, SM-13496', 'linkedDiseasesDrug_string': 'Schizophrenia (MONDO_0005090), Bipolar Disorder (MONDO_0004985), Bipolar I Disorder (EFO_0009963)', 'yearOfFirstApproval': 2010, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'DRD2 (ENSG00000149295), HTR2A (ENSG00000102468)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_3925', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_string': 'Latuda', 'drugSynonyms_string': 'Lurasidone hcl, Lurasidone hydrochloride, SM-13496', 'linkedDiseasesDrug_string': 'Schizophrenia (MONDO_0005090), Bipolar Disorder (MONDO_0004985), Bipolar I Disorder (EFO_0009963)', 'yearOfFirstApproval': 2010, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'DRD2 (ENSG00000149295), HTR2A (ENSG00000102468)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.991 | Q17 | What gene does the drug Vandetanib target? | The drug Vandetanib targets 25 genes: EPHA3, EPHB4, FLT4, EPHA1, ERBB4, ERBB3, EPHB6, EPHA2, EPHB1, SRC, RET, EPHA4, EPHB2, TEK, EPHA10, KDR, PTK6, EPHA7, EPHB3, EGFR, EPHA8, EPHA5, FLT1, ERBB2 and EPHA6. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%vandetanib%" OR LOWER(tradeNames_string) LIKE "%vandetanib%" OR LOWER(drugSynonyms_string) LIKE "%vandetanib%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1936', 'drugName': 'Vandetanib', 'tradeNames_string': 'Caprelsa, Zactima', 'drugSynonyms_string': 'GNF-PF-2188, NSC-744325, NSC-760766, Vandetanib, ZD-64, ZD-6474, ZD6474', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Multiple Myeloma (EFO_0001378), Papillary Thyroid Carcinoma (EFO_0000641), Neuroblastoma (EFO_0000621), Ureter Cancer (MONDO_0008627), Verrucous Carcinoma (EFO_0007535), Thyroid Carcinoma (EFO_0002892), Gastrointestinal Stromal Tumor (MONDO_0011719), Colorectal Carcinoma (EFO_1001951), Esophageal Carcinoma (EFO_0002916), Prostate Carcinoma (EFO_0001663), Ovarian Cancer (MONDO_0008170), Gastric Cancer (MONDO_0001056), Breast Neoplasm (EFO_0003869), Anaplastic Astrocytoma (EFO_0002499), Hepatocellular Carcinoma (EFO_0000182), Gliosarcoma (EFO_1001465), Prostate Cancer (MONDO_0008315), Breast Cancer (MONDO_0007254), Oligoastrocytoma (EFO_0000630), Medullary Thyroid Gland Carcinoma (MONDO_0015277), Acute Myeloid Leukemia (EFO_0000222), Head And Neck Squamous Cell Carcinoma (EFO_0000181), Metastasis (EFO_0009708), Malignant Glioma (MONDO_0100342), Urethra Cancer (MONDO_0004192), Central Nervous System Neoplasm (EFO_1000158), Pancreatic Carcinoma (EFO_0002618), Anaplastic Oligodendroglioma (EFO_0002501), Thyroid Neoplasm (EFO_0003841), Small Cell Lung Carcinoma (EFO_0000702), Mesothelioma (EFO_0000588), Clear Cell Renal Carcinoma (EFO_0000349), Thyroid Cancer (MONDO_0002108), Peritoneum Cancer (MONDO_0002087), Rectum Cancer (EFO_1000657), Head And Neck Malignant Neoplasia (EFO_0006859), Diffuse Intrinsic Pontine Glioma (EFO_1000026), Lung Cancer (MONDO_0008903), Neoplasm (EFO_0000616), Fallopian Tube Cancer (MONDO_0002158), Urinary Bladder Cancer (MONDO_0001187), Non-Small Cell Lung Carcinoma (EFO_0003060), Colorectal Adenocarcinoma (EFO_0000365), Kidney Cancer (MONDO_0002367), Glioblastoma Multiforme (EFO_0000519), Stomach Neoplasm (EFO_0003897), Follicular Thyroid Carcinoma (EFO_0000501)', 'yearOfFirstApproval': 2011, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'TEK (ENSG00000120156), ERBB2 (ENSG00000141736), EGFR (ENSG00000146648), ERBB4 (ENSG00000178568), ERBB3 (ENSG00000065361), EPHA2 (ENSG00000142627), EPHB2 (ENSG00000133216), EPHA5 (ENSG00000145242), EPHA4 (ENSG00000116106), EPHA8 (ENSG00000070886), EPHA6 (ENSG00000080224), EPHA7 (ENSG00000135333), EPHB3 (ENSG00000182580), EPHA3 (ENSG00000044524), EPHB1 (ENSG00000154928), EPHB4 (ENSG00000196411), EPHA1 (ENSG00000146904), EPHB6 (ENSG00000106123), EPHA10 (ENSG00000183317), SRC (ENSG00000197122), RET (ENSG00000165731), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), PTK6 (ENSG00000101213)', 'numberLinkedTargets': 25}, {'UUID': 'DrugGeneTargets_v2_1934', 'drugName': 'Vandetanib', 'tradeNames_string': 'Caprelsa, Zactima', 'drugSynonyms_string': 'GNF-PF-2188, NSC-744325, NSC-760766, Vandetanib, ZD-64, ZD-6474, ZD6474', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Multiple Myeloma (EFO_0001378), Papillary Thyroid Carcinoma (EFO_0000641), Neuroblastoma (EFO_0000621), Ureter Cancer (MONDO_0008627), Verrucous Carcinoma (EFO_0007535), Thyroid Carcinoma (EFO_0002892), Gastrointestinal Stromal Tumor (MONDO_0011719), Colorectal Carcinoma (EFO_1001951), Esophageal Carcinoma (EFO_0002916), Prostate Carcinoma (EFO_0001663), Ovarian Cancer (MONDO_0008170), Gastric Cancer (MONDO_0001056), Breast Neoplasm (EFO_0003869), Anaplastic Astrocytoma (EFO_0002499), Hepatocellular Carcinoma (EFO_0000182), Gliosarcoma (EFO_1001465), Prostate Cancer (MONDO_0008315), Breast Cancer (MONDO_0007254), Oligoastrocytoma (EFO_0000630), Medullary Thyroid Gland Carcinoma (MONDO_0015277), Acute Myeloid Leukemia (EFO_0000222), Head And Neck Squamous Cell Carcinoma (EFO_0000181), Metastasis (EFO_0009708), Malignant Glioma (MONDO_0100342), Urethra Cancer (MONDO_0004192), Central Nervous System Neoplasm (EFO_1000158), Pancreatic Carcinoma (EFO_0002618), Anaplastic Oligodendroglioma (EFO_0002501), Thyroid Neoplasm (EFO_0003841), Small Cell Lung Carcinoma (EFO_0000702), Mesothelioma (EFO_0000588), Clear Cell Renal Carcinoma (EFO_0000349), Thyroid Cancer (MONDO_0002108), Peritoneum Cancer (MONDO_0002087), Rectum Cancer (EFO_1000657), Head And Neck Malignant Neoplasia (EFO_0006859), Diffuse Intrinsic Pontine Glioma (EFO_1000026), Lung Cancer (MONDO_0008903), Neoplasm (EFO_0000616), Fallopian Tube Cancer (MONDO_0002158), Urinary Bladder Cancer (MONDO_0001187), Non-Small Cell Lung Carcinoma (EFO_0003060), Colorectal Adenocarcinoma (EFO_0000365), Kidney Cancer (MONDO_0002367), Glioblastoma Multiforme (EFO_0000519), Stomach Neoplasm (EFO_0003897), Follicular Thyroid Carcinoma (EFO_0000501)', 'yearOfFirstApproval': 2011, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'TEK (ENSG00000120156), ERBB2 (ENSG00000141736), EGFR (ENSG00000146648), ERBB4 (ENSG00000178568), ERBB3 (ENSG00000065361), EPHA2 (ENSG00000142627), EPHB2 (ENSG00000133216), EPHA5 (ENSG00000145242), EPHA4 (ENSG00000116106), EPHA8 (ENSG00000070886), EPHA6 (ENSG00000080224), EPHA7 (ENSG00000135333), EPHB3 (ENSG00000182580), EPHA3 (ENSG00000044524), EPHB1 (ENSG00000154928), EPHB4 (ENSG00000196411), EPHA1 (ENSG00000146904), EPHB6 (ENSG00000106123), EPHA10 (ENSG00000183317), SRC (ENSG00000197122), RET (ENSG00000165731), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), PTK6 (ENSG00000101213)', 'numberLinkedTargets': 25}, {'UUID': 'DrugGeneTargets_v2_1932', 'drugName': 'Vandetanib', 'tradeNames_string': 'Caprelsa, Zactima', 'drugSynonyms_string': 'GNF-PF-2188, NSC-744325, NSC-760766, Vandetanib, ZD-64, ZD-6474, ZD6474', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Multiple Myeloma (EFO_0001378), Papillary Thyroid Carcinoma (EFO_0000641), Neuroblastoma (EFO_0000621), Ureter Cancer (MONDO_0008627), Verrucous Carcinoma (EFO_0007535), Thyroid Carcinoma (EFO_0002892), Gastrointestinal Stromal Tumor (MONDO_0011719), Colorectal Carcinoma (EFO_1001951), Esophageal Carcinoma (EFO_0002916), Prostate Carcinoma (EFO_0001663), Ovarian Cancer (MONDO_0008170), Gastric Cancer (MONDO_0001056), Breast Neoplasm (EFO_0003869), Anaplastic Astrocytoma (EFO_0002499), Hepatocellular Carcinoma (EFO_0000182), Gliosarcoma (EFO_1001465), Prostate Cancer (MONDO_0008315), Breast Cancer (MONDO_0007254), Oligoastrocytoma (EFO_0000630), Medullary Thyroid Gland Carcinoma (MONDO_0015277), Acute Myeloid Leukemia (EFO_0000222), Head And Neck Squamous Cell Carcinoma (EFO_0000181), Metastasis (EFO_0009708), Malignant Glioma (MONDO_0100342), Urethra Cancer (MONDO_0004192), Central Nervous System Neoplasm (EFO_1000158), Pancreatic Carcinoma (EFO_0002618), Anaplastic Oligodendroglioma (EFO_0002501), Thyroid Neoplasm (EFO_0003841), Small Cell Lung Carcinoma (EFO_0000702), Mesothelioma (EFO_0000588), Clear Cell Renal Carcinoma (EFO_0000349), Thyroid Cancer (MONDO_0002108), Peritoneum Cancer (MONDO_0002087), Rectum Cancer (EFO_1000657), Head And Neck Malignant Neoplasia (EFO_0006859), Diffuse Intrinsic Pontine Glioma (EFO_1000026), Lung Cancer (MONDO_0008903), Neoplasm (EFO_0000616), Fallopian Tube Cancer (MONDO_0002158), Urinary Bladder Cancer (MONDO_0001187), Non-Small Cell Lung Carcinoma (EFO_0003060), Colorectal Adenocarcinoma (EFO_0000365), Kidney Cancer (MONDO_0002367), Glioblastoma Multiforme (EFO_0000519), Stomach Neoplasm (EFO_0003897), Follicular Thyroid Carcinoma (EFO_0000501)', 'yearOfFirstApproval': 2011, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'TEK (ENSG00000120156), ERBB2 (ENSG00000141736), EGFR (ENSG00000146648), ERBB4 (ENSG00000178568), ERBB3 (ENSG00000065361), EPHA2 (ENSG00000142627), EPHB2 (ENSG00000133216), EPHA5 (ENSG00000145242), EPHA4 (ENSG00000116106), EPHA8 (ENSG00000070886), EPHA6 (ENSG00000080224), EPHA7 (ENSG00000135333), EPHB3 (ENSG00000182580), EPHA3 (ENSG00000044524), EPHB1 (ENSG00000154928), EPHB4 (ENSG00000196411), EPHA1 (ENSG00000146904), EPHB6 (ENSG00000106123), EPHA10 (ENSG00000183317), SRC (ENSG00000197122), RET (ENSG00000165731), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), PTK6 (ENSG00000101213)', 'numberLinkedTargets': 25}, {'UUID': 'DrugGeneTargets_v2_1931', 'drugName': 'Vandetanib', 'tradeNames_string': 'Caprelsa, Zactima', 'drugSynonyms_string': 'GNF-PF-2188, NSC-744325, NSC-760766, Vandetanib, ZD-64, ZD-6474, ZD6474', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Multiple Myeloma (EFO_0001378), Papillary Thyroid Carcinoma (EFO_0000641), Neuroblastoma (EFO_0000621), Ureter Cancer (MONDO_0008627), Verrucous Carcinoma (EFO_0007535), Thyroid Carcinoma (EFO_0002892), Gastrointestinal Stromal Tumor (MONDO_0011719), Colorectal Carcinoma (EFO_1001951), Esophageal Carcinoma (EFO_0002916), Prostate Carcinoma (EFO_0001663), Ovarian Cancer (MONDO_0008170), Gastric Cancer (MONDO_0001056), Breast Neoplasm (EFO_0003869), Anaplastic Astrocytoma (EFO_0002499), Hepatocellular Carcinoma (EFO_0000182), Gliosarcoma (EFO_1001465), Prostate Cancer (MONDO_0008315), Breast Cancer (MONDO_0007254), Oligoastrocytoma (EFO_0000630), Medullary Thyroid Gland Carcinoma (MONDO_0015277), Acute Myeloid Leukemia (EFO_0000222), Head And Neck Squamous Cell Carcinoma (EFO_0000181), Metastasis (EFO_0009708), Malignant Glioma (MONDO_0100342), Urethra Cancer (MONDO_0004192), Central Nervous System Neoplasm (EFO_1000158), Pancreatic Carcinoma (EFO_0002618), Anaplastic Oligodendroglioma (EFO_0002501), Thyroid Neoplasm (EFO_0003841), Small Cell Lung Carcinoma (EFO_0000702), Mesothelioma (EFO_0000588), Clear Cell Renal Carcinoma (EFO_0000349), Thyroid Cancer (MONDO_0002108), Peritoneum Cancer (MONDO_0002087), Rectum Cancer (EFO_1000657), Head And Neck Malignant Neoplasia (EFO_0006859), Diffuse Intrinsic Pontine Glioma (EFO_1000026), Lung Cancer (MONDO_0008903), Neoplasm (EFO_0000616), Fallopian Tube Cancer (MONDO_0002158), Urinary Bladder Cancer (MONDO_0001187), Non-Small Cell Lung Carcinoma (EFO_0003060), Colorectal Adenocarcinoma (EFO_0000365), Kidney Cancer (MONDO_0002367), Glioblastoma Multiforme (EFO_0000519), Stomach Neoplasm (EFO_0003897), Follicular Thyroid Carcinoma (EFO_0000501)', 'yearOfFirstApproval': 2011, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'TEK (ENSG00000120156), ERBB2 (ENSG00000141736), EGFR (ENSG00000146648), ERBB4 (ENSG00000178568), ERBB3 (ENSG00000065361), EPHA2 (ENSG00000142627), EPHB2 (ENSG00000133216), EPHA5 (ENSG00000145242), EPHA4 (ENSG00000116106), EPHA8 (ENSG00000070886), EPHA6 (ENSG00000080224), EPHA7 (ENSG00000135333), EPHB3 (ENSG00000182580), EPHA3 (ENSG00000044524), EPHB1 (ENSG00000154928), EPHB4 (ENSG00000196411), EPHA1 (ENSG00000146904), EPHB6 (ENSG00000106123), EPHA10 (ENSG00000183317), SRC (ENSG00000197122), RET (ENSG00000165731), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), PTK6 (ENSG00000101213)', 'numberLinkedTargets': 25}, {'UUID': 'DrugGeneTargets_v2_1937', 'drugName': 'Vandetanib', 'tradeNames_string': 'Caprelsa, Zactima', 'drugSynonyms_string': 'GNF-PF-2188, NSC-744325, NSC-760766, Vandetanib, ZD-64, ZD-6474, ZD6474', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Multiple Myeloma (EFO_0001378), Papillary Thyroid Carcinoma (EFO_0000641), Neuroblastoma (EFO_0000621), Ureter Cancer (MONDO_0008627), Verrucous Carcinoma (EFO_0007535), Thyroid Carcinoma (EFO_0002892), Gastrointestinal Stromal Tumor (MONDO_0011719), Colorectal Carcinoma (EFO_1001951), Esophageal Carcinoma (EFO_0002916), Prostate Carcinoma (EFO_0001663), Ovarian Cancer (MONDO_0008170), Gastric Cancer (MONDO_0001056), Breast Neoplasm (EFO_0003869), Anaplastic Astrocytoma (EFO_0002499), Hepatocellular Carcinoma (EFO_0000182), Gliosarcoma (EFO_1001465), Prostate Cancer (MONDO_0008315), Breast Cancer (MONDO_0007254), Oligoastrocytoma (EFO_0000630), Medullary Thyroid Gland Carcinoma (MONDO_0015277), Acute Myeloid Leukemia (EFO_0000222), Head And Neck Squamous Cell Carcinoma (EFO_0000181), Metastasis (EFO_0009708), Malignant Glioma (MONDO_0100342), Urethra Cancer (MONDO_0004192), Central Nervous System Neoplasm (EFO_1000158), Pancreatic Carcinoma (EFO_0002618), Anaplastic Oligodendroglioma (EFO_0002501), Thyroid Neoplasm (EFO_0003841), Small Cell Lung Carcinoma (EFO_0000702), Mesothelioma (EFO_0000588), Clear Cell Renal Carcinoma (EFO_0000349), Thyroid Cancer (MONDO_0002108), Peritoneum Cancer (MONDO_0002087), Rectum Cancer (EFO_1000657), Head And Neck Malignant Neoplasia (EFO_0006859), Diffuse Intrinsic Pontine Glioma (EFO_1000026), Lung Cancer (MONDO_0008903), Neoplasm (EFO_0000616), Fallopian Tube Cancer (MONDO_0002158), Urinary Bladder Cancer (MONDO_0001187), Non-Small Cell Lung Carcinoma (EFO_0003060), Colorectal Adenocarcinoma (EFO_0000365), Kidney Cancer (MONDO_0002367), Glioblastoma Multiforme (EFO_0000519), Stomach Neoplasm (EFO_0003897), Follicular Thyroid Carcinoma (EFO_0000501)', 'yearOfFirstApproval': 2011, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'TEK (ENSG00000120156), ERBB2 (ENSG00000141736), EGFR (ENSG00000146648), ERBB4 (ENSG00000178568), ERBB3 (ENSG00000065361), EPHA2 (ENSG00000142627), EPHB2 (ENSG00000133216), EPHA5 (ENSG00000145242), EPHA4 (ENSG00000116106), EPHA8 (ENSG00000070886), EPHA6 (ENSG00000080224), EPHA7 (ENSG00000135333), EPHB3 (ENSG00000182580), EPHA3 (ENSG00000044524), EPHB1 (ENSG00000154928), EPHB4 (ENSG00000196411), EPHA1 (ENSG00000146904), EPHB6 (ENSG00000106123), EPHA10 (ENSG00000183317), SRC (ENSG00000197122), RET (ENSG00000165731), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), PTK6 (ENSG00000101213)', 'numberLinkedTargets': 25}, {'UUID': 'DrugGeneTargets_v2_1935', 'drugName': 'Vandetanib', 'tradeNames_string': 'Caprelsa, Zactima', 'drugSynonyms_string': 'GNF-PF-2188, NSC-744325, NSC-760766, Vandetanib, ZD-64, ZD-6474, ZD6474', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Multiple Myeloma (EFO_0001378), Papillary Thyroid Carcinoma (EFO_0000641), Neuroblastoma (EFO_0000621), Ureter Cancer (MONDO_0008627), Verrucous Carcinoma (EFO_0007535), Thyroid Carcinoma (EFO_0002892), Gastrointestinal Stromal Tumor (MONDO_0011719), Colorectal Carcinoma (EFO_1001951), Esophageal Carcinoma (EFO_0002916), Prostate Carcinoma (EFO_0001663), Ovarian Cancer (MONDO_0008170), Gastric Cancer (MONDO_0001056), Breast Neoplasm (EFO_0003869), Anaplastic Astrocytoma (EFO_0002499), Hepatocellular Carcinoma (EFO_0000182), Gliosarcoma (EFO_1001465), Prostate Cancer (MONDO_0008315), Breast Cancer (MONDO_0007254), Oligoastrocytoma (EFO_0000630), Medullary Thyroid Gland Carcinoma (MONDO_0015277), Acute Myeloid Leukemia (EFO_0000222), Head And Neck Squamous Cell Carcinoma (EFO_0000181), Metastasis (EFO_0009708), Malignant Glioma (MONDO_0100342), Urethra Cancer (MONDO_0004192), Central Nervous System Neoplasm (EFO_1000158), Pancreatic Carcinoma (EFO_0002618), Anaplastic Oligodendroglioma (EFO_0002501), Thyroid Neoplasm (EFO_0003841), Small Cell Lung Carcinoma (EFO_0000702), Mesothelioma (EFO_0000588), Clear Cell Renal Carcinoma (EFO_0000349), Thyroid Cancer (MONDO_0002108), Peritoneum Cancer (MONDO_0002087), Rectum Cancer (EFO_1000657), Head And Neck Malignant Neoplasia (EFO_0006859), Diffuse Intrinsic Pontine Glioma (EFO_1000026), Lung Cancer (MONDO_0008903), Neoplasm (EFO_0000616), Fallopian Tube Cancer (MONDO_0002158), Urinary Bladder Cancer (MONDO_0001187), Non-Small Cell Lung Carcinoma (EFO_0003060), Colorectal Adenocarcinoma (EFO_0000365), Kidney Cancer (MONDO_0002367), Glioblastoma Multiforme (EFO_0000519), Stomach Neoplasm (EFO_0003897), Follicular Thyroid Carcinoma (EFO_0000501)', 'yearOfFirstApproval': 2011, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'TEK (ENSG00000120156), ERBB2 (ENSG00000141736), EGFR (ENSG00000146648), ERBB4 (ENSG00000178568), ERBB3 (ENSG00000065361), EPHA2 (ENSG00000142627), EPHB2 (ENSG00000133216), EPHA5 (ENSG00000145242), EPHA4 (ENSG00000116106), EPHA8 (ENSG00000070886), EPHA6 (ENSG00000080224), EPHA7 (ENSG00000135333), EPHB3 (ENSG00000182580), EPHA3 (ENSG00000044524), EPHB1 (ENSG00000154928), EPHB4 (ENSG00000196411), EPHA1 (ENSG00000146904), EPHB6 (ENSG00000106123), EPHA10 (ENSG00000183317), SRC (ENSG00000197122), RET (ENSG00000165731), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), PTK6 (ENSG00000101213)', 'numberLinkedTargets': 25}, {'UUID': 'DrugGeneTargets_v2_1933', 'drugName': 'Vandetanib', 'tradeNames_string': 'Caprelsa, Zactima', 'drugSynonyms_string': 'GNF-PF-2188, NSC-744325, NSC-760766, Vandetanib, ZD-64, ZD-6474, ZD6474', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Multiple Myeloma (EFO_0001378), Papillary Thyroid Carcinoma (EFO_0000641), Neuroblastoma (EFO_0000621), Ureter Cancer (MONDO_0008627), Verrucous Carcinoma (EFO_0007535), Thyroid Carcinoma (EFO_0002892), Gastrointestinal Stromal Tumor (MONDO_0011719), Colorectal Carcinoma (EFO_1001951), Esophageal Carcinoma (EFO_0002916), Prostate Carcinoma (EFO_0001663), Ovarian Cancer (MONDO_0008170), Gastric Cancer (MONDO_0001056), Breast Neoplasm (EFO_0003869), Anaplastic Astrocytoma (EFO_0002499), Hepatocellular Carcinoma (EFO_0000182), Gliosarcoma (EFO_1001465), Prostate Cancer (MONDO_0008315), Breast Cancer (MONDO_0007254), Oligoastrocytoma (EFO_0000630), Medullary Thyroid Gland Carcinoma (MONDO_0015277), Acute Myeloid Leukemia (EFO_0000222), Head And Neck Squamous Cell Carcinoma (EFO_0000181), Metastasis (EFO_0009708), Malignant Glioma (MONDO_0100342), Urethra Cancer (MONDO_0004192), Central Nervous System Neoplasm (EFO_1000158), Pancreatic Carcinoma (EFO_0002618), Anaplastic Oligodendroglioma (EFO_0002501), Thyroid Neoplasm (EFO_0003841), Small Cell Lung Carcinoma (EFO_0000702), Mesothelioma (EFO_0000588), Clear Cell Renal Carcinoma (EFO_0000349), Thyroid Cancer (MONDO_0002108), Peritoneum Cancer (MONDO_0002087), Rectum Cancer (EFO_1000657), Head And Neck Malignant Neoplasia (EFO_0006859), Diffuse Intrinsic Pontine Glioma (EFO_1000026), Lung Cancer (MONDO_0008903), Neoplasm (EFO_0000616), Fallopian Tube Cancer (MONDO_0002158), Urinary Bladder Cancer (MONDO_0001187), Non-Small Cell Lung Carcinoma (EFO_0003060), Colorectal Adenocarcinoma (EFO_0000365), Kidney Cancer (MONDO_0002367), Glioblastoma Multiforme (EFO_0000519), Stomach Neoplasm (EFO_0003897), Follicular Thyroid Carcinoma (EFO_0000501)', 'yearOfFirstApproval': 2011, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'TEK (ENSG00000120156), ERBB2 (ENSG00000141736), EGFR (ENSG00000146648), ERBB4 (ENSG00000178568), ERBB3 (ENSG00000065361), EPHA2 (ENSG00000142627), EPHB2 (ENSG00000133216), EPHA5 (ENSG00000145242), EPHA4 (ENSG00000116106), EPHA8 (ENSG00000070886), EPHA6 (ENSG00000080224), EPHA7 (ENSG00000135333), EPHB3 (ENSG00000182580), EPHA3 (ENSG00000044524), EPHB1 (ENSG00000154928), EPHB4 (ENSG00000196411), EPHA1 (ENSG00000146904), EPHB6 (ENSG00000106123), EPHA10 (ENSG00000183317), SRC (ENSG00000197122), RET (ENSG00000165731), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), PTK6 (ENSG00000101213)', 'numberLinkedTargets': 25}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1574 | Q17 | What gene does the drug Clopidogrel Bisulfate target? | The drug Clopidogrel Bisulfate targets the gene P2RY12. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%clopidogrel bisulfate%" OR LOWER(tradeNames_string) LIKE "%clopidogrel bisulfate%" OR LOWER(drugSynonyms_string) LIKE "%clopidogrel bisulfate%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5437', 'drugName': 'Clopidogrel Bisulfate', 'tradeNames_string': 'Clopidogrel bisulfate, Plavix', 'drugSynonyms_string': 'Clopidogrel (as bisulfate), Clopidogrel (as hydrogen sulfate), Clopidogrel bisulfate, Clopidogrel bisulphate, Clopidogrel bms, Clopidogrel hydrogen sulfate, Clopidogrel hydrogen sulphate, Clopidogrel ratiopharm, Clopidogrel sulfate, Clopidogrel teva, Clopidogrel zentiva, Clopidogrel-bgr, Clopidogrel-bms, Isocover, Pidogrel, SR 25990C, SR-25990C', 'linkedDiseasesDrug_string': 'Breast Neoplasm (EFO_0003869), Coronary Artery Disease (EFO_0001645), Peripheral Arterial Disease (EFO_0004265), Gastrointestinal Hemorrhage (HP_0002239), Stroke (EFO_0000712), Myocardial Infarction (EFO_0000612), Acute Coronary Syndrome (EFO_0005672), Intermediate Coronary Syndrome (EFO_1000985), Ischemia (EFO_0000556)', 'yearOfFirstApproval': 1997, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'P2RY12 (ENSG00000169313)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.45 | Q17 | What gene does the drug Xl-228 target? | The drug Xl-228 is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target 12 genes: FYN, LCK, ABL1, SRC, FGR, IGF1R, SRMS, HCK, BLK, YES1, LYN and FRK | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%xl-228%" OR LOWER(tradeNames_string) LIKE "%xl-228%" OR LOWER(drugSynonyms_string) LIKE "%xl-228%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4107', 'drugName': 'Xl-228', 'tradeNames_string': '', 'drugSynonyms_string': 'Exel-2280, XL228, Xl-228', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Chronic Myelogenous Leukemia (EFO_0000339), Acute Lymphoblastic Leukemia (EFO_0000220), Lymphoma (EFO_0000574)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 1, 'drugIsApproved': False, 'newLinkedTargets_string': 'ABL1 (ENSG00000097007), FYN (ENSG00000010810), SRC (ENSG00000197122), LCK (ENSG00000182866), YES1 (ENSG00000176105), BLK (ENSG00000136573), HCK (ENSG00000101336), LYN (ENSG00000254087), FRK (ENSG00000111816), FGR (ENSG00000000938), SRMS (ENSG00000125508), IGF1R (ENSG00000140443)', 'numberLinkedTargets': 12}, {'UUID': 'DrugGeneTargets_v2_4108', 'drugName': 'Xl-228', 'tradeNames_string': '', 'drugSynonyms_string': 'Exel-2280, XL228, Xl-228', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Chronic Myelogenous Leukemia (EFO_0000339), Acute Lymphoblastic Leukemia (EFO_0000220), Lymphoma (EFO_0000574)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 1, 'drugIsApproved': False, 'newLinkedTargets_string': 'ABL1 (ENSG00000097007), FYN (ENSG00000010810), SRC (ENSG00000197122), LCK (ENSG00000182866), YES1 (ENSG00000176105), BLK (ENSG00000136573), HCK (ENSG00000101336), LYN (ENSG00000254087), FRK (ENSG00000111816), FGR (ENSG00000000938), SRMS (ENSG00000125508), IGF1R (ENSG00000140443)', 'numberLinkedTargets': 12}, {'UUID': 'DrugGeneTargets_v2_4109', 'drugName': 'Xl-228', 'tradeNames_string': '', 'drugSynonyms_string': 'Exel-2280, XL228, Xl-228', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Chronic Myelogenous Leukemia (EFO_0000339), Acute Lymphoblastic Leukemia (EFO_0000220), Lymphoma (EFO_0000574)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 1, 'drugIsApproved': False, 'newLinkedTargets_string': 'ABL1 (ENSG00000097007), FYN (ENSG00000010810), SRC (ENSG00000197122), LCK (ENSG00000182866), YES1 (ENSG00000176105), BLK (ENSG00000136573), HCK (ENSG00000101336), LYN (ENSG00000254087), FRK (ENSG00000111816), FGR (ENSG00000000938), SRMS (ENSG00000125508), IGF1R (ENSG00000140443)', 'numberLinkedTargets': 12}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1608 | Q17 | What gene does the drug Trelagliptin Succinate target? | The drug Trelagliptin Succinate is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene DPP4. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%trelagliptin succinate%" OR LOWER(tradeNames_string) LIKE "%trelagliptin succinate%" OR LOWER(drugSynonyms_string) LIKE "%trelagliptin succinate%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3478', 'drugName': 'Trelagliptin Succinate', 'tradeNames_string': '', 'drugSynonyms_string': 'SYR-111472 SUCCINATE, SYR-472, SYR111472 SUCCINATE, Trelagliptin succinate, Zafatek', 'linkedDiseasesDrug_string': 'Diabetes Mellitus (EFO_0000400), Type 2 Diabetes Mellitus (MONDO_0005148)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 3, 'drugIsApproved': False, 'newLinkedTargets_string': 'DPP4 (ENSG00000197635)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.171 | Q17 | What gene does the drug Tripelennamine target? | The drug Tripelennamine targets the gene HRH1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%tripelennamine%" OR LOWER(tradeNames_string) LIKE "%tripelennamine%" OR LOWER(drugSynonyms_string) LIKE "%tripelennamine%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2166', 'drugName': 'Tripelennamine', 'tradeNames_string': '', 'drugSynonyms_string': 'NSC-118946, PBZ, PBZ-SR, Tripelennamine', 'linkedDiseasesDrug_string': 'Allergic Disease (MONDO_0005271), Pruritus (HP_0000989)', 'yearOfFirstApproval': 1948, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HRH1 (ENSG00000196639)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_703', 'drugName': 'Tripelennamine Citrate', 'tradeNames_string': '', 'drugSynonyms_string': 'NSC-757360, Tripelennamine citrate', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1948, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HRH1 (ENSG00000196639)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_5081', 'drugName': 'Tripelennamine Hydrochloride', 'tradeNames_string': 'Pbz-sr, Tripelennamine hydrochloride', 'drugSynonyms_string': 'Azaron, Dehistin, NSC-409943, Pyribenzamine, Tripelennamine chloride, Tripelennamine hcl, Tripelennamine hydrochloride, Vetibenzamina', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1948, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HRH1 (ENSG00000196639)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.307 | Q17 | What gene does the drug Pacritinib target? | The drug Pacritinib targets 2 genes: FLT3 and JAK2. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%pacritinib%" OR LOWER(tradeNames_string) LIKE "%pacritinib%" OR LOWER(drugSynonyms_string) LIKE "%pacritinib%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4275', 'drugName': 'Pacritinib', 'tradeNames_string': '', 'drugSynonyms_string': 'ONX-0803, Pacritinib, SB-1518, SB1518, Sb-1518', 'linkedDiseasesDrug_string': 'Primary Myelofibrosis (EFO_0002430), Mantle Cell Lymphoma (EFO_1001469), Breast Cancer (MONDO_0007254), Neoplasm (EFO_0000616), Myeloproliferative Disorder (EFO_0004251), Chronic Lymphocytic Leukemia (EFO_0000095), Leukemia (EFO_0000565), Graft Versus Host Disease (MONDO_0013730), Covid-19 (MONDO_0100096), Non-Small Cell Lung Carcinoma (EFO_0003060), Myelofibrosis (MONDO_0044903), Acute Myeloid Leukemia (EFO_0000222), Prostate Cancer (MONDO_0008315), Colorectal Carcinoma (EFO_1001951), Polycythemia Vera (EFO_0002429), Hodgkins Lymphoma (EFO_0000183)', 'yearOfFirstApproval': 2022, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'FLT3 (ENSG00000122025), JAK2 (ENSG00000096968)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_4274', 'drugName': 'Pacritinib', 'tradeNames_string': '', 'drugSynonyms_string': 'ONX-0803, Pacritinib, SB-1518, SB1518, Sb-1518', 'linkedDiseasesDrug_string': 'Primary Myelofibrosis (EFO_0002430), Mantle Cell Lymphoma (EFO_1001469), Breast Cancer (MONDO_0007254), Neoplasm (EFO_0000616), Myeloproliferative Disorder (EFO_0004251), Chronic Lymphocytic Leukemia (EFO_0000095), Leukemia (EFO_0000565), Graft Versus Host Disease (MONDO_0013730), Covid-19 (MONDO_0100096), Non-Small Cell Lung Carcinoma (EFO_0003060), Myelofibrosis (MONDO_0044903), Acute Myeloid Leukemia (EFO_0000222), Prostate Cancer (MONDO_0008315), Colorectal Carcinoma (EFO_1001951), Polycythemia Vera (EFO_0002429), Hodgkins Lymphoma (EFO_0000183)', 'yearOfFirstApproval': 2022, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'FLT3 (ENSG00000122025), JAK2 (ENSG00000096968)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_1107', 'drugName': 'Pacritinib Citrate', 'tradeNames_string': 'Vonjo', 'drugSynonyms_string': 'Pacritinib citrate', 'linkedDiseasesDrug_string': 'Polycythemia Vera (EFO_0002429), Primary Myelofibrosis (EFO_0002430)', 'yearOfFirstApproval': 2022, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'JAK2 (ENSG00000096968), FLT3 (ENSG00000122025)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_1106', 'drugName': 'Pacritinib Citrate', 'tradeNames_string': 'Vonjo', 'drugSynonyms_string': 'Pacritinib citrate', 'linkedDiseasesDrug_string': 'Polycythemia Vera (EFO_0002429), Primary Myelofibrosis (EFO_0002430)', 'yearOfFirstApproval': 2022, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'JAK2 (ENSG00000096968), FLT3 (ENSG00000122025)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1957 | Q17 | What gene does the drug Naratriptan Hydrochloride target? | The drug Naratriptan Hydrochloride targets 2 genes: HTR1B and HTR1D. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%naratriptan hydrochloride%" OR LOWER(tradeNames_string) LIKE "%naratriptan hydrochloride%" OR LOWER(drugSynonyms_string) LIKE "%naratriptan hydrochloride%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5845', 'drugName': 'Naratriptan Hydrochloride', 'tradeNames_string': 'Amerge, Naramig, Naratriptan', 'drugSynonyms_string': 'GR 85548A, GR-85548A, Naratriptan hcl, Naratriptan hydrochloride', 'linkedDiseasesDrug_string': 'Migraine Disorder (MONDO_0005277), Headache (HP_0002315)', 'yearOfFirstApproval': 1998, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HTR1B (ENSG00000135312), HTR1D (ENSG00000179546)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_5846', 'drugName': 'Naratriptan Hydrochloride', 'tradeNames_string': 'Amerge, Naramig, Naratriptan', 'drugSynonyms_string': 'GR 85548A, GR-85548A, Naratriptan hcl, Naratriptan hydrochloride', 'linkedDiseasesDrug_string': 'Migraine Disorder (MONDO_0005277), Headache (HP_0002315)', 'yearOfFirstApproval': 1998, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HTR1B (ENSG00000135312), HTR1D (ENSG00000179546)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1105 | Q17 | What gene does the drug Eletriptan Hydrobromide target? | The drug Eletriptan Hydrobromide targets 3 genes: HTR1B, HTR1F and HTR1D. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%eletriptan hydrobromide%" OR LOWER(tradeNames_string) LIKE "%eletriptan hydrobromide%" OR LOWER(drugSynonyms_string) LIKE "%eletriptan hydrobromide%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3980', 'drugName': 'Eletriptan Hydrobromide', 'tradeNames_string': 'Relpax', 'drugSynonyms_string': 'Eletriptan hbr, Eletriptan hydrobromide, NSC-759258, UK-116,044-04, UK-116044-04', 'linkedDiseasesDrug_string': 'Migraine Disorder (MONDO_0005277)', 'yearOfFirstApproval': 2002, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HTR1F (ENSG00000179097), HTR1D (ENSG00000179546), HTR1B (ENSG00000135312)', 'numberLinkedTargets': 3}, {'UUID': 'DrugGeneTargets_v2_3981', 'drugName': 'Eletriptan Hydrobromide', 'tradeNames_string': 'Relpax', 'drugSynonyms_string': 'Eletriptan hbr, Eletriptan hydrobromide, NSC-759258, UK-116,044-04, UK-116044-04', 'linkedDiseasesDrug_string': 'Migraine Disorder (MONDO_0005277)', 'yearOfFirstApproval': 2002, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HTR1F (ENSG00000179097), HTR1D (ENSG00000179546), HTR1B (ENSG00000135312)', 'numberLinkedTargets': 3}, {'UUID': 'DrugGeneTargets_v2_3982', 'drugName': 'Eletriptan Hydrobromide', 'tradeNames_string': 'Relpax', 'drugSynonyms_string': 'Eletriptan hbr, Eletriptan hydrobromide, NSC-759258, UK-116,044-04, UK-116044-04', 'linkedDiseasesDrug_string': 'Migraine Disorder (MONDO_0005277)', 'yearOfFirstApproval': 2002, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HTR1F (ENSG00000179097), HTR1D (ENSG00000179546), HTR1B (ENSG00000135312)', 'numberLinkedTargets': 3}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1925 | Q17 | What gene does the drug Bazedoxifene Acetate target? | The drug Bazedoxifene Acetate targets 2 genes: ESR2 and ESR1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%bazedoxifene acetate%" OR LOWER(tradeNames_string) LIKE "%bazedoxifene acetate%" OR LOWER(drugSynonyms_string) LIKE "%bazedoxifene acetate%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1341', 'drugName': 'Bazedoxifene Acetate', 'tradeNames_string': '', 'drugSynonyms_string': 'Bazedoxifen acetate, Bazedoxifene acetate, Conbriza, Duavive, WAY-140424', 'linkedDiseasesDrug_string': 'Osteoporosis (EFO_0003882), Menopause (EFO_0003922), Relapsing-Remitting Multiple Sclerosis (EFO_0003929), Postmenopausal Osteoporosis (EFO_0003854)', 'yearOfFirstApproval': 2009, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ESR2 (ENSG00000140009), ESR1 (ENSG00000091831)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1038 | Q17 | What gene does the drug Dibenzepin target? | The drug Dibenzepin targets 2 genes: SLC6A2 and HRH1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%dibenzepin%" OR LOWER(tradeNames_string) LIKE "%dibenzepin%" OR LOWER(drugSynonyms_string) LIKE "%dibenzepin%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4129', 'drugName': 'Dibenzepin', 'tradeNames_string': '', 'drugSynonyms_string': 'Dibenzepin', 'linkedDiseasesDrug_string': 'Unipolar Depression (EFO_0003761)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HRH1 (ENSG00000196639), SLC6A2 (ENSG00000103546)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_4130', 'drugName': 'Dibenzepin', 'tradeNames_string': '', 'drugSynonyms_string': 'Dibenzepin', 'linkedDiseasesDrug_string': 'Unipolar Depression (EFO_0003761)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HRH1 (ENSG00000196639), SLC6A2 (ENSG00000103546)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.658 | Q17 | What gene does the drug Marimastat target? | The drug Marimastat is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target 6 genes: MMP7, MMP12, MMP1, MMP3, MMP2 and MMP9 | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%marimastat%" OR LOWER(tradeNames_string) LIKE "%marimastat%" OR LOWER(drugSynonyms_string) LIKE "%marimastat%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5864', 'drugName': 'Marimastat', 'tradeNames_string': '', 'drugSynonyms_string': 'BB 2516, BB-2516, GI 5712, GI-5712, KB-R 8898, Marimastat, NSC-719333, TA 2516, TA-2516', 'linkedDiseasesDrug_string': 'Breast Cancer (MONDO_0007254), Lung Cancer (MONDO_0008903)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 3, 'drugIsApproved': False, 'newLinkedTargets_string': 'MMP9 (ENSG00000100985), MMP3 (ENSG00000149968), MMP7 (ENSG00000137673), MMP1 (ENSG00000196611), MMP2 (ENSG00000087245), MMP12 (ENSG00000262406)', 'numberLinkedTargets': 6}, {'UUID': 'DrugGeneTargets_v2_5860', 'drugName': 'Marimastat', 'tradeNames_string': '', 'drugSynonyms_string': 'BB 2516, BB-2516, GI 5712, GI-5712, KB-R 8898, Marimastat, NSC-719333, TA 2516, TA-2516', 'linkedDiseasesDrug_string': 'Breast Cancer (MONDO_0007254), Lung Cancer (MONDO_0008903)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 3, 'drugIsApproved': False, 'newLinkedTargets_string': 'MMP9 (ENSG00000100985), MMP3 (ENSG00000149968), MMP7 (ENSG00000137673), MMP1 (ENSG00000196611), MMP2 (ENSG00000087245), MMP12 (ENSG00000262406)', 'numberLinkedTargets': 6}, {'UUID': 'DrugGeneTargets_v2_5859', 'drugName': 'Marimastat', 'tradeNames_string': '', 'drugSynonyms_string': 'BB 2516, BB-2516, GI 5712, GI-5712, KB-R 8898, Marimastat, NSC-719333, TA 2516, TA-2516', 'linkedDiseasesDrug_string': 'Breast Cancer (MONDO_0007254), Lung Cancer (MONDO_0008903)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 3, 'drugIsApproved': False, 'newLinkedTargets_string': 'MMP9 (ENSG00000100985), MMP3 (ENSG00000149968), MMP7 (ENSG00000137673), MMP1 (ENSG00000196611), MMP2 (ENSG00000087245), MMP12 (ENSG00000262406)', 'numberLinkedTargets': 6}, {'UUID': 'DrugGeneTargets_v2_5862', 'drugName': 'Marimastat', 'tradeNames_string': '', 'drugSynonyms_string': 'BB 2516, BB-2516, GI 5712, GI-5712, KB-R 8898, Marimastat, NSC-719333, TA 2516, TA-2516', 'linkedDiseasesDrug_string': 'Breast Cancer (MONDO_0007254), Lung Cancer (MONDO_0008903)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 3, 'drugIsApproved': False, 'newLinkedTargets_string': 'MMP9 (ENSG00000100985), MMP3 (ENSG00000149968), MMP7 (ENSG00000137673), MMP1 (ENSG00000196611), MMP2 (ENSG00000087245), MMP12 (ENSG00000262406)', 'numberLinkedTargets': 6}, {'UUID': 'DrugGeneTargets_v2_5863', 'drugName': 'Marimastat', 'tradeNames_string': '', 'drugSynonyms_string': 'BB 2516, BB-2516, GI 5712, GI-5712, KB-R 8898, Marimastat, NSC-719333, TA 2516, TA-2516', 'linkedDiseasesDrug_string': 'Breast Cancer (MONDO_0007254), Lung Cancer (MONDO_0008903)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 3, 'drugIsApproved': False, 'newLinkedTargets_string': 'MMP9 (ENSG00000100985), MMP3 (ENSG00000149968), MMP7 (ENSG00000137673), MMP1 (ENSG00000196611), MMP2 (ENSG00000087245), MMP12 (ENSG00000262406)', 'numberLinkedTargets': 6}, {'UUID': 'DrugGeneTargets_v2_5861', 'drugName': 'Marimastat', 'tradeNames_string': '', 'drugSynonyms_string': 'BB 2516, BB-2516, GI 5712, GI-5712, KB-R 8898, Marimastat, NSC-719333, TA 2516, TA-2516', 'linkedDiseasesDrug_string': 'Breast Cancer (MONDO_0007254), Lung Cancer (MONDO_0008903)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 3, 'drugIsApproved': False, 'newLinkedTargets_string': 'MMP9 (ENSG00000100985), MMP3 (ENSG00000149968), MMP7 (ENSG00000137673), MMP1 (ENSG00000196611), MMP2 (ENSG00000087245), MMP12 (ENSG00000262406)', 'numberLinkedTargets': 6}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.373 | Q17 | What gene does the drug Benzquinamide target? | The drug Benzquinamide targets the gene DRD2. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%benzquinamide%" OR LOWER(tradeNames_string) LIKE "%benzquinamide%" OR LOWER(drugSynonyms_string) LIKE "%benzquinamide%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_384', 'drugName': 'Benzquinamide', 'tradeNames_string': 'Emete-con, Quantril', 'drugSynonyms_string': 'Benzchinamide, Benzquinamide, NSC-108159, NSC-169193, NSC-64375, P-2647, Promecon', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1974, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'DRD2 (ENSG00000149295)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_1440', 'drugName': 'Benzquinamide Hydrochloride', 'tradeNames_string': 'Emete-con', 'drugSynonyms_string': 'Benzquinamide hcl, Benzquinamide hydrochloride', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1974, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'DRD2 (ENSG00000149295)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1661 | Q17 | What gene does the drug Zansecimab target? | The drug Zansecimab is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene ANGPT2. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%zansecimab%" OR LOWER(tradeNames_string) LIKE "%zansecimab%" OR LOWER(drugSynonyms_string) LIKE "%zansecimab%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1159', 'drugName': 'Zansecimab', 'tradeNames_string': '', 'drugSynonyms_string': 'LY-3127804, LY3127804, Ly3127804, Zansecimab', 'linkedDiseasesDrug_string': 'Neoplasm (EFO_0000616), Covid-19 (MONDO_0100096), Pneumonia (EFO_0003106)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'ANGPT2 (ENSG00000091879)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1513 | Q17 | What gene does the drug Albiglutide target? | The drug Albiglutide targets the gene GLP1R. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%albiglutide%" OR LOWER(tradeNames_string) LIKE "%albiglutide%" OR LOWER(drugSynonyms_string) LIKE "%albiglutide%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1615', 'drugName': 'Albiglutide', 'tradeNames_string': 'Eperzan', 'drugSynonyms_string': 'Albiglutide, Albiglutide (genetical recombination), GSK-716155, GSK716155, Tanzeum', 'linkedDiseasesDrug_string': 'Diabetes Mellitus (EFO_0000400), Type 2 Diabetes Mellitus (MONDO_0005148), Congestive Heart Failure (EFO_0000373), Type 1 Diabetes Mellitus (MONDO_0005147)', 'yearOfFirstApproval': 2014, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'GLP1R (ENSG00000112164)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.778 | Q17 | What gene does the drug Ezogabine target? | The drug Ezogabine targets 5 genes: KCNQ4, KCNQ3, KCNQ5, KCNQ2 and KCNQ1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%ezogabine%" OR LOWER(tradeNames_string) LIKE "%ezogabine%" OR LOWER(drugSynonyms_string) LIKE "%ezogabine%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3665', 'drugName': 'Ezogabine', 'tradeNames_string': 'Potiga, Trobalt', 'drugSynonyms_string': 'AWD-21360, AWD21-360, D-23129, Ezogabine, GKE-841, GW-582892X, GW582892X, Retigabine, WAY-143841', 'linkedDiseasesDrug_string': 'Amyotrophic Lateral Sclerosis (MONDO_0004976), Postherpetic Neuralgia (MONDO_0041052), Major Depressive Disorder (MONDO_0002009), Epilepsy (EFO_0000474), Depressive Disorder (MONDO_0002050), Seizure (HP_0001250)', 'yearOfFirstApproval': 2011, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'KCNQ1 (ENSG00000053918), KCNQ2 (ENSG00000075043), KCNQ3 (ENSG00000184156), KCNQ5 (ENSG00000185760), KCNQ4 (ENSG00000117013)', 'numberLinkedTargets': 5}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.328 | Q17 | What gene does the drug Morphine target? | The drug Morphine targets the gene OPRM1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%morphine%" OR LOWER(tradeNames_string) LIKE "%morphine%" OR LOWER(drugSynonyms_string) LIKE "%morphine%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3300', 'drugName': 'Apomorphine Hydrochloride', 'tradeNames_string': 'Apo-go, Apo-go pen, Apo-go pfs, Apokyn, Apomorph hcl, Britaject, Bromophin, Dacepton, Diagesil, Diamorph hcl, Diamorph roche, Diamorph,cocaine,chlorpromazine, Diaphine, Euphorin, Kynmobi, Uprima', 'drugSynonyms_string': 'Apokinon, Apomine, Apomorphine HCl, Apomorphine hcl, Apomorphine hydrochloride, Apomorphine hydrochloride hemihydrate, Apomorphine hydrochloride hydrate, Apomorphinum muriaticum, Diamorphine hydrochloride , Ixense, Kw-6500, NSC-11442, NSC-755875, Taluvian', 'linkedDiseasesDrug_string': 'Neoplasm (EFO_0000616), Osteoporosis (EFO_0003882), Parkinson Disease (MONDO_0005180)', 'yearOfFirstApproval': 2004, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'DRD2 (ENSG00000149295), DRD3 (ENSG00000151577), DRD4 (ENSG00000069696)', 'numberLinkedTargets': 3}, {'UUID': 'DrugGeneTargets_v2_3650', 'drugName': 'Morphine Sulfate', 'tradeNames_string': 'Arymo er, Astramorph pf, Avinza, Depodur, Duramorph, Duramorph pf, Duromorph, Filnarine sr, Infumorph, Kadian, Moraxen, Morcap sr, Morphabond, Morphabond er, Morphgesic sr, Morphine sulfate, Morphine sulfate (autoinjector), Ms contin, Mst continus, Oramorph, Oramorph sr, Oramorph udv, Rhotard, Sevredol, Srm-rhotard, Zomorph', 'drugSynonyms_string': 'Arymo, Astramorph, Dolcontin, Kapanol, Morcap, Morphine sulfate, Morphine sulfate anhydrous, Morphine sulfate cii, Morphine sulfate hydrate, Morphine sulfate pentahydrate, Morphine sulfate,anhydrous, Morphine sulphate, Morphine sulphate anhydrous, Morphine sulphate pentahydrate, Morphini sulfas, Moscontin, NSC-11441', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Opioid Use Disorder (EFO_0010702), Drug Dependence (EFO_0003890), Neonatal Abstinence Syndrome (EFO_0005799), Chronic Pain (HP_0012532), Pain (EFO_0003843), Osteoarthritis, Knee (EFO_0004616), Myocardial Infarction (EFO_0000612), Pulmonary Arterial Hypertension (EFO_0001361), Sickle Cell Anemia (MONDO_0011382), Hallux Valgus (HP_0001822), Low Back Pain (HP_0003419), Obstructive Sleep Apnea (EFO_0003918), Idiopathic Pulmonary Fibrosis (EFO_0000768), Pruritus (HP_0000989), Opioid Dependence (EFO_0005611)', 'yearOfFirstApproval': 1984, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'OPRM1 (ENSG00000112038)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_3858', 'drugName': 'Diacetylmorphine', 'tradeNames_string': '', 'drugSynonyms_string': 'Diacetylmorphine, IDS-NH-001, IDS-NH-001(SECT.3), J6.494G', 'linkedDiseasesDrug_string': 'Opioid Use Disorder (EFO_0010702), Drug Dependence (EFO_0003890), Opioid Dependence (EFO_0005611), Heroin Dependence (EFO_0004240)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'OPRM1 (ENSG00000112038)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_1990', 'drugName': 'Codeine Phosphate', 'tradeNames_string': 'Ambenyl cough syrup, Bepro, Colrex compound, Evacode, Galcodine', 'drugSynonyms_string': 'Codeine phosphate, Codeine phosphate anhydrous, Codeine phosphate bp, Codeine phosphate cii, Codeine phosphate hemihydrate, Codeine phosphate hydrate, Codeini phosphas, Methylmorphine', 'linkedDiseasesDrug_string': 'Drug Dependence (EFO_0003890), Hiv Infection (EFO_0000764), Migraine Disorder (MONDO_0005277), Cough (HP_0012735), Pain (EFO_0003843), Muscle Spasm (HP_0003394)', 'yearOfFirstApproval': 1952, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'OPRK1 (ENSG00000082556), OPRD1 (ENSG00000116329), OPRM1 (ENSG00000112038)', 'numberLinkedTargets': 3}, {'UUID': 'DrugGeneTargets_v2_3259', 'drugName': 'Apomorphine', 'tradeNames_string': '', 'drugSynonyms_string': '6a.beta.-aporphine-10,11-diol, APL-130277, Apomorphine, Apomorphinum, VR-040, VR040', 'linkedDiseasesDrug_string': 'Osteoporosis (EFO_0003882), Erectile Dysfunction (EFO_0004234), Neoplasm (EFO_0000616), Parkinson Disease (MONDO_0005180), Brain Injury (MONDO_0043510), Hallucinations (HP_0000738), Alcohol Dependence (MONDO_0007079)', 'yearOfFirstApproval': 2004, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'DRD2 (ENSG00000149295), DRD3 (ENSG00000151577), DRD4 (ENSG00000069696)', 'numberLinkedTargets': 3}, {'UUID': 'DrugGeneTargets_v2_245', 'drugName': 'Morphine', 'tradeNames_string': '', 'drugSynonyms_string': 'Anhydrous morphine, Avinza, Depodur, Hydromorphone hydrochloride impurity, morphine-, IDS-NM-009, Infumorph, Kadian, Morphia, Morphine, Morphine (anhydrous), Morphine anhydrous, Morphine extended release, Morphine polistirex, Morphium, N02AA01, Nepenthe, Ospalivina', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Rheumatic Disease (EFO_0005755), Hemorrhage (MP_0001914), Pain (EFO_0003843), Neonatal Abstinence Syndrome (EFO_0005799), Obesity (EFO_0001073), Pulmonary Arterial Hypertension (EFO_0001361), Injury (EFO_0000546), Idiopathic Pulmonary Fibrosis (EFO_0000768), Pregnancy (EFO_0002950), Nephrolithiasis (EFO_0004253), Prostate Cancer (MONDO_0008315), Rotator Cuff Tear (EFO_1001250), Osteoarthritis, Knee (EFO_0004616), Neuropathic Pain (EFO_0005762), Acute Myocardial Infarction (EFO_0008583), Acute Myeloid Leukemia (EFO_0000222), Scoliosis (EFO_0004273), Respiratory Depression (EFO_0009842), Rib Fracture (EFO_0009620), Bone Fracture (EFO_0003931), Pruritus (HP_0000989), Heroin Dependence (EFO_0004240), Restless Legs Syndrome (EFO_0004270), Cardiac Arrest (EFO_0009492), Drug Dependence (EFO_0003890), Premature Birth (EFO_0003917), Renal Colic (EFO_1001412), Sickle Cell Anemia (MONDO_0011382), Chronic Obstructive Pulmonary Disease (EFO_0000341), Back Pain (HP_0003418), Myocardial Infarction (EFO_0000612), Constipation (HP_0002019), Obstructive Sleep Apnea (EFO_0003918), Recurrent Tonsillitis (HP_0011110), Opioid Dependence (EFO_0005611), Shortness Of Breath (EFO_0009727), Head And Neck Malignant Neoplasia (EFO_0006859), Opioid Use Disorder (EFO_0010702), Neoplasm (EFO_0000616), Post-Operative Sign Or Symptom (EFO_0005323), Adenocarcinoma (EFO_0000228), Stomatitis (EFO_0009688), Chronic Pain (HP_0012532), Blood Coagulation Disease (EFO_0009314), Mucositis (EFO_1001898), Hallux Valgus (HP_0001822), Low Back Pain (HP_0003419), Multiple Bone Fractures (EFO_0009513)', 'yearOfFirstApproval': 1984, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'OPRM1 (ENSG00000112038)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1988 | Q17 | What gene does the drug Sermorelin Acetate target? | The drug Sermorelin Acetate targets the gene GHRHR. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%sermorelin acetate%" OR LOWER(tradeNames_string) LIKE "%sermorelin acetate%" OR LOWER(drugSynonyms_string) LIKE "%sermorelin acetate%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5465', 'drugName': 'Sermorelin Acetate', 'tradeNames_string': 'Geref', 'drugSynonyms_string': 'Groliberin, Sermorelin, Sermorelin acetate', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1990, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'GHRHR (ENSG00000106128)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1924 | Q17 | What gene does the drug Brivaracetam target? | The drug Brivaracetam targets the gene SV2A. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%brivaracetam%" OR LOWER(tradeNames_string) LIKE "%brivaracetam%" OR LOWER(drugSynonyms_string) LIKE "%brivaracetam%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4908', 'drugName': 'Brivaracetam', 'tradeNames_string': 'Briviact', 'drugSynonyms_string': 'Brivaracetam, UCB 34714, UCB-34714', 'linkedDiseasesDrug_string': 'Unverricht-Lundborg Disease (Orphanet_308), Postherpetic Neuralgia (MONDO_0041052), Brain Neoplasm (EFO_0003833), Epilepsy (EFO_0000474), Seizure (HP_0001250), Spinal Cord Injury (EFO_1001919)', 'yearOfFirstApproval': 2016, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SV2A (ENSG00000159164)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.931 | Q17 | What gene does the drug Tivozanib target? | The drug Tivozanib targets 5 genes: FLT4, KIT, FLT1, KDR and PDGFRB. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%tivozanib%" OR LOWER(tradeNames_string) LIKE "%tivozanib%" OR LOWER(drugSynonyms_string) LIKE "%tivozanib%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_876', 'drugName': 'Tivozanib', 'tradeNames_string': 'Fotivda', 'drugSynonyms_string': 'ASP-4130, AV-951, KIL8951, KRN-951, Kil-8951, Krn-951, Tivozanib', 'linkedDiseasesDrug_string': 'Hepatocellular Carcinoma (EFO_0000182), Prostate Cancer (MONDO_0008315), Fallopian Tube Cancer (MONDO_0002158), Breast Cancer (MONDO_0007254), Neoplasm (EFO_0000616), Liver Disease (EFO_0001421), Non-Small Cell Lung Carcinoma (EFO_0003060), Soft Tissue Sarcoma (EFO_1001968), Renal Cell Carcinoma (EFO_0000681), Glioblastoma Multiforme (EFO_0000519), Colorectal Carcinoma (EFO_1001951), Cholangiocarcinoma (EFO_0005221), Ovarian Cancer (MONDO_0008170)', 'yearOfFirstApproval': 2021, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), KIT (ENSG00000157404), PDGFRB (ENSG00000113721)', 'numberLinkedTargets': 5}, {'UUID': 'DrugGeneTargets_v2_2105', 'drugName': 'Tivozanib Hydrochloride', 'tradeNames_string': 'Fotivda', 'drugSynonyms_string': 'AV-951, Tivozanib hydrochloride, Tivozanib hydrochloride monohydrate', 'linkedDiseasesDrug_string': 'Renal Cell Carcinoma (EFO_0000681), Liver Disease (EFO_0001421), Breast Cancer (MONDO_0007254)', 'yearOfFirstApproval': 2021, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), KIT (ENSG00000157404), PDGFRB (ENSG00000113721)', 'numberLinkedTargets': 5}, {'UUID': 'DrugGeneTargets_v2_2104', 'drugName': 'Tivozanib Hydrochloride', 'tradeNames_string': 'Fotivda', 'drugSynonyms_string': 'AV-951, Tivozanib hydrochloride, Tivozanib hydrochloride monohydrate', 'linkedDiseasesDrug_string': 'Renal Cell Carcinoma (EFO_0000681), Liver Disease (EFO_0001421), Breast Cancer (MONDO_0007254)', 'yearOfFirstApproval': 2021, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), KIT (ENSG00000157404), PDGFRB (ENSG00000113721)', 'numberLinkedTargets': 5}, {'UUID': 'DrugGeneTargets_v2_874', 'drugName': 'Tivozanib', 'tradeNames_string': 'Fotivda', 'drugSynonyms_string': 'ASP-4130, AV-951, KIL8951, KRN-951, Kil-8951, Krn-951, Tivozanib', 'linkedDiseasesDrug_string': 'Hepatocellular Carcinoma (EFO_0000182), Prostate Cancer (MONDO_0008315), Fallopian Tube Cancer (MONDO_0002158), Breast Cancer (MONDO_0007254), Neoplasm (EFO_0000616), Liver Disease (EFO_0001421), Non-Small Cell Lung Carcinoma (EFO_0003060), Soft Tissue Sarcoma (EFO_1001968), Renal Cell Carcinoma (EFO_0000681), Glioblastoma Multiforme (EFO_0000519), Colorectal Carcinoma (EFO_1001951), Cholangiocarcinoma (EFO_0005221), Ovarian Cancer (MONDO_0008170)', 'yearOfFirstApproval': 2021, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), KIT (ENSG00000157404), PDGFRB (ENSG00000113721)', 'numberLinkedTargets': 5}, {'UUID': 'DrugGeneTargets_v2_875', 'drugName': 'Tivozanib', 'tradeNames_string': 'Fotivda', 'drugSynonyms_string': 'ASP-4130, AV-951, KIL8951, KRN-951, Kil-8951, Krn-951, Tivozanib', 'linkedDiseasesDrug_string': 'Hepatocellular Carcinoma (EFO_0000182), Prostate Cancer (MONDO_0008315), Fallopian Tube Cancer (MONDO_0002158), Breast Cancer (MONDO_0007254), Neoplasm (EFO_0000616), Liver Disease (EFO_0001421), Non-Small Cell Lung Carcinoma (EFO_0003060), Soft Tissue Sarcoma (EFO_1001968), Renal Cell Carcinoma (EFO_0000681), Glioblastoma Multiforme (EFO_0000519), Colorectal Carcinoma (EFO_1001951), Cholangiocarcinoma (EFO_0005221), Ovarian Cancer (MONDO_0008170)', 'yearOfFirstApproval': 2021, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), KIT (ENSG00000157404), PDGFRB (ENSG00000113721)', 'numberLinkedTargets': 5}, {'UUID': 'DrugGeneTargets_v2_2106', 'drugName': 'Tivozanib Hydrochloride', 'tradeNames_string': 'Fotivda', 'drugSynonyms_string': 'AV-951, Tivozanib hydrochloride, Tivozanib hydrochloride monohydrate', 'linkedDiseasesDrug_string': 'Renal Cell Carcinoma (EFO_0000681), Liver Disease (EFO_0001421), Breast Cancer (MONDO_0007254)', 'yearOfFirstApproval': 2021, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), KIT (ENSG00000157404), PDGFRB (ENSG00000113721)', 'numberLinkedTargets': 5}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.188 | Q17 | What gene does the drug Iph-2101 target? | The drug Iph-2101 is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target 3 genes: KIR2DL3, KIR2DL1 and KIR2DL2 | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%iph-2101%" OR LOWER(tradeNames_string) LIKE "%iph-2101%" OR LOWER(drugSynonyms_string) LIKE "%iph-2101%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4723', 'drugName': 'Iph-2101', 'tradeNames_string': '', 'drugSynonyms_string': '1-7F9, IHP-2101, IPH-2101, IPH2101, Iph-2101', 'linkedDiseasesDrug_string': 'Acute Myeloid Leukemia (EFO_0000222), Multiple Myeloma (EFO_0001378)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'KIR2DL2 (ENSG00000275546), KIR2DL1 (ENSG00000125498), KIR2DL3 (ENSG00000243772)', 'numberLinkedTargets': 3}, {'UUID': 'DrugGeneTargets_v2_4724', 'drugName': 'Iph-2101', 'tradeNames_string': '', 'drugSynonyms_string': '1-7F9, IHP-2101, IPH-2101, IPH2101, Iph-2101', 'linkedDiseasesDrug_string': 'Acute Myeloid Leukemia (EFO_0000222), Multiple Myeloma (EFO_0001378)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'KIR2DL2 (ENSG00000275546), KIR2DL1 (ENSG00000125498), KIR2DL3 (ENSG00000243772)', 'numberLinkedTargets': 3}, {'UUID': 'DrugGeneTargets_v2_4725', 'drugName': 'Iph-2101', 'tradeNames_string': '', 'drugSynonyms_string': '1-7F9, IHP-2101, IPH-2101, IPH2101, Iph-2101', 'linkedDiseasesDrug_string': 'Acute Myeloid Leukemia (EFO_0000222), Multiple Myeloma (EFO_0001378)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'KIR2DL2 (ENSG00000275546), KIR2DL1 (ENSG00000125498), KIR2DL3 (ENSG00000243772)', 'numberLinkedTargets': 3}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1595 | Q17 | What gene does the drug Atabecestat target? | The drug Atabecestat is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene BACE1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%atabecestat%" OR LOWER(tradeNames_string) LIKE "%atabecestat%" OR LOWER(drugSynonyms_string) LIKE "%atabecestat%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_416', 'drugName': 'Atabecestat', 'tradeNames_string': '', 'drugSynonyms_string': 'Atabecestat, JNJ-54861911, JNJ-54861911-AAA, Jnj-54861911, RSC- 385896, RSC-385896', 'linkedDiseasesDrug_string': 'Alzheimer Disease (MONDO_0004975)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'BACE1 (ENSG00000186318)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.772 | Q17 | What gene does the drug Aclidinium target? | The drug Aclidinium targets the gene CHRM3. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%aclidinium%" OR LOWER(tradeNames_string) LIKE "%aclidinium%" OR LOWER(drugSynonyms_string) LIKE "%aclidinium%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_6136', 'drugName': 'Aclidinium Bromide', 'tradeNames_string': 'Eklira, Tudorza pressair', 'drugSynonyms_string': '14115700, Aclidinium bromide, Genuair, LAS 34273, LAS 34273 MICRONIZED, LAS W-330, LAS-34273, LAS-34273 MICRONIZED, LAS-W-330', 'linkedDiseasesDrug_string': 'Asthma (MONDO_0004979), Chronic Bronchitis (EFO_0006505), Nicotine Dependence (EFO_0003768), Chronic Obstructive Pulmonary Disease (EFO_0000341), Airway Obstruction (HP_0006536), Emphysema (EFO_0000464)', 'yearOfFirstApproval': 2012, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CHRM3 (ENSG00000133019)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_4890', 'drugName': 'Aclidinium', 'tradeNames_string': '', 'drugSynonyms_string': 'Aclidinium, Aclidinium cation, Aclidinium ion', 'linkedDiseasesDrug_string': 'Asthma (MONDO_0004979), Chronic Bronchitis (EFO_0006505), Nicotine Dependence (EFO_0003768), Chronic Obstructive Pulmonary Disease (EFO_0000341), Airway Obstruction (HP_0006536), Emphysema (EFO_0000464)', 'yearOfFirstApproval': 2012, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CHRM3 (ENSG00000133019)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1203 | Q17 | What gene does the drug Fentanyl Citrate target? | The drug Fentanyl Citrate targets the gene OPRM1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%fentanyl citrate%" OR LOWER(tradeNames_string) LIKE "%fentanyl citrate%" OR LOWER(drugSynonyms_string) LIKE "%fentanyl citrate%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_733', 'drugName': 'Fentanyl Citrate', 'tradeNames_string': 'Abstral, Actiq, Fentanyl, Fentanyl citrate, Fentanyl citrate preservative free, Fentora, Lazanda, Onsolis, Sublimaze, Sublimaze preservative free, Thalamonal', 'drugSynonyms_string': 'Fentanyl buccal, Fentanyl citrate, Fentanyl citrate cii, Instanyl, Kw-2246, Leptanal, MCN-JR-4263-49, R-4263', 'linkedDiseasesDrug_string': 'Shortness Of Breath (EFO_0009727), Cancer (MONDO_0004992), Dyspnea (HP_0002094), Pulpitis (EFO_1001139), Pain (EFO_0003843), Chronic Pain (HP_0012532), Neuropathic Pain (EFO_0005762), Interstitial Lung Disease (EFO_0004244), Low Back Pain (HP_0003419), Injury (EFO_0000546)', 'yearOfFirstApproval': 1968, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'OPRM1 (ENSG00000112038)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.500 | Q17 | What gene does the drug Thiamylal target? | The drug Thiamylal targets 16 genes: GABRG2, GABRE, GABRA4, GABRQ, GABRD, GABRA3, GABRP, GABRA5, GABRG3, GABRB2, GABRB3, GABRG1, GABRA2, GABRB1, GABRA6 and GABRA1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%thiamylal%" OR LOWER(tradeNames_string) LIKE "%thiamylal%" OR LOWER(drugSynonyms_string) LIKE "%thiamylal%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3421', 'drugName': 'Thiamylal Sodium', 'tradeNames_string': 'Surital', 'drugSynonyms_string': 'NSC-759558, Sodium thiamylal, Thiamylal sodium, Thiamylal sodium salt', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1982, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863)', 'numberLinkedTargets': 16}, {'UUID': 'DrugGeneTargets_v2_5165', 'drugName': 'Thiamylal', 'tradeNames_string': '', 'drugSynonyms_string': 'NSC-120815, Thiamylal', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1982, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863)', 'numberLinkedTargets': 16}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1064 | Q17 | What gene does the drug Nalbuphine Hydrochloride target? | The drug Nalbuphine Hydrochloride targets 3 genes: OPRK1, OPRM1 and OPRD1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%nalbuphine hydrochloride%" OR LOWER(tradeNames_string) LIKE "%nalbuphine hydrochloride%" OR LOWER(drugSynonyms_string) LIKE "%nalbuphine hydrochloride%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1991', 'drugName': 'Nalbuphine Hydrochloride', 'tradeNames_string': 'Nalbuphine, Nalbuphine hydrochloride, Nubain', 'drugSynonyms_string': 'EN-2234A, NSC-757829, Nalbufine hydrochloride, Nalbuphine hcl, Nalbuphine hydrochloride', 'linkedDiseasesDrug_string': 'Rotator Cuff Tear (EFO_1001250), Post-Operative Sign Or Symptom (EFO_0005323), Liver Disease (EFO_0001421), Pain (EFO_0003843), Delirium (EFO_0009267), Acute Myeloid Leukemia (EFO_0000222), Cleft Palate (HP_0000175), Pruritus (HP_0000989), Opioid Dependence (EFO_0005611)', 'yearOfFirstApproval': 1979, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'OPRK1 (ENSG00000082556), OPRD1 (ENSG00000116329), OPRM1 (ENSG00000112038)', 'numberLinkedTargets': 3}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1111 | Q17 | What gene does the drug Levoketoconazole target? | The drug Levoketoconazole targets 4 genes: CYP11A1, CYP17A1, CYP11B2 and CYP11B1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%levoketoconazole%" OR LOWER(tradeNames_string) LIKE "%levoketoconazole%" OR LOWER(drugSynonyms_string) LIKE "%levoketoconazole%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3930', 'drugName': 'Levoketoconazole', 'tradeNames_string': 'Extina, Ketosidin, Ketozole, Nizoral, Nizoral A-D, Panfungol, Recorlev, Xolegel', 'drugSynonyms_string': '(-)-(2s,4r)-ketoconazole, 2s,4r ketoconazole, 2s,4r-ketoconazole, COR-003, COR003, DIO-902, Ketoconazole, (2s,4r)-, Levoketoconazole, Nizoral, Normocort, R-41400', 'linkedDiseasesDrug_string': "Pituitary-Dependent Cushing'S Disease (EFO_1001110), Type 2 Diabetes Mellitus (MONDO_0005148), Cushing Syndrome (EFO_0003099), Adrenal Gland Hyperfunction (EFO_1000797)", 'yearOfFirstApproval': 2021, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CYP11B1 (ENSG00000160882), CYP11B2 (ENSG00000179142), CYP17A1 (ENSG00000148795), CYP11A1 (ENSG00000140459)', 'numberLinkedTargets': 4}, {'UUID': 'DrugGeneTargets_v2_3929', 'drugName': 'Levoketoconazole', 'tradeNames_string': 'Extina, Ketosidin, Ketozole, Nizoral, Nizoral A-D, Panfungol, Recorlev, Xolegel', 'drugSynonyms_string': '(-)-(2s,4r)-ketoconazole, 2s,4r ketoconazole, 2s,4r-ketoconazole, COR-003, COR003, DIO-902, Ketoconazole, (2s,4r)-, Levoketoconazole, Nizoral, Normocort, R-41400', 'linkedDiseasesDrug_string': "Pituitary-Dependent Cushing'S Disease (EFO_1001110), Type 2 Diabetes Mellitus (MONDO_0005148), Cushing Syndrome (EFO_0003099), Adrenal Gland Hyperfunction (EFO_1000797)", 'yearOfFirstApproval': 2021, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CYP11B1 (ENSG00000160882), CYP11B2 (ENSG00000179142), CYP17A1 (ENSG00000148795), CYP11A1 (ENSG00000140459)', 'numberLinkedTargets': 4}, {'UUID': 'DrugGeneTargets_v2_3932', 'drugName': 'Levoketoconazole', 'tradeNames_string': 'Extina, Ketosidin, Ketozole, Nizoral, Nizoral A-D, Panfungol, Recorlev, Xolegel', 'drugSynonyms_string': '(-)-(2s,4r)-ketoconazole, 2s,4r ketoconazole, 2s,4r-ketoconazole, COR-003, COR003, DIO-902, Ketoconazole, (2s,4r)-, Levoketoconazole, Nizoral, Normocort, R-41400', 'linkedDiseasesDrug_string': "Pituitary-Dependent Cushing'S Disease (EFO_1001110), Type 2 Diabetes Mellitus (MONDO_0005148), Cushing Syndrome (EFO_0003099), Adrenal Gland Hyperfunction (EFO_1000797)", 'yearOfFirstApproval': 2021, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CYP11B1 (ENSG00000160882), CYP11B2 (ENSG00000179142), CYP17A1 (ENSG00000148795), CYP11A1 (ENSG00000140459)', 'numberLinkedTargets': 4}, {'UUID': 'DrugGeneTargets_v2_3931', 'drugName': 'Levoketoconazole', 'tradeNames_string': 'Extina, Ketosidin, Ketozole, Nizoral, Nizoral A-D, Panfungol, Recorlev, Xolegel', 'drugSynonyms_string': '(-)-(2s,4r)-ketoconazole, 2s,4r ketoconazole, 2s,4r-ketoconazole, COR-003, COR003, DIO-902, Ketoconazole, (2s,4r)-, Levoketoconazole, Nizoral, Normocort, R-41400', 'linkedDiseasesDrug_string': "Pituitary-Dependent Cushing'S Disease (EFO_1001110), Type 2 Diabetes Mellitus (MONDO_0005148), Cushing Syndrome (EFO_0003099), Adrenal Gland Hyperfunction (EFO_1000797)", 'yearOfFirstApproval': 2021, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CYP11B1 (ENSG00000160882), CYP11B2 (ENSG00000179142), CYP17A1 (ENSG00000148795), CYP11A1 (ENSG00000140459)', 'numberLinkedTargets': 4}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.536 | Q17 | What gene does the drug Azd-8848 target? | The drug Azd-8848 is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene TLR7. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%azd-8848%" OR LOWER(tradeNames_string) LIKE "%azd-8848%" OR LOWER(drugSynonyms_string) LIKE "%azd-8848%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3550', 'drugName': 'Azd-8848', 'tradeNames_string': '', 'drugSynonyms_string': 'AZD8848, Azd 8848, Azd-8848, Azd8848, DSP-3025, Dsp-3025', 'linkedDiseasesDrug_string': 'Allergic Rhinitis (EFO_0005854)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'TLR7 (ENSG00000196664)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1601 | Q17 | What gene does the drug Selegiline target? | The drug Selegiline targets the gene MAOB. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%selegiline%" OR LOWER(tradeNames_string) LIKE "%selegiline%" OR LOWER(drugSynonyms_string) LIKE "%selegiline%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_991', 'drugName': 'Selegiline Hydrochloride', 'tradeNames_string': 'Centrapryl 10, Centrapryl 5, Eldepryl, Ensam, Selegiline hydrochloride, Stilline 10, Stilline 5, Vivapryl, Zelapar', 'drugSynonyms_string': 'L-deprenyl, NSC-759259, Selegiline hcl, Selegiline hydrochloride', 'linkedDiseasesDrug_string': 'Alzheimer Disease (MONDO_0004975), Cannabis Dependence (EFO_0007191)', 'yearOfFirstApproval': 1989, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'MAOB (ENSG00000069535)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_4707', 'drugName': 'Selegiline', 'tradeNames_string': 'Eldepryl, Emsam, Zelapar', 'drugSynonyms_string': 'Eldepryl, L-selegiline, Selegiline, Zelapar', 'linkedDiseasesDrug_string': 'Alzheimer Disease (MONDO_0004975), Methamphetamine Dependence (EFO_0004701), Unipolar Depression (EFO_0003761), Nicotine Dependence (EFO_0003768), Borderline Personality Disorder (HP_0012076), Parkinson Disease (MONDO_0005180), Cannabis Dependence (EFO_0007191), Cocaine Dependence (EFO_0002610), Major Depressive Disorder (MONDO_0002009), Depressive Disorder (MONDO_0002050), Schizophrenia (MONDO_0005090), Prostate Adenocarcinoma (EFO_0000673)', 'yearOfFirstApproval': 1989, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'MAOB (ENSG00000069535)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.752 | Q17 | What gene does the drug Desogestrel target? | The drug Desogestrel targets the gene PGR. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%desogestrel%" OR LOWER(tradeNames_string) LIKE "%desogestrel%" OR LOWER(drugSynonyms_string) LIKE "%desogestrel%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2631', 'drugName': 'Desogestrel', 'tradeNames_string': 'Aizea, Cerazette, Cerelle, Desomono, Feanolla, Nacrez, Zelleta', 'drugSynonyms_string': 'Desogestrel, Mircette, ORG 2969, ORG-2969', 'linkedDiseasesDrug_string': 'Hemorrhage (MP_0001914), Ondine Syndrome (Orphanet_661), Polycystic Ovary Syndrome (EFO_0000660), Amenorrhea (EFO_0010269)', 'yearOfFirstApproval': 1992, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'PGR (ENSG00000082175)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1933 | Q17 | What gene does the drug Dabigatran Etexilate target? | The drug Dabigatran Etexilate targets the gene F2. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%dabigatran etexilate%" OR LOWER(tradeNames_string) LIKE "%dabigatran etexilate%" OR LOWER(drugSynonyms_string) LIKE "%dabigatran etexilate%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5711', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_string': 'Pradaxa', 'drugSynonyms_string': 'BIBR 1048 MS, BIBR-1048-MS, Dabigatran etexilate mesilate, Dabigatran etexilate mesylate', 'linkedDiseasesDrug_string': 'Acute Pancreatitis (EFO_1000652), Stroke (EFO_0000712), Deep Vein Thrombosis (EFO_0003907), Atrial Fibrillation (EFO_0000275)', 'yearOfFirstApproval': 2010, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'F2 (ENSG00000180210)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_952', 'drugName': 'Dabigatran Etexilate', 'tradeNames_string': 'Pradaxa', 'drugSynonyms_string': 'BIBR 1048, BIBR 1048 BS RS1, BIBR-1048, BIBR-1048-BS-RS1, Dabigatran etexilate, Dabigatran etexilate methanesulfonate', 'linkedDiseasesDrug_string': 'Recurrent Thrombophlebitis (HP_0004419), Chronic Kidney Disease (EFO_0003884), Coronary Artery Disease (EFO_0001645), Abnormality Of Blood And Blood-Forming Tissues (HP_0001871), Stroke (EFO_0000712), Deep Vein Thrombosis (EFO_0003907), Venous Thromboembolism (EFO_0004286), Non-Alcoholic Fatty Liver Disease (EFO_0003095), Thromboembolism (HP_0001907), Venous Thrombosis (HP_0004936), Thrombotic Disease (MONDO_0000831), Renal Insufficiency (HP_0000083), Acute Pancreatitis (EFO_1000652), Prostate Adenocarcinoma (EFO_0000673), Atrial Fibrillation (EFO_0000275)', 'yearOfFirstApproval': 2010, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'F2 (ENSG00000180210)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1367 | Q17 | What gene does the drug Zamicastat target? | The drug Zamicastat is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene DBH. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%zamicastat%" OR LOWER(tradeNames_string) LIKE "%zamicastat%" OR LOWER(drugSynonyms_string) LIKE "%zamicastat%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2943', 'drugName': 'Zamicastat', 'tradeNames_string': '', 'drugSynonyms_string': 'Zamicastat', 'linkedDiseasesDrug_string': 'Pulmonary Arterial Hypertension (EFO_0001361)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'DBH (ENSG00000123454)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1444 | Q17 | What gene does the drug Lasmiditan Succinate target? | The drug Lasmiditan Succinate targets the gene HTR1F. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%lasmiditan succinate%" OR LOWER(tradeNames_string) LIKE "%lasmiditan succinate%" OR LOWER(drugSynonyms_string) LIKE "%lasmiditan succinate%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1894', 'drugName': 'Lasmiditan Succinate', 'tradeNames_string': 'Reyvow', 'drugSynonyms_string': 'LY-573144, LY-683974, LY683974, Lasmiditan hemisuccinate, Lasmiditan succinate', 'linkedDiseasesDrug_string': 'Migraine Disorder (MONDO_0005277)', 'yearOfFirstApproval': 2020, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HTR1F (ENSG00000179097)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.178 | Q17 | What gene does the drug Amphetamine Adipate target? | The drug Amphetamine Adipate targets 2 genes: SLC6A2 and SLC6A3. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%amphetamine adipate%" OR LOWER(tradeNames_string) LIKE "%amphetamine adipate%" OR LOWER(drugSynonyms_string) LIKE "%amphetamine adipate%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3242', 'drugName': 'Dextroamphetamine Adipate', 'tradeNames_string': '', 'drugSynonyms_string': 'D-amphetamine adipate, Dextroamphetamine adipate', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1975, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SLC18A2 (ENSG00000165646), SLC6A2 (ENSG00000103546), SLC6A3 (ENSG00000142319)', 'numberLinkedTargets': 3}, {'UUID': 'DrugGeneTargets_v2_4235', 'drugName': 'Amphetamine Adipate', 'tradeNames_string': '', 'drugSynonyms_string': 'Amphetamine adipate', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1975, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SLC6A2 (ENSG00000103546), SLC6A3 (ENSG00000142319)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_4236', 'drugName': 'Amphetamine Adipate', 'tradeNames_string': '', 'drugSynonyms_string': 'Amphetamine adipate', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1975, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SLC6A2 (ENSG00000103546), SLC6A3 (ENSG00000142319)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_3243', 'drugName': 'Dextroamphetamine Adipate', 'tradeNames_string': '', 'drugSynonyms_string': 'D-amphetamine adipate, Dextroamphetamine adipate', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1975, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SLC18A2 (ENSG00000165646), SLC6A2 (ENSG00000103546), SLC6A3 (ENSG00000142319)', 'numberLinkedTargets': 3}, {'UUID': 'DrugGeneTargets_v2_3241', 'drugName': 'Dextroamphetamine Adipate', 'tradeNames_string': '', 'drugSynonyms_string': 'D-amphetamine adipate, Dextroamphetamine adipate', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1975, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SLC18A2 (ENSG00000165646), SLC6A2 (ENSG00000103546), SLC6A3 (ENSG00000142319)', 'numberLinkedTargets': 3}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.470 | Q17 | What gene does the drug Yttrium Y 90 Ibritumomab Tiuxetan target? | The drug Yttrium Y 90 Ibritumomab Tiuxetan targets the gene MS4A1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%yttrium y 90 ibritumomab tiuxetan%" OR LOWER(tradeNames_string) LIKE "%yttrium y 90 ibritumomab tiuxetan%" OR LOWER(drugSynonyms_string) LIKE "%yttrium y 90 ibritumomab tiuxetan%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1480', 'drugName': 'Yttrium Y 90 Ibritumomab Tiuxetan', 'tradeNames_string': '', 'drugSynonyms_string': '(90)y-ibritumomab tiuxetan, 90y ibritumomab tiuxetan, 90y-ibritumomab, BAY-86-5128, Ibritumomab tiuxetan, Ibritumomab tiuxetan y-90, Ibritumomab tiuxetan yttrium y-90, Yttrium y 90 ibritumomab tiuxetan, Yttrium y-90 ibritumomab tiuxetan', 'linkedDiseasesDrug_string': 'Multiple Myeloma (EFO_0001378), Non-Hodgkins Lymphoma (EFO_0005952), Mantle Cell Lymphoma (EFO_1001469), Chronic Lymphocytic Leukemia (EFO_0000095), Leukemia (EFO_0000565), Neoplasm Of Mature B-Cells (EFO_0000096), Lymphoma, Aids-Related (EFO_1001365), Follicular Lymphoma (MONDO_0018906), Graft Versus Host Disease (MONDO_0013730), Lymphoblastic Lymphoma (MONDO_0000873), Lymphoma (EFO_0000574), Anaplastic Large Cell Lymphoma (EFO_0003032), Waldenstrom Macroglobulinemia (EFO_0009441), Burkitts Lymphoma (EFO_0000309), Diffuse Large B-Cell Lymphoma (EFO_0000403), Malt Lymphoma (EFO_0000191), Hodgkins Lymphoma (EFO_0000183)', 'yearOfFirstApproval': 2002, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'MS4A1 (ENSG00000156738)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1337 | Q17 | What gene does the drug Lumasiran Sodium target? | The drug Lumasiran Sodium targets the gene HAO1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%lumasiran sodium%" OR LOWER(tradeNames_string) LIKE "%lumasiran sodium%" OR LOWER(drugSynonyms_string) LIKE "%lumasiran sodium%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1071', 'drugName': 'Lumasiran Sodium', 'tradeNames_string': 'Oxlumo', 'drugSynonyms_string': 'Lumasiran sodium', 'linkedDiseasesDrug_string': 'Primary Hyperoxaluria Type 1 (MONDO_0009823)', 'yearOfFirstApproval': 2020, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HAO1 (ENSG00000101323)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1611 | Q17 | What gene does the drug Pyrilamine Maleate target? | The drug Pyrilamine Maleate targets the gene HRH1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%pyrilamine maleate%" OR LOWER(tradeNames_string) LIKE "%pyrilamine maleate%" OR LOWER(drugSynonyms_string) LIKE "%pyrilamine maleate%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3763', 'drugName': 'Pyrilamine Maleate', 'tradeNames_string': 'Pyrilamine maleate', 'drugSynonyms_string': 'Antamine, Anthisan, Dorantamin, Enrumay, Histalon, Histan, Histapyran, Histatex, Mepyramine maleate, NSC-3604, Neo-antergan, Paraminyl, Parmal, Pyramal, Pyrilamine maleate, Stamine, Stangen, Thylogen', 'linkedDiseasesDrug_string': 'Seasonal Allergic Rhinitis (EFO_0003956)', 'yearOfFirstApproval': 1973, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HRH1 (ENSG00000196639)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.126 | Q17 | What gene does the drug Difamilast target? | The drug Difamilast is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target 4 genes: PDE4A, PDE4D, PDE4B and PDE4C | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%difamilast%" OR LOWER(tradeNames_string) LIKE "%difamilast%" OR LOWER(drugSynonyms_string) LIKE "%difamilast%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4073', 'drugName': 'Difamilast', 'tradeNames_string': '', 'drugSynonyms_string': 'Difamilast, OPA-15406', 'linkedDiseasesDrug_string': 'Atopic Eczema (EFO_0000274)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 3, 'drugIsApproved': False, 'newLinkedTargets_string': 'PDE4A (ENSG00000065989), PDE4D (ENSG00000113448), PDE4B (ENSG00000184588), PDE4C (ENSG00000105650)', 'numberLinkedTargets': 4}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.355 | Q17 | What gene does the drug Clomiphene target? | The drug Clomiphene targets the gene ESR1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%clomiphene%" OR LOWER(tradeNames_string) LIKE "%clomiphene%" OR LOWER(drugSynonyms_string) LIKE "%clomiphene%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2969', 'drugName': 'Clomiphene', 'tradeNames_string': '', 'drugSynonyms_string': 'Clomifene, Clomiphene', 'linkedDiseasesDrug_string': 'Hypogonadism (MONDO_0002146), Polycystic Ovary Syndrome (EFO_0000660), Female Infertility (EFO_0008560), Hemorrhage (MP_0001914), Acromegaly (EFO_1001485), Uterine Fibroid (EFO_0000731), Obesity (EFO_0001073), Infertility (EFO_0000545), Azoospermia (EFO_0000279), Hypogonadotropic Hypogonadism (MONDO_0018555), Reproductive System Disease (EFO_0000512), Anovulation (MONDO_0002775)', 'yearOfFirstApproval': 1967, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ESR1 (ENSG00000091831)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_6194', 'drugName': 'Clomiphene Citrate', 'tradeNames_string': 'Clomid, Clomiphene citrate, Clophene, Milophene, Serophene', 'drugSynonyms_string': 'Chloramiphene, Clomid, Clomifene citrate, Clomifeni citras, Clomiphene citrate, Clomiphene citrate (1:1), Clostilbegyt, Ikaclomine, MER-41, MRL-41, NSC-35770, Pergotime', 'linkedDiseasesDrug_string': 'Hemorrhage (MP_0001914), Polycystic Ovary Syndrome (EFO_0000660), Female Infertility (EFO_0008560), Infertility (EFO_0000545)', 'yearOfFirstApproval': 1967, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ESR1 (ENSG00000091831)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_6138', 'drugName': 'Enclomiphene', 'tradeNames_string': '', 'drugSynonyms_string': 'Cisclomiphene, Clomiphene trans-form, Enclomifene, Enclomiphene, ICI-46476, ISOMER B, ISOMER-B, Isomer B, Milophene, RMI 16,289, RMI-16289, Rmi-16,289, Serophene', 'linkedDiseasesDrug_string': 'Hypogonadism (MONDO_0002146), Polycystic Ovary Syndrome (EFO_0000660), Infertility (EFO_0000545), Obesity (EFO_0001073), Hypogonadotropic Hypogonadism (MONDO_0018555)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 3, 'drugIsApproved': False, 'newLinkedTargets_string': 'ESR1 (ENSG00000091831)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.388 | Q17 | What gene does the drug Sunitinib target? | The drug Sunitinib targets 9 genes: FLT4, FLT3, RET, KIT, FLT1, KDR, CSF1R, PDGFRB and PDGFRA. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%sunitinib%" OR LOWER(tradeNames_string) LIKE "%sunitinib%" OR LOWER(drugSynonyms_string) LIKE "%sunitinib%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3923', 'drugName': 'Sunitinib Malate', 'tradeNames_string': 'Sunitinib malate, Sutent', 'drugSynonyms_string': 'PHA-290940AD, SU-010398, SU-011248 L-MALATE SALT, SU010398, SU011248 L-MALATE SALT, Sunitinib l-malate, Sunitinib malate, Sutent', 'linkedDiseasesDrug_string': "Cancer (MONDO_0004992), Multiple Myeloma (EFO_0001378), Papillary Thyroid Carcinoma (EFO_0000641), Islet Cell Tumor (EFO_0007331), Chronic Lymphocytic Leukemia (EFO_0000095), Mixed Glioma (MONDO_0003268), Thymic Carcinoma (EFO_1000576), Oligodendroglioma (EFO_0000632), Gastrointestinal Stromal Tumor (MONDO_0011719), Metastatic Melanoma (EFO_0002617), Colorectal Carcinoma (EFO_1001951), Laryngeal Squamous Cell Carcinoma (EFO_0006352), Prostate Adenocarcinoma (EFO_0000673), Anaplastic Astrocytoma (EFO_0002499), Gliosarcoma (EFO_1001465), Papillary Renal Cell Carcinoma (EFO_0000640), Hepatocellular Carcinoma (EFO_0000182), Prostate Cancer (MONDO_0008315), Breast Neoplasm (EFO_0003869), Breast Cancer (MONDO_0007254), Medullary Thyroid Gland Carcinoma (MONDO_0015277), Acute Lymphoblastic Leukemia (EFO_0000220), Male Breast Carcinoma (EFO_0006861), Acute Myeloid Leukemia (EFO_0000222), Pancreatic Endocrine Carcinoma (EFO_0007416), Diffuse Large B-Cell Lymphoma (EFO_0000403), Urethra Cancer (MONDO_0004192), Inflammatory Breast Carcinoma (EFO_1000984), Pancreatic Carcinoma (EFO_0002618), Neuroendocrine Neoplasm (EFO_1001901), Hypopharyngeal Carcinoma (EFO_0002938), Small Cell Lung Carcinoma (EFO_0000702), Urinary Bladder Carcinoma (MONDO_0004986), Mesothelioma (EFO_0000588), Clear Cell Renal Carcinoma (EFO_0000349), Soft Tissue Sarcoma (EFO_1001968), Renal Cell Carcinoma (EFO_0000681), Peritoneum Cancer (MONDO_0002087), Von Hippel-Lindau Disease (MONDO_0008667), Malignant Epithelial Tumor Of Ovary (MONDO_0018364), Kidney Neoplasm (EFO_0003865), Oropharyngeal Carcinoma (MONDO_0044926), Liver Cancer (MONDO_0002691), Fallopian Tube Cancer (MONDO_0002158), Lung Cancer (MONDO_0008903), Neoplasm (EFO_0000616), Urinary Bladder Cancer (MONDO_0001187), Non-Small Cell Lung Carcinoma (EFO_0003060), Kaposi'S Sarcoma (EFO_0000558), Kidney Cancer (MONDO_0002367), Glioblastoma Multiforme (EFO_0000519), Stomach Neoplasm (EFO_0003897), Follicular Thyroid Carcinoma (EFO_0000501), Esophageal Cancer (MONDO_0007576), Germ Cell Tumor (EFO_0000514)", 'yearOfFirstApproval': 2006, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853), RET (ENSG00000165731), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), CSF1R (ENSG00000182578), FLT3 (ENSG00000122025), KIT (ENSG00000157404)', 'numberLinkedTargets': 9}, {'UUID': 'DrugGeneTargets_v2_3451', 'drugName': 'Sunitinib', 'tradeNames_string': 'Sutent', 'drugSynonyms_string': 'NSC-736511, NSC-750690, SU-011248, SU-11248, SU011248, Sunitinib, Sutent', 'linkedDiseasesDrug_string': "Multiple Myeloma (EFO_0001378), Papillary Thyroid Carcinoma (EFO_0000641), Oligodendroglioma (EFO_0000632), Papillary Renal Cell Carcinoma (EFO_0000640), Inflammatory Breast Carcinoma (EFO_1000984), Neuroendocrine Neoplasm (EFO_1001901), Urinary Bladder Carcinoma (MONDO_0004986), Clear Cell Renal Carcinoma (EFO_0000349), Brain Neoplasm (EFO_0003833), Malignant Epithelial Tumor Of Ovary (MONDO_0018364), Carcinoma (EFO_0000313), Liver Cancer (MONDO_0002691), Osteosarcoma (EFO_0000637), Lung Cancer (MONDO_0008903), Glioblastoma Multiforme (EFO_0000519), Germ Cell Tumor (EFO_0000514), Cancer (MONDO_0004992), Pancreatic Neuroendocrine Tumor (EFO_1000045), Islet Cell Tumor (EFO_0007331), Chronic Lymphocytic Leukemia (EFO_0000095), Thymic Carcinoma (EFO_1000576), Gastrointestinal Stromal Tumor (MONDO_0011719), Colorectal Carcinoma (EFO_1001951), Gliosarcoma (EFO_1001465), Hepatocellular Carcinoma (EFO_0000182), Fallopian Tube Carcinoma (EFO_1000251), Medullary Thyroid Gland Carcinoma (MONDO_0015277), Acute Lymphoblastic Leukemia (EFO_0000220), Acute Myeloid Leukemia (EFO_0000222), Diffuse Large B-Cell Lymphoma (EFO_0000403), Hypopharyngeal Carcinoma (EFO_0002938), Small Cell Lung Carcinoma (EFO_0000702), Urogenital Neoplasm (EFO_0003863), Non-Small Cell Lung Carcinoma (EFO_0003060), Adrenal Gland Pheochromocytoma (EFO_0000239), Urothelial Carcinoma (EFO_0008528), Laryngeal Squamous Cell Carcinoma (EFO_0006352), Gastric Cancer (MONDO_0001056), Ovarian Cancer (MONDO_0008170), Anaplastic Astrocytoma (EFO_0002499), Breast Neoplasm (EFO_0003869), Breast Cancer (MONDO_0007254), Head And Neck Squamous Cell Carcinoma (EFO_0000181), Cholangiocarcinoma (EFO_0005221), Pancreatic Carcinoma (EFO_0002618), Mesothelioma (EFO_0000588), Carcinoid Tumor (EFO_0004243), Peritoneum Cancer (MONDO_0002087), Oropharyngeal Carcinoma (MONDO_0044926), Thymoma (EFO_1000581), Neoplasm (EFO_0000616), Adenocarcinoma (EFO_0000228), Urinary Bladder Cancer (MONDO_0001187), Metastatic Prostate Cancer (EFO_0000196), Sarcoma (EFO_0000691), Stomach Neoplasm (EFO_0003897), Alveolar Soft Part Sarcoma (EFO_0007143), Von Hippel-Lindau Disease (MONDO_0008667), Mixed Glioma (MONDO_0003268), Thyroid Carcinoma (EFO_0002892), Metastatic Melanoma (EFO_0002617), Prostate Adenocarcinoma (EFO_0000673), Ascites (HP_0001541), Prostate Cancer (MONDO_0008315), Colorectal Neoplasm (EFO_0004142), Male Breast Carcinoma (EFO_0006861), Pancreatic Endocrine Carcinoma (EFO_0007416), Urethra Cancer (MONDO_0004192), Soft Tissue Sarcoma (EFO_1001968), Renal Cell Carcinoma (EFO_0000681), Kidney Neoplasm (EFO_0003865), Ebola Hemorrhagic Fever (EFO_0007243), Fallopian Tube Cancer (MONDO_0002158), Nasopharyngeal Neoplasm (EFO_0004252), Kaposi'S Sarcoma (EFO_0000558), Kidney Cancer (MONDO_0002367), Adrenal Cortex Carcinoma (EFO_1000796), Melanoma (EFO_0000756), Follicular Thyroid Carcinoma (EFO_0000501), Esophageal Cancer (MONDO_0007576), Bladder Tumor (EFO_0000294)", 'yearOfFirstApproval': 2006, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'RET (ENSG00000165731), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), CSF1R (ENSG00000182578), FLT3 (ENSG00000122025), KIT (ENSG00000157404), PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853)', 'numberLinkedTargets': 9}, {'UUID': 'DrugGeneTargets_v2_3452', 'drugName': 'Sunitinib', 'tradeNames_string': 'Sutent', 'drugSynonyms_string': 'NSC-736511, NSC-750690, SU-011248, SU-11248, SU011248, Sunitinib, Sutent', 'linkedDiseasesDrug_string': "Multiple Myeloma (EFO_0001378), Papillary Thyroid Carcinoma (EFO_0000641), Oligodendroglioma (EFO_0000632), Papillary Renal Cell Carcinoma (EFO_0000640), Inflammatory Breast Carcinoma (EFO_1000984), Neuroendocrine Neoplasm (EFO_1001901), Urinary Bladder Carcinoma (MONDO_0004986), Clear Cell Renal Carcinoma (EFO_0000349), Brain Neoplasm (EFO_0003833), Malignant Epithelial Tumor Of Ovary (MONDO_0018364), Carcinoma (EFO_0000313), Liver Cancer (MONDO_0002691), Osteosarcoma (EFO_0000637), Lung Cancer (MONDO_0008903), Glioblastoma Multiforme (EFO_0000519), Germ Cell Tumor (EFO_0000514), Cancer (MONDO_0004992), Pancreatic Neuroendocrine Tumor (EFO_1000045), Islet Cell Tumor (EFO_0007331), Chronic Lymphocytic Leukemia (EFO_0000095), Thymic Carcinoma (EFO_1000576), Gastrointestinal Stromal Tumor (MONDO_0011719), Colorectal Carcinoma (EFO_1001951), Gliosarcoma (EFO_1001465), Hepatocellular Carcinoma (EFO_0000182), Fallopian Tube Carcinoma (EFO_1000251), Medullary Thyroid Gland Carcinoma (MONDO_0015277), Acute Lymphoblastic Leukemia (EFO_0000220), Acute Myeloid Leukemia (EFO_0000222), Diffuse Large B-Cell Lymphoma (EFO_0000403), Hypopharyngeal Carcinoma (EFO_0002938), Small Cell Lung Carcinoma (EFO_0000702), Urogenital Neoplasm (EFO_0003863), Non-Small Cell Lung Carcinoma (EFO_0003060), Adrenal Gland Pheochromocytoma (EFO_0000239), Urothelial Carcinoma (EFO_0008528), Laryngeal Squamous Cell Carcinoma (EFO_0006352), Gastric Cancer (MONDO_0001056), Ovarian Cancer (MONDO_0008170), Anaplastic Astrocytoma (EFO_0002499), Breast Neoplasm (EFO_0003869), Breast Cancer (MONDO_0007254), Head And Neck Squamous Cell Carcinoma (EFO_0000181), Cholangiocarcinoma (EFO_0005221), Pancreatic Carcinoma (EFO_0002618), Mesothelioma (EFO_0000588), Carcinoid Tumor (EFO_0004243), Peritoneum Cancer (MONDO_0002087), Oropharyngeal Carcinoma (MONDO_0044926), Thymoma (EFO_1000581), Neoplasm (EFO_0000616), Adenocarcinoma (EFO_0000228), Urinary Bladder Cancer (MONDO_0001187), Metastatic Prostate Cancer (EFO_0000196), Sarcoma (EFO_0000691), Stomach Neoplasm (EFO_0003897), Alveolar Soft Part Sarcoma (EFO_0007143), Von Hippel-Lindau Disease (MONDO_0008667), Mixed Glioma (MONDO_0003268), Thyroid Carcinoma (EFO_0002892), Metastatic Melanoma (EFO_0002617), Prostate Adenocarcinoma (EFO_0000673), Ascites (HP_0001541), Prostate Cancer (MONDO_0008315), Colorectal Neoplasm (EFO_0004142), Male Breast Carcinoma (EFO_0006861), Pancreatic Endocrine Carcinoma (EFO_0007416), Urethra Cancer (MONDO_0004192), Soft Tissue Sarcoma (EFO_1001968), Renal Cell Carcinoma (EFO_0000681), Kidney Neoplasm (EFO_0003865), Ebola Hemorrhagic Fever (EFO_0007243), Fallopian Tube Cancer (MONDO_0002158), Nasopharyngeal Neoplasm (EFO_0004252), Kaposi'S Sarcoma (EFO_0000558), Kidney Cancer (MONDO_0002367), Adrenal Cortex Carcinoma (EFO_1000796), Melanoma (EFO_0000756), Follicular Thyroid Carcinoma (EFO_0000501), Esophageal Cancer (MONDO_0007576), Bladder Tumor (EFO_0000294)", 'yearOfFirstApproval': 2006, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'RET (ENSG00000165731), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), CSF1R (ENSG00000182578), FLT3 (ENSG00000122025), KIT (ENSG00000157404), PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853)', 'numberLinkedTargets': 9}, {'UUID': 'DrugGeneTargets_v2_3453', 'drugName': 'Sunitinib', 'tradeNames_string': 'Sutent', 'drugSynonyms_string': 'NSC-736511, NSC-750690, SU-011248, SU-11248, SU011248, Sunitinib, Sutent', 'linkedDiseasesDrug_string': "Multiple Myeloma (EFO_0001378), Papillary Thyroid Carcinoma (EFO_0000641), Oligodendroglioma (EFO_0000632), Papillary Renal Cell Carcinoma (EFO_0000640), Inflammatory Breast Carcinoma (EFO_1000984), Neuroendocrine Neoplasm (EFO_1001901), Urinary Bladder Carcinoma (MONDO_0004986), Clear Cell Renal Carcinoma (EFO_0000349), Brain Neoplasm (EFO_0003833), Malignant Epithelial Tumor Of Ovary (MONDO_0018364), Carcinoma (EFO_0000313), Liver Cancer (MONDO_0002691), Osteosarcoma (EFO_0000637), Lung Cancer (MONDO_0008903), Glioblastoma Multiforme (EFO_0000519), Germ Cell Tumor (EFO_0000514), Cancer (MONDO_0004992), Pancreatic Neuroendocrine Tumor (EFO_1000045), Islet Cell Tumor (EFO_0007331), Chronic Lymphocytic Leukemia (EFO_0000095), Thymic Carcinoma (EFO_1000576), Gastrointestinal Stromal Tumor (MONDO_0011719), Colorectal Carcinoma (EFO_1001951), Gliosarcoma (EFO_1001465), Hepatocellular Carcinoma (EFO_0000182), Fallopian Tube Carcinoma (EFO_1000251), Medullary Thyroid Gland Carcinoma (MONDO_0015277), Acute Lymphoblastic Leukemia (EFO_0000220), Acute Myeloid Leukemia (EFO_0000222), Diffuse Large B-Cell Lymphoma (EFO_0000403), Hypopharyngeal Carcinoma (EFO_0002938), Small Cell Lung Carcinoma (EFO_0000702), Urogenital Neoplasm (EFO_0003863), Non-Small Cell Lung Carcinoma (EFO_0003060), Adrenal Gland Pheochromocytoma (EFO_0000239), Urothelial Carcinoma (EFO_0008528), Laryngeal Squamous Cell Carcinoma (EFO_0006352), Gastric Cancer (MONDO_0001056), Ovarian Cancer (MONDO_0008170), Anaplastic Astrocytoma (EFO_0002499), Breast Neoplasm (EFO_0003869), Breast Cancer (MONDO_0007254), Head And Neck Squamous Cell Carcinoma (EFO_0000181), Cholangiocarcinoma (EFO_0005221), Pancreatic Carcinoma (EFO_0002618), Mesothelioma (EFO_0000588), Carcinoid Tumor (EFO_0004243), Peritoneum Cancer (MONDO_0002087), Oropharyngeal Carcinoma (MONDO_0044926), Thymoma (EFO_1000581), Neoplasm (EFO_0000616), Adenocarcinoma (EFO_0000228), Urinary Bladder Cancer (MONDO_0001187), Metastatic Prostate Cancer (EFO_0000196), Sarcoma (EFO_0000691), Stomach Neoplasm (EFO_0003897), Alveolar Soft Part Sarcoma (EFO_0007143), Von Hippel-Lindau Disease (MONDO_0008667), Mixed Glioma (MONDO_0003268), Thyroid Carcinoma (EFO_0002892), Metastatic Melanoma (EFO_0002617), Prostate Adenocarcinoma (EFO_0000673), Ascites (HP_0001541), Prostate Cancer (MONDO_0008315), Colorectal Neoplasm (EFO_0004142), Male Breast Carcinoma (EFO_0006861), Pancreatic Endocrine Carcinoma (EFO_0007416), Urethra Cancer (MONDO_0004192), Soft Tissue Sarcoma (EFO_1001968), Renal Cell Carcinoma (EFO_0000681), Kidney Neoplasm (EFO_0003865), Ebola Hemorrhagic Fever (EFO_0007243), Fallopian Tube Cancer (MONDO_0002158), Nasopharyngeal Neoplasm (EFO_0004252), Kaposi'S Sarcoma (EFO_0000558), Kidney Cancer (MONDO_0002367), Adrenal Cortex Carcinoma (EFO_1000796), Melanoma (EFO_0000756), Follicular Thyroid Carcinoma (EFO_0000501), Esophageal Cancer (MONDO_0007576), Bladder Tumor (EFO_0000294)", 'yearOfFirstApproval': 2006, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'RET (ENSG00000165731), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), CSF1R (ENSG00000182578), FLT3 (ENSG00000122025), KIT (ENSG00000157404), PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853)', 'numberLinkedTargets': 9}, {'UUID': 'DrugGeneTargets_v2_3450', 'drugName': 'Sunitinib', 'tradeNames_string': 'Sutent', 'drugSynonyms_string': 'NSC-736511, NSC-750690, SU-011248, SU-11248, SU011248, Sunitinib, Sutent', 'linkedDiseasesDrug_string': "Multiple Myeloma (EFO_0001378), Papillary Thyroid Carcinoma (EFO_0000641), Oligodendroglioma (EFO_0000632), Papillary Renal Cell Carcinoma (EFO_0000640), Inflammatory Breast Carcinoma (EFO_1000984), Neuroendocrine Neoplasm (EFO_1001901), Urinary Bladder Carcinoma (MONDO_0004986), Clear Cell Renal Carcinoma (EFO_0000349), Brain Neoplasm (EFO_0003833), Malignant Epithelial Tumor Of Ovary (MONDO_0018364), Carcinoma (EFO_0000313), Liver Cancer (MONDO_0002691), Osteosarcoma (EFO_0000637), Lung Cancer (MONDO_0008903), Glioblastoma Multiforme (EFO_0000519), Germ Cell Tumor (EFO_0000514), Cancer (MONDO_0004992), Pancreatic Neuroendocrine Tumor (EFO_1000045), Islet Cell Tumor (EFO_0007331), Chronic Lymphocytic Leukemia (EFO_0000095), Thymic Carcinoma (EFO_1000576), Gastrointestinal Stromal Tumor (MONDO_0011719), Colorectal Carcinoma (EFO_1001951), Gliosarcoma (EFO_1001465), Hepatocellular Carcinoma (EFO_0000182), Fallopian Tube Carcinoma (EFO_1000251), Medullary Thyroid Gland Carcinoma (MONDO_0015277), Acute Lymphoblastic Leukemia (EFO_0000220), Acute Myeloid Leukemia (EFO_0000222), Diffuse Large B-Cell Lymphoma (EFO_0000403), Hypopharyngeal Carcinoma (EFO_0002938), Small Cell Lung Carcinoma (EFO_0000702), Urogenital Neoplasm (EFO_0003863), Non-Small Cell Lung Carcinoma (EFO_0003060), Adrenal Gland Pheochromocytoma (EFO_0000239), Urothelial Carcinoma (EFO_0008528), Laryngeal Squamous Cell Carcinoma (EFO_0006352), Gastric Cancer (MONDO_0001056), Ovarian Cancer (MONDO_0008170), Anaplastic Astrocytoma (EFO_0002499), Breast Neoplasm (EFO_0003869), Breast Cancer (MONDO_0007254), Head And Neck Squamous Cell Carcinoma (EFO_0000181), Cholangiocarcinoma (EFO_0005221), Pancreatic Carcinoma (EFO_0002618), Mesothelioma (EFO_0000588), Carcinoid Tumor (EFO_0004243), Peritoneum Cancer (MONDO_0002087), Oropharyngeal Carcinoma (MONDO_0044926), Thymoma (EFO_1000581), Neoplasm (EFO_0000616), Adenocarcinoma (EFO_0000228), Urinary Bladder Cancer (MONDO_0001187), Metastatic Prostate Cancer (EFO_0000196), Sarcoma (EFO_0000691), Stomach Neoplasm (EFO_0003897), Alveolar Soft Part Sarcoma (EFO_0007143), Von Hippel-Lindau Disease (MONDO_0008667), Mixed Glioma (MONDO_0003268), Thyroid Carcinoma (EFO_0002892), Metastatic Melanoma (EFO_0002617), Prostate Adenocarcinoma (EFO_0000673), Ascites (HP_0001541), Prostate Cancer (MONDO_0008315), Colorectal Neoplasm (EFO_0004142), Male Breast Carcinoma (EFO_0006861), Pancreatic Endocrine Carcinoma (EFO_0007416), Urethra Cancer (MONDO_0004192), Soft Tissue Sarcoma (EFO_1001968), Renal Cell Carcinoma (EFO_0000681), Kidney Neoplasm (EFO_0003865), Ebola Hemorrhagic Fever (EFO_0007243), Fallopian Tube Cancer (MONDO_0002158), Nasopharyngeal Neoplasm (EFO_0004252), Kaposi'S Sarcoma (EFO_0000558), Kidney Cancer (MONDO_0002367), Adrenal Cortex Carcinoma (EFO_1000796), Melanoma (EFO_0000756), Follicular Thyroid Carcinoma (EFO_0000501), Esophageal Cancer (MONDO_0007576), Bladder Tumor (EFO_0000294)", 'yearOfFirstApproval': 2006, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'RET (ENSG00000165731), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), CSF1R (ENSG00000182578), FLT3 (ENSG00000122025), KIT (ENSG00000157404), PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853)', 'numberLinkedTargets': 9}, {'UUID': 'DrugGeneTargets_v2_3921', 'drugName': 'Sunitinib Malate', 'tradeNames_string': 'Sunitinib malate, Sutent', 'drugSynonyms_string': 'PHA-290940AD, SU-010398, SU-011248 L-MALATE SALT, SU010398, SU011248 L-MALATE SALT, Sunitinib l-malate, Sunitinib malate, Sutent', 'linkedDiseasesDrug_string': "Cancer (MONDO_0004992), Multiple Myeloma (EFO_0001378), Papillary Thyroid Carcinoma (EFO_0000641), Islet Cell Tumor (EFO_0007331), Chronic Lymphocytic Leukemia (EFO_0000095), Mixed Glioma (MONDO_0003268), Thymic Carcinoma (EFO_1000576), Oligodendroglioma (EFO_0000632), Gastrointestinal Stromal Tumor (MONDO_0011719), Metastatic Melanoma (EFO_0002617), Colorectal Carcinoma (EFO_1001951), Laryngeal Squamous Cell Carcinoma (EFO_0006352), Prostate Adenocarcinoma (EFO_0000673), Anaplastic Astrocytoma (EFO_0002499), Gliosarcoma (EFO_1001465), Papillary Renal Cell Carcinoma (EFO_0000640), Hepatocellular Carcinoma (EFO_0000182), Prostate Cancer (MONDO_0008315), Breast Neoplasm (EFO_0003869), Breast Cancer (MONDO_0007254), Medullary Thyroid Gland Carcinoma (MONDO_0015277), Acute Lymphoblastic Leukemia (EFO_0000220), Male Breast Carcinoma (EFO_0006861), Acute Myeloid Leukemia (EFO_0000222), Pancreatic Endocrine Carcinoma (EFO_0007416), Diffuse Large B-Cell Lymphoma (EFO_0000403), Urethra Cancer (MONDO_0004192), Inflammatory Breast Carcinoma (EFO_1000984), Pancreatic Carcinoma (EFO_0002618), Neuroendocrine Neoplasm (EFO_1001901), Hypopharyngeal Carcinoma (EFO_0002938), Small Cell Lung Carcinoma (EFO_0000702), Urinary Bladder Carcinoma (MONDO_0004986), Mesothelioma (EFO_0000588), Clear Cell Renal Carcinoma (EFO_0000349), Soft Tissue Sarcoma (EFO_1001968), Renal Cell Carcinoma (EFO_0000681), Peritoneum Cancer (MONDO_0002087), Von Hippel-Lindau Disease (MONDO_0008667), Malignant Epithelial Tumor Of Ovary (MONDO_0018364), Kidney Neoplasm (EFO_0003865), Oropharyngeal Carcinoma (MONDO_0044926), Liver Cancer (MONDO_0002691), Fallopian Tube Cancer (MONDO_0002158), Lung Cancer (MONDO_0008903), Neoplasm (EFO_0000616), Urinary Bladder Cancer (MONDO_0001187), Non-Small Cell Lung Carcinoma (EFO_0003060), Kaposi'S Sarcoma (EFO_0000558), Kidney Cancer (MONDO_0002367), Glioblastoma Multiforme (EFO_0000519), Stomach Neoplasm (EFO_0003897), Follicular Thyroid Carcinoma (EFO_0000501), Esophageal Cancer (MONDO_0007576), Germ Cell Tumor (EFO_0000514)", 'yearOfFirstApproval': 2006, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853), RET (ENSG00000165731), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), CSF1R (ENSG00000182578), FLT3 (ENSG00000122025), KIT (ENSG00000157404)', 'numberLinkedTargets': 9}, {'UUID': 'DrugGeneTargets_v2_3919', 'drugName': 'Sunitinib Malate', 'tradeNames_string': 'Sunitinib malate, Sutent', 'drugSynonyms_string': 'PHA-290940AD, SU-010398, SU-011248 L-MALATE SALT, SU010398, SU011248 L-MALATE SALT, Sunitinib l-malate, Sunitinib malate, Sutent', 'linkedDiseasesDrug_string': "Cancer (MONDO_0004992), Multiple Myeloma (EFO_0001378), Papillary Thyroid Carcinoma (EFO_0000641), Islet Cell Tumor (EFO_0007331), Chronic Lymphocytic Leukemia (EFO_0000095), Mixed Glioma (MONDO_0003268), Thymic Carcinoma (EFO_1000576), Oligodendroglioma (EFO_0000632), Gastrointestinal Stromal Tumor (MONDO_0011719), Metastatic Melanoma (EFO_0002617), Colorectal Carcinoma (EFO_1001951), Laryngeal Squamous Cell Carcinoma (EFO_0006352), Prostate Adenocarcinoma (EFO_0000673), Anaplastic Astrocytoma (EFO_0002499), Gliosarcoma (EFO_1001465), Papillary Renal Cell Carcinoma (EFO_0000640), Hepatocellular Carcinoma (EFO_0000182), Prostate Cancer (MONDO_0008315), Breast Neoplasm (EFO_0003869), Breast Cancer (MONDO_0007254), Medullary Thyroid Gland Carcinoma (MONDO_0015277), Acute Lymphoblastic Leukemia (EFO_0000220), Male Breast Carcinoma (EFO_0006861), Acute Myeloid Leukemia (EFO_0000222), Pancreatic Endocrine Carcinoma (EFO_0007416), Diffuse Large B-Cell Lymphoma (EFO_0000403), Urethra Cancer (MONDO_0004192), Inflammatory Breast Carcinoma (EFO_1000984), Pancreatic Carcinoma (EFO_0002618), Neuroendocrine Neoplasm (EFO_1001901), Hypopharyngeal Carcinoma (EFO_0002938), Small Cell Lung Carcinoma (EFO_0000702), Urinary Bladder Carcinoma (MONDO_0004986), Mesothelioma (EFO_0000588), Clear Cell Renal Carcinoma (EFO_0000349), Soft Tissue Sarcoma (EFO_1001968), Renal Cell Carcinoma (EFO_0000681), Peritoneum Cancer (MONDO_0002087), Von Hippel-Lindau Disease (MONDO_0008667), Malignant Epithelial Tumor Of Ovary (MONDO_0018364), Kidney Neoplasm (EFO_0003865), Oropharyngeal Carcinoma (MONDO_0044926), Liver Cancer (MONDO_0002691), Fallopian Tube Cancer (MONDO_0002158), Lung Cancer (MONDO_0008903), Neoplasm (EFO_0000616), Urinary Bladder Cancer (MONDO_0001187), Non-Small Cell Lung Carcinoma (EFO_0003060), Kaposi'S Sarcoma (EFO_0000558), Kidney Cancer (MONDO_0002367), Glioblastoma Multiforme (EFO_0000519), Stomach Neoplasm (EFO_0003897), Follicular Thyroid Carcinoma (EFO_0000501), Esophageal Cancer (MONDO_0007576), Germ Cell Tumor (EFO_0000514)", 'yearOfFirstApproval': 2006, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853), RET (ENSG00000165731), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), CSF1R (ENSG00000182578), FLT3 (ENSG00000122025), KIT (ENSG00000157404)', 'numberLinkedTargets': 9}, {'UUID': 'DrugGeneTargets_v2_3918', 'drugName': 'Sunitinib Malate', 'tradeNames_string': 'Sunitinib malate, Sutent', 'drugSynonyms_string': 'PHA-290940AD, SU-010398, SU-011248 L-MALATE SALT, SU010398, SU011248 L-MALATE SALT, Sunitinib l-malate, Sunitinib malate, Sutent', 'linkedDiseasesDrug_string': "Cancer (MONDO_0004992), Multiple Myeloma (EFO_0001378), Papillary Thyroid Carcinoma (EFO_0000641), Islet Cell Tumor (EFO_0007331), Chronic Lymphocytic Leukemia (EFO_0000095), Mixed Glioma (MONDO_0003268), Thymic Carcinoma (EFO_1000576), Oligodendroglioma (EFO_0000632), Gastrointestinal Stromal Tumor (MONDO_0011719), Metastatic Melanoma (EFO_0002617), Colorectal Carcinoma (EFO_1001951), Laryngeal Squamous Cell Carcinoma (EFO_0006352), Prostate Adenocarcinoma (EFO_0000673), Anaplastic Astrocytoma (EFO_0002499), Gliosarcoma (EFO_1001465), Papillary Renal Cell Carcinoma (EFO_0000640), Hepatocellular Carcinoma (EFO_0000182), Prostate Cancer (MONDO_0008315), Breast Neoplasm (EFO_0003869), Breast Cancer (MONDO_0007254), Medullary Thyroid Gland Carcinoma (MONDO_0015277), Acute Lymphoblastic Leukemia (EFO_0000220), Male Breast Carcinoma (EFO_0006861), Acute Myeloid Leukemia (EFO_0000222), Pancreatic Endocrine Carcinoma (EFO_0007416), Diffuse Large B-Cell Lymphoma (EFO_0000403), Urethra Cancer (MONDO_0004192), Inflammatory Breast Carcinoma (EFO_1000984), Pancreatic Carcinoma (EFO_0002618), Neuroendocrine Neoplasm (EFO_1001901), Hypopharyngeal Carcinoma (EFO_0002938), Small Cell Lung Carcinoma (EFO_0000702), Urinary Bladder Carcinoma (MONDO_0004986), Mesothelioma (EFO_0000588), Clear Cell Renal Carcinoma (EFO_0000349), Soft Tissue Sarcoma (EFO_1001968), Renal Cell Carcinoma (EFO_0000681), Peritoneum Cancer (MONDO_0002087), Von Hippel-Lindau Disease (MONDO_0008667), Malignant Epithelial Tumor Of Ovary (MONDO_0018364), Kidney Neoplasm (EFO_0003865), Oropharyngeal Carcinoma (MONDO_0044926), Liver Cancer (MONDO_0002691), Fallopian Tube Cancer (MONDO_0002158), Lung Cancer (MONDO_0008903), Neoplasm (EFO_0000616), Urinary Bladder Cancer (MONDO_0001187), Non-Small Cell Lung Carcinoma (EFO_0003060), Kaposi'S Sarcoma (EFO_0000558), Kidney Cancer (MONDO_0002367), Glioblastoma Multiforme (EFO_0000519), Stomach Neoplasm (EFO_0003897), Follicular Thyroid Carcinoma (EFO_0000501), Esophageal Cancer (MONDO_0007576), Germ Cell Tumor (EFO_0000514)", 'yearOfFirstApproval': 2006, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853), RET (ENSG00000165731), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), CSF1R (ENSG00000182578), FLT3 (ENSG00000122025), KIT (ENSG00000157404)', 'numberLinkedTargets': 9}, {'UUID': 'DrugGeneTargets_v2_3454', 'drugName': 'Sunitinib', 'tradeNames_string': 'Sutent', 'drugSynonyms_string': 'NSC-736511, NSC-750690, SU-011248, SU-11248, SU011248, Sunitinib, Sutent', 'linkedDiseasesDrug_string': "Multiple Myeloma (EFO_0001378), Papillary Thyroid Carcinoma (EFO_0000641), Oligodendroglioma (EFO_0000632), Papillary Renal Cell Carcinoma (EFO_0000640), Inflammatory Breast Carcinoma (EFO_1000984), Neuroendocrine Neoplasm (EFO_1001901), Urinary Bladder Carcinoma (MONDO_0004986), Clear Cell Renal Carcinoma (EFO_0000349), Brain Neoplasm (EFO_0003833), Malignant Epithelial Tumor Of Ovary (MONDO_0018364), Carcinoma (EFO_0000313), Liver Cancer (MONDO_0002691), Osteosarcoma (EFO_0000637), Lung Cancer (MONDO_0008903), Glioblastoma Multiforme (EFO_0000519), Germ Cell Tumor (EFO_0000514), Cancer (MONDO_0004992), Pancreatic Neuroendocrine Tumor (EFO_1000045), Islet Cell Tumor (EFO_0007331), Chronic Lymphocytic Leukemia (EFO_0000095), Thymic Carcinoma (EFO_1000576), Gastrointestinal Stromal Tumor (MONDO_0011719), Colorectal Carcinoma (EFO_1001951), Gliosarcoma (EFO_1001465), Hepatocellular Carcinoma (EFO_0000182), Fallopian Tube Carcinoma (EFO_1000251), Medullary Thyroid Gland Carcinoma (MONDO_0015277), Acute Lymphoblastic Leukemia (EFO_0000220), Acute Myeloid Leukemia (EFO_0000222), Diffuse Large B-Cell Lymphoma (EFO_0000403), Hypopharyngeal Carcinoma (EFO_0002938), Small Cell Lung Carcinoma (EFO_0000702), Urogenital Neoplasm (EFO_0003863), Non-Small Cell Lung Carcinoma (EFO_0003060), Adrenal Gland Pheochromocytoma (EFO_0000239), Urothelial Carcinoma (EFO_0008528), Laryngeal Squamous Cell Carcinoma (EFO_0006352), Gastric Cancer (MONDO_0001056), Ovarian Cancer (MONDO_0008170), Anaplastic Astrocytoma (EFO_0002499), Breast Neoplasm (EFO_0003869), Breast Cancer (MONDO_0007254), Head And Neck Squamous Cell Carcinoma (EFO_0000181), Cholangiocarcinoma (EFO_0005221), Pancreatic Carcinoma (EFO_0002618), Mesothelioma (EFO_0000588), Carcinoid Tumor (EFO_0004243), Peritoneum Cancer (MONDO_0002087), Oropharyngeal Carcinoma (MONDO_0044926), Thymoma (EFO_1000581), Neoplasm (EFO_0000616), Adenocarcinoma (EFO_0000228), Urinary Bladder Cancer (MONDO_0001187), Metastatic Prostate Cancer (EFO_0000196), Sarcoma (EFO_0000691), Stomach Neoplasm (EFO_0003897), Alveolar Soft Part Sarcoma (EFO_0007143), Von Hippel-Lindau Disease (MONDO_0008667), Mixed Glioma (MONDO_0003268), Thyroid Carcinoma (EFO_0002892), Metastatic Melanoma (EFO_0002617), Prostate Adenocarcinoma (EFO_0000673), Ascites (HP_0001541), Prostate Cancer (MONDO_0008315), Colorectal Neoplasm (EFO_0004142), Male Breast Carcinoma (EFO_0006861), Pancreatic Endocrine Carcinoma (EFO_0007416), Urethra Cancer (MONDO_0004192), Soft Tissue Sarcoma (EFO_1001968), Renal Cell Carcinoma (EFO_0000681), Kidney Neoplasm (EFO_0003865), Ebola Hemorrhagic Fever (EFO_0007243), Fallopian Tube Cancer (MONDO_0002158), Nasopharyngeal Neoplasm (EFO_0004252), Kaposi'S Sarcoma (EFO_0000558), Kidney Cancer (MONDO_0002367), Adrenal Cortex Carcinoma (EFO_1000796), Melanoma (EFO_0000756), Follicular Thyroid Carcinoma (EFO_0000501), Esophageal Cancer (MONDO_0007576), Bladder Tumor (EFO_0000294)", 'yearOfFirstApproval': 2006, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'RET (ENSG00000165731), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), CSF1R (ENSG00000182578), FLT3 (ENSG00000122025), KIT (ENSG00000157404), PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853)', 'numberLinkedTargets': 9}, {'UUID': 'DrugGeneTargets_v2_3449', 'drugName': 'Sunitinib', 'tradeNames_string': 'Sutent', 'drugSynonyms_string': 'NSC-736511, NSC-750690, SU-011248, SU-11248, SU011248, Sunitinib, Sutent', 'linkedDiseasesDrug_string': "Multiple Myeloma (EFO_0001378), Papillary Thyroid Carcinoma (EFO_0000641), Oligodendroglioma (EFO_0000632), Papillary Renal Cell Carcinoma (EFO_0000640), Inflammatory Breast Carcinoma (EFO_1000984), Neuroendocrine Neoplasm (EFO_1001901), Urinary Bladder Carcinoma (MONDO_0004986), Clear Cell Renal Carcinoma (EFO_0000349), Brain Neoplasm (EFO_0003833), Malignant Epithelial Tumor Of Ovary (MONDO_0018364), Carcinoma (EFO_0000313), Liver Cancer (MONDO_0002691), Osteosarcoma (EFO_0000637), Lung Cancer (MONDO_0008903), Glioblastoma Multiforme (EFO_0000519), Germ Cell Tumor (EFO_0000514), Cancer (MONDO_0004992), Pancreatic Neuroendocrine Tumor (EFO_1000045), Islet Cell Tumor (EFO_0007331), Chronic Lymphocytic Leukemia (EFO_0000095), Thymic Carcinoma (EFO_1000576), Gastrointestinal Stromal Tumor (MONDO_0011719), Colorectal Carcinoma (EFO_1001951), Gliosarcoma (EFO_1001465), Hepatocellular Carcinoma (EFO_0000182), Fallopian Tube Carcinoma (EFO_1000251), Medullary Thyroid Gland Carcinoma (MONDO_0015277), Acute Lymphoblastic Leukemia (EFO_0000220), Acute Myeloid Leukemia (EFO_0000222), Diffuse Large B-Cell Lymphoma (EFO_0000403), Hypopharyngeal Carcinoma (EFO_0002938), Small Cell Lung Carcinoma (EFO_0000702), Urogenital Neoplasm (EFO_0003863), Non-Small Cell Lung Carcinoma (EFO_0003060), Adrenal Gland Pheochromocytoma (EFO_0000239), Urothelial Carcinoma (EFO_0008528), Laryngeal Squamous Cell Carcinoma (EFO_0006352), Gastric Cancer (MONDO_0001056), Ovarian Cancer (MONDO_0008170), Anaplastic Astrocytoma (EFO_0002499), Breast Neoplasm (EFO_0003869), Breast Cancer (MONDO_0007254), Head And Neck Squamous Cell Carcinoma (EFO_0000181), Cholangiocarcinoma (EFO_0005221), Pancreatic Carcinoma (EFO_0002618), Mesothelioma (EFO_0000588), Carcinoid Tumor (EFO_0004243), Peritoneum Cancer (MONDO_0002087), Oropharyngeal Carcinoma (MONDO_0044926), Thymoma (EFO_1000581), Neoplasm (EFO_0000616), Adenocarcinoma (EFO_0000228), Urinary Bladder Cancer (MONDO_0001187), Metastatic Prostate Cancer (EFO_0000196), Sarcoma (EFO_0000691), Stomach Neoplasm (EFO_0003897), Alveolar Soft Part Sarcoma (EFO_0007143), Von Hippel-Lindau Disease (MONDO_0008667), Mixed Glioma (MONDO_0003268), Thyroid Carcinoma (EFO_0002892), Metastatic Melanoma (EFO_0002617), Prostate Adenocarcinoma (EFO_0000673), Ascites (HP_0001541), Prostate Cancer (MONDO_0008315), Colorectal Neoplasm (EFO_0004142), Male Breast Carcinoma (EFO_0006861), Pancreatic Endocrine Carcinoma (EFO_0007416), Urethra Cancer (MONDO_0004192), Soft Tissue Sarcoma (EFO_1001968), Renal Cell Carcinoma (EFO_0000681), Kidney Neoplasm (EFO_0003865), Ebola Hemorrhagic Fever (EFO_0007243), Fallopian Tube Cancer (MONDO_0002158), Nasopharyngeal Neoplasm (EFO_0004252), Kaposi'S Sarcoma (EFO_0000558), Kidney Cancer (MONDO_0002367), Adrenal Cortex Carcinoma (EFO_1000796), Melanoma (EFO_0000756), Follicular Thyroid Carcinoma (EFO_0000501), Esophageal Cancer (MONDO_0007576), Bladder Tumor (EFO_0000294)", 'yearOfFirstApproval': 2006, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'RET (ENSG00000165731), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), CSF1R (ENSG00000182578), FLT3 (ENSG00000122025), KIT (ENSG00000157404), PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853)', 'numberLinkedTargets': 9}, {'UUID': 'DrugGeneTargets_v2_3922', 'drugName': 'Sunitinib Malate', 'tradeNames_string': 'Sunitinib malate, Sutent', 'drugSynonyms_string': 'PHA-290940AD, SU-010398, SU-011248 L-MALATE SALT, SU010398, SU011248 L-MALATE SALT, Sunitinib l-malate, Sunitinib malate, Sutent', 'linkedDiseasesDrug_string': "Cancer (MONDO_0004992), Multiple Myeloma (EFO_0001378), Papillary Thyroid Carcinoma (EFO_0000641), Islet Cell Tumor (EFO_0007331), Chronic Lymphocytic Leukemia (EFO_0000095), Mixed Glioma (MONDO_0003268), Thymic Carcinoma (EFO_1000576), Oligodendroglioma (EFO_0000632), Gastrointestinal Stromal Tumor (MONDO_0011719), Metastatic Melanoma (EFO_0002617), Colorectal Carcinoma (EFO_1001951), Laryngeal Squamous Cell Carcinoma (EFO_0006352), Prostate Adenocarcinoma (EFO_0000673), Anaplastic Astrocytoma (EFO_0002499), Gliosarcoma (EFO_1001465), Papillary Renal Cell Carcinoma (EFO_0000640), Hepatocellular Carcinoma (EFO_0000182), Prostate Cancer (MONDO_0008315), Breast Neoplasm (EFO_0003869), Breast Cancer (MONDO_0007254), Medullary Thyroid Gland Carcinoma (MONDO_0015277), Acute Lymphoblastic Leukemia (EFO_0000220), Male Breast Carcinoma (EFO_0006861), Acute Myeloid Leukemia (EFO_0000222), Pancreatic Endocrine Carcinoma (EFO_0007416), Diffuse Large B-Cell Lymphoma (EFO_0000403), Urethra Cancer (MONDO_0004192), Inflammatory Breast Carcinoma (EFO_1000984), Pancreatic Carcinoma (EFO_0002618), Neuroendocrine Neoplasm (EFO_1001901), Hypopharyngeal Carcinoma (EFO_0002938), Small Cell Lung Carcinoma (EFO_0000702), Urinary Bladder Carcinoma (MONDO_0004986), Mesothelioma (EFO_0000588), Clear Cell Renal Carcinoma (EFO_0000349), Soft Tissue Sarcoma (EFO_1001968), Renal Cell Carcinoma (EFO_0000681), Peritoneum Cancer (MONDO_0002087), Von Hippel-Lindau Disease (MONDO_0008667), Malignant Epithelial Tumor Of Ovary (MONDO_0018364), Kidney Neoplasm (EFO_0003865), Oropharyngeal Carcinoma (MONDO_0044926), Liver Cancer (MONDO_0002691), Fallopian Tube Cancer (MONDO_0002158), Lung Cancer (MONDO_0008903), Neoplasm (EFO_0000616), Urinary Bladder Cancer (MONDO_0001187), Non-Small Cell Lung Carcinoma (EFO_0003060), Kaposi'S Sarcoma (EFO_0000558), Kidney Cancer (MONDO_0002367), Glioblastoma Multiforme (EFO_0000519), Stomach Neoplasm (EFO_0003897), Follicular Thyroid Carcinoma (EFO_0000501), Esophageal Cancer (MONDO_0007576), Germ Cell Tumor (EFO_0000514)", 'yearOfFirstApproval': 2006, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853), RET (ENSG00000165731), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), CSF1R (ENSG00000182578), FLT3 (ENSG00000122025), KIT (ENSG00000157404)', 'numberLinkedTargets': 9}, {'UUID': 'DrugGeneTargets_v2_3920', 'drugName': 'Sunitinib Malate', 'tradeNames_string': 'Sunitinib malate, Sutent', 'drugSynonyms_string': 'PHA-290940AD, SU-010398, SU-011248 L-MALATE SALT, SU010398, SU011248 L-MALATE SALT, Sunitinib l-malate, Sunitinib malate, Sutent', 'linkedDiseasesDrug_string': "Cancer (MONDO_0004992), Multiple Myeloma (EFO_0001378), Papillary Thyroid Carcinoma (EFO_0000641), Islet Cell Tumor (EFO_0007331), Chronic Lymphocytic Leukemia (EFO_0000095), Mixed Glioma (MONDO_0003268), Thymic Carcinoma (EFO_1000576), Oligodendroglioma (EFO_0000632), Gastrointestinal Stromal Tumor (MONDO_0011719), Metastatic Melanoma (EFO_0002617), Colorectal Carcinoma (EFO_1001951), Laryngeal Squamous Cell Carcinoma (EFO_0006352), Prostate Adenocarcinoma (EFO_0000673), Anaplastic Astrocytoma (EFO_0002499), Gliosarcoma (EFO_1001465), Papillary Renal Cell Carcinoma (EFO_0000640), Hepatocellular Carcinoma (EFO_0000182), Prostate Cancer (MONDO_0008315), Breast Neoplasm (EFO_0003869), Breast Cancer (MONDO_0007254), Medullary Thyroid Gland Carcinoma (MONDO_0015277), Acute Lymphoblastic Leukemia (EFO_0000220), Male Breast Carcinoma (EFO_0006861), Acute Myeloid Leukemia (EFO_0000222), Pancreatic Endocrine Carcinoma (EFO_0007416), Diffuse Large B-Cell Lymphoma (EFO_0000403), Urethra Cancer (MONDO_0004192), Inflammatory Breast Carcinoma (EFO_1000984), Pancreatic Carcinoma (EFO_0002618), Neuroendocrine Neoplasm (EFO_1001901), Hypopharyngeal Carcinoma (EFO_0002938), Small Cell Lung Carcinoma (EFO_0000702), Urinary Bladder Carcinoma (MONDO_0004986), Mesothelioma (EFO_0000588), Clear Cell Renal Carcinoma (EFO_0000349), Soft Tissue Sarcoma (EFO_1001968), Renal Cell Carcinoma (EFO_0000681), Peritoneum Cancer (MONDO_0002087), Von Hippel-Lindau Disease (MONDO_0008667), Malignant Epithelial Tumor Of Ovary (MONDO_0018364), Kidney Neoplasm (EFO_0003865), Oropharyngeal Carcinoma (MONDO_0044926), Liver Cancer (MONDO_0002691), Fallopian Tube Cancer (MONDO_0002158), Lung Cancer (MONDO_0008903), Neoplasm (EFO_0000616), Urinary Bladder Cancer (MONDO_0001187), Non-Small Cell Lung Carcinoma (EFO_0003060), Kaposi'S Sarcoma (EFO_0000558), Kidney Cancer (MONDO_0002367), Glioblastoma Multiforme (EFO_0000519), Stomach Neoplasm (EFO_0003897), Follicular Thyroid Carcinoma (EFO_0000501), Esophageal Cancer (MONDO_0007576), Germ Cell Tumor (EFO_0000514)", 'yearOfFirstApproval': 2006, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853), RET (ENSG00000165731), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), CSF1R (ENSG00000182578), FLT3 (ENSG00000122025), KIT (ENSG00000157404)', 'numberLinkedTargets': 9}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.